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Abstract 
This thesis describes the incorporation of nanoparticles into polymers as 
antibacterial surfaces for preventing hospital-acquired infections (HAIs). 
With a high prevalence of HAIs, the use of antibacterial materials can 
contribute in reducing bacterial contamination associated with frequently 
touched surfaces in hospitals (e.g. push plates, bed rails, or keyboards). The 
combination of nanoparticles and light-activated antibacterial agents 
demonstrate lethal bactericidal activity when encapsulated into medical 
grade polymer sheets. Upon white light activation, these polymers exhibit 
significant photobactericidal activity against a range of Gram-negative and 
Gram-positive bacteria via the production of reactive oxygen species at the 
polymer surface, through multi-site mechanistic pathways (Type I and/or 
Type II). These samples are tested under various light intensities to mimic 
clinical surroundings, but more significantly, some materials show highly 
efficacious antibacterial activity in dark conditions.  
All polymers are prepared using a simple ‘swell-encapsulation-shrink’ 
method, which impregnates the nanoparticles into the polymer substrate 
and on the surface. These include copper and zinc oxide nanoparticles 
synthesised with different capping agents. The antibacterial activity of a 
commonly used biocide encapsulated into the polymer is also assessed. 
The photosensitiser (crystal violet) is then coated onto the polymer surface 
in the case of ZnO nanoparticles and activated by white light (~500 – 6600 
lux).  
The combination of crystal violet and zinc oxide nanoparticles is 
investigated further by adapting the microbiological protocol to more 
closely replicate a clinical environment and using a lower intensity of light 
to carry out the antibacterial testing. In addition, the mechanisms 
operating within the crystal violet and zinc oxide system are examined 
using specific inhibitors and singlet oxygen quenchers to determine 
 iv 
whether Type I, Type II, or both photochemical pathways are responsible 
for the reduction of bacteria in the light and dark. 
The samples were tested against a range of hospital pathogens, including 
Escherichia coli, Staphylococcus aureus, methicillin-resistant Staphylococcus 
aureus, Pseudomonas aeruginosa and Clostridium difficile endospores. The 
novel and highly effective antimicrobial materials detailed in this thesis 
demonstrate a very strong potential to be used in hospitals for reducing 
the incidence of HAIs.  
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Chapter 1 
1. Hospital-Acquired Infections 
 
1.1 Introductory remarks 
This thesis describes the development of antibacterial surfaces for reducing 
the incidence of hospital-acquired infections (HAIs). The main focus is on 
the antibacterial activity of polymers coated with photosensitisers and 
encapsulated with nanoparticles following white light activation and in the 
dark. This literature review chapter details the incidence of HAIs, the 
problem of antimicrobial resistance and summarises the common bacterial 
pathogens found in hospital environments. The chapter then focuses on 
current prevention strategies for combating these infections, as well as the 
advantages and disadvantages of alternative cleaning/sterilisation 
methods. There is a detailed comparison of potential antimicrobial surfaces 
that can be used to combat HAIs, as well as a brief introduction into the 
use of light-activated antibacterial surfaces.  
 
1.2 Introduction to the Incidence of Hospital-Acquired Infections 
HAIs, also known as nosocomial infections, are infections that occur in 
patients in a hospital or healthcare facility which were not present at the 
time of admission. These can include infections that are acquired in the 
hospital but appear after discharge.1 The incidence of HAIs has been 
growing exponentially since 1980 due to the emergence of multidrug-
resistant bacteria,2 affecting both developed and developing countries 
around the world.  Out of every 100 patients who are hospitalised, 7 in 
developed and 10 in developing countries will obtain at least one HAI,3 
significantly affecting low- and middle-income countries more than high-
income countries. At any time, more than 1.4 million people suffer from an 
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infection acquired in a hospital occurring from surgical wounds, urinary 
tract infections (UTIs) and lower respiratory tract infections.4 Various 
pathogens attach onto medical devices and implants, such as venous and 
urinary catheters, resulting in increases in hospital cost and discomfort for 
patients when they have to be replaced.5  
HAIs are also spread by direct contact between patients, healthcare 
workers and microorganisms present within hospital environments.6 When 
a person who carries the microorganism is admitted to the hospital, they 
are a potential source of infection for patients and staff. Subsequently, 
patients who become infected are a further source of infection. Patient-to-
patient transmission of pathogens is encouraged by poor infection 
controls, such as accommodating multiple patients in one room, 
overcrowded conditions within the hospital and transferring patients from 
one unit to another.7 In addition to this, patients with compromised or 
weaker immune systems have an increased susceptibility to infections.8 
Healthcare workers can also carry the pathogen on their hands from direct 
contact with an infected patient or a colonised surface. Once surfaces 
become contaminated, patients and surrounding surfaces in the vicinity are 
also susceptible to bacterial contamination, which is a major concern as the 
environment can act as a reservoir for infectious bacteria.6 Numerous 
studies have shown that environmental contamination can persist for 
many days and months with several pathogens, including methicillin-
resistant Staphylococcus aureus (MRSA),9 vancomycin-resistant 
Enterococcus (VRE),10 norovirus11 and Clostridium difficile (C. difficile).12 
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Fig. 1.1 Factors affecting the incidence of HAIs. 
 
The prevalence of HAIs varies across patient groups and hospital wards, 
partly due to differences in surgical procedures within certain settings. A 
survey conducted in 2011 found that the prevalence of nosocomial 
infections was highest amongst patients in intensive care units (ICUs) and 
surgical wards (23.4% and 8% of patients, respectively).13 This may be due 
to the fact that ICUs care for the most vulnerable patients and procedures 
common in ICUs and surgical wards (e.g. catheterisation) are associated 
with increased risk of infection.14  
The endemic burden of HAIs affects hundreds of millions of patients every 
year, causing emotional stress, disabilities and a reduced quality of life.1 
They are also one of the leading causes of death and result in significant 
financial and economic costs for the healthcare industry.3 A main 
contributor to these costs is prolonged hospital stay for infected patients, 
which also increases the need for drugs, isolation wards, and the use of 
additional laboratory facilities. Nosocomial infections will become an even 
greater public health issue as new microorganisms emerge and antibiotic 
resistance increases.16 
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 1.3 Antimicrobial Resistance 
The discovery of antibiotics in the 1930s transformed medicine and the 
way we care for patients.16 Common illnesses became treatable with 
antibiotics as they served an important role in keeping the public healthy. 
However, nearly 90 years later, a critical point has been reached in treating 
infections as new drugs are not being developed rapidly enough in order to 
keep ahead of the natural ability of bacteria to evolve as they defend 
themselves against antibiotics.17 As a result, our most powerful drugs are 
becoming futile and antibiotic resistance has become one of the greatest 
global threats to human health.  Nearly 2 million Americans develop HAIs 
per year that are mostly due to multi-drug resistant pathogens, causing 
around 99,000 deaths.18 Just one organism, MRSA, kills more Americans 
every year than Parkinson’s disease, HIV/AIDs, emphysema and homicide 
combined.19 Multi-drug resistant Gram-negative bacteria cause a high 
percentage of HAIs, including UTIs, pneumonia and bloodstream 
infections.20 Patients with infections caused by drug-resistant bacteria are 
generally more at risk from suffering worse clinical complications and even 
death, and consume more hospital resources than patients infected with 
non-resistant forms of the same bacteria.18 
Antibiotic resistance is the resistance of a microorganism to a specific 
antibiotic drug that was originally effective in treating the infections caused 
by it.21 These resistant microorganisms can survive in the presence of 
antibacterial drugs so that standard treatment becomes ineffective, 
allowing the infection to spread and pose a risk to others.22 Antimicrobial 
resistance, a broader term, is the resistance to drugs for treating infections 
caused by other microbes as well, such as viruses (e.g. HIV), fungi (e.g. 
Candida) and parasites (e.g. malaria).21 As new resistance mechanisms 
emerge, our ability to treat common infections weakens, resulting in 
disability, prolonged illnesses, higher expenditures and a greater risk of 
death.23 Antibiotic resistance occurs due to inappropriate use, as 
antibiotics are not taken at the correct dosage and time and are prescribed 
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unnecessarily (e.g. for viral infections or for bacteria that are already 
resistant). People may consume leftover antibiotics from previous 
prescriptions and pressure doctors for new prescriptions because they 
want a quick relief from symptoms, regardless of the cause of illness.24 
Additionally, patients are frequently prescribed the wrong selection and 
dosage of antibiotics which are unnecessary for treatment.23  
 
 
Fig. 1.2 Antibiotic resistance cycle 
 
1.4 Common Pathogens in Hospitals  
Most HAIs occur from the patients’ own endogenous flora, however, an 
estimated 20 - 40% are a result of cross-infection via healthcare workers in 
contact with patients or by touching contaminated surfaces.25 Various 
pathogens can persist for several days and months on surfaces, including 
MRSA, VRE, Acinetobacter species, C. difficile and norovirus.26 These 
pathogens can adhere to surfaces by forming biofilms within 24 hours.27 In 
fact, most antimicrobial therapies are unable to kill biofilms as the 
concentration of disinfectants required to kill sessile bacteria may be 1000 
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times higher than that required to kill planktonic bacteria of the same 
strain.27 Some studies suggest that Gram-negative bacteria survive longer 
on surfaces than Gram-positive28 and others suggest that the type of 
surface can affect adhesion, i.e. a longer persistence of bacteria on plastic 
or steel compared to glass.29 Environmental factors also affect the survival 
of bacteria, viruses and fungi on surfaces, as increased humidity (> 70%) 
and lower temperatures (4 – 6oC) can increase persistence.12 The 
characteristics and symptoms of some clinically-relevant infections are 
summarised in Table 1.1.  
 
 
Table 1.1  Examples of pathogens causing nosocomial infections 
 
MRSA and C. difficile infections can be a major concern for hospitalised 
patients and are regularly publicised when looking at the state of HAIs.6 In 
recent years, successful efforts have been made to reduce the rates of 
these deadly pathogens in hospitals. Based on results obtained from a 
selection of hospitals in England, there was a large reduction in both MRSA 
and C. difficile rates in 2012 compared to 2006.13 Despite this reduction, 
preventative efforts are still required to keep the incidence of these 
infections low. However, infections with other organisms, such as Klebsiella 
pneumoniae (K. pneuomoniae) and E. coli have been rapidly emerging, as 
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infections common in the respiratory tract, urinary tract and on surgical 
sites are still rife.30 These bacteria belong to a class of organisms called 
Enterobacteriaceae, which are found in the human intestine and are 
difficult to treat as they are highly resistant to antibiotics.31,32 
 
1.4.1 Methicillin-resistant Staphylococcus aureus 
MRSA is a type of Staphylococcus bacterium that is resistant to antibiotics 
known as beta-lactams.33 These antibiotics include methicillin, penicillin, 
oxacillin and amoxicillin.33.34 Methicillin resistance in S. aureus was 
primarily identified in the 1960s amongst hospitalised patients by 
contamination from healthcare workers. After this outbreak, extensive 
basic cleaning regimes were put into practice to minimise the spread of this 
“superbug”. After cleaning shared common areas and changing the blood 
pressure cuffs of patients, fewer patients were colonised with the 
bacteria.35 The number of cleaning hours doubled from 60 h to 120 h a 
week and as a result, there was an immediate reduction in the number of 
newly-infected patients, saving around £30,000 in hospital costs.36  
 
1.4.2 Escherichia coli 
E. coli  is a Gram-negative bacterium that normally lives in human and 
animal intestines because it is necessary for bowel function and is an 
important part of a healthy human intestinal tract.38 However, it becomes 
problematic when entering our bloodstreams or tissues inside the body, 
causing up to 40% of septicaemia and 75% of meningitis cases.20 It thrives 
in moist hospital environments and can also be found in solutions, 
humidifiers, endotracheal tubes, medical devices and equipment.38  E. coli 
is responsible for 1 in 2000 neonatal meningitis cases, which is caused  by 
invading the bloodstream of infants from the nasopharynx and carried to 
the meninges.39 It is also the leading cause of bloody diarrhoea as some E. 
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coli strains are responsible for intestinal diseases.40 In addition to this, E. 
coli is widely known for causing 90% of UTIs.41 In some people (children 
under 5 in particular) the infection causes haemolytic uremic syndrome 
which is a severely complicated disease that destroys red blood cells and 
causes kidney failure.42   
Recent studies showed that between 2009 and 2014, the incidence of 
drug-resistant E. coli in the US doubled from a rate of 5.28 incidents to a 
rate of 10.5 incidents per 100,000 patients, with an average age of 72 years 
old for infected patients.43 A recent report from Public Health England 
(PHE) showed that more people suffered from significant antibiotic-
resistant infections between 2010 and 2014. E. coli-related bloodstream 
infections increased by 15.6% and K. pneumoniae-related infections 
increased by 20.8%.44  
 
1.4.3 Pseudomonas aeruginosa  
Gram-negative bacteria cause around 30% of bloodstream infections in 
ICUs, in particular, species of Klebsiella sp., E. coli, Enterobacter sp. and P. 
aeruginosa. Studies show that water sources in healthcare environments 
are a persistent reservoir for Pseudomonas spp. and pose a serious risk for 
vulnerable patients.14 P. aeruginosa can be transmitted from contaminated 
sinks to hands during hand-washing44 and adhere onto surfaces such as 
pipes, water lines, sink traps and hospital drains.36 It is a versatile pathogen 
which causes various infection types, particularly in critically ill or 
immunocompromised patients.14 Reports from the National Nosocomial 
Infections Surveillance system (1986 – 2003) described P. aeruginosa as the 
second most common cause of pneumonia (18.1%), the third most 
common cause of UTIs (16.3%) and the eighth most frequently isolated 
pathogen from the bloodstream (3.4%).46 
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1.4.4 Clostridium difficile 
Hospital-acquired C. difficile infection (CDI) is a main cause of morbidity 
and mortality, because C. difficile is resistant to several antibiotics. It is an 
anaerobic Gram-positive bacterium and is able to form dormant spores 
which are resistant to drying and heating.47 The ability of these spores to 
survive for many months poses a major threat to hospitals. One of the few 
ways to kill C. difficile spores is by using chlorinated products, such as 
bleach.14 Highly concentrated products are even more effective 
disinfectants because they can release higher levels of free chlorine (e.g. 
5000 mg/litre).48 However, the efficacy of these disinfectants to eliminate 
environmental spores depends on many factors, such as contact time of 
disinfectants, training and knowledge of staff, and the time allocated to 
staff for cleaning.36  
CDIs are often caused from surfaces contaminated with faecal species, 
which then spreads from human contact.49 Once C. difficile is ingested and 
reaches the human intestine, it germinates into its vegetative form. It then   
secretes toxins which cause severe diarrhoea, abdominal pain or colitis.51 
In 2009, around 340,000 patients remained hospitalised due to CDI in the 
US, causing many fatalities.51 C. difficile has mutated over time and is now 
resistant to many antibiotics. It is commonly found on hospital surfaces, 
including bed frames, floors and sinks, with outbreaks occurring where 
disinfectants are found to be ineffective against spores.52  
 
1.5 Prevention Strategies  
When surfaces such as clinical equipment or medical devices are 
contaminated, they can promote the transfer of microorganisms between 
patients and healthcare workers. This is also the case for frequently 
touched surfaces such as bed rails, mattresses, bedside tables, toilets, and 
any surface within a ward that an infected patient has previously stayed in. 
In fact, newly admitted patients are at high risk of being contaminated with 
 10 
the same pathogen that infected the previous patient in that room.36 If any 
frequently touched surfaces are found to contain more than 250 – 500 
CFU/100 cm2, improvements in cleaning and disinfecting should be 
employed.53 In an ICU, it was found that nurses call buttons were 
harbouring 7118 CFU/100 cm2 and bed rails contained 17,336 cfu/100 
cm2.54 Studies have shown that ~50% of toilets, toilet floors and bed rails 
were contaminated with C. difficile, and found some surfaces harbouring 
around 1300 colonies when sampled with a sponge.49  
The US-based CDC (Centers for Disease Control and Prevention) has issued 
guidelines for cleaning and disinfecting the environment as well as 
personal protective equipment and hand hygiene.55 Hand hygiene 
contributes significantly to the spread of HAIs among patients and staff and 
is responsible for 20 – 40% of cross-infection via the hands of healthcare 
personnel.56 Decontamination of hands prior to patient contact is vital in 
minimising the spread of bacteria and the use of gloves does not fully 
protect them either.57 Alcohol gel hand sanitisers can be effective if there is 
no organic material on the persons hands and if it is in direct contact with 
the bacteria or virus.58 However, this should not be substituted for basic 
hand washing with soap and water.59 
Hospital surfaces are cleaned hourly, daily or weekly depending on if the 
surfaces appear dirty, there are spillages, or after patient discharge. In the 
UK, routine cleaning is performed manually by using basic equipment such 
as mops, wipes, cloths, buckets and brushes.60 Electronic cleaning 
equipment is also utilised (e.g. vacuum cleaners).61 The frequency and 
means of cleaning also depends on the surface itself; whether it is critical 
or non-critical. Critical surfaces include frequently touched surfaces and 
thus, must be cleaned and disinfected more thoroughly and regularly.62 
However, cleaning without a disinfectant merely redeposits the bacteria, 
rather than killing them, and this results in biofilm formation.63 The CDC 
recommends the use of bleach and other chemical disinfectants such as 
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aldehydes, alcohols and quaternary ammonium compounds to eliminate 
microorganisms.64 
Disinfection typically involves the use of chemical agents which eliminate 
most microbes (excluding spores)65 and sterilisation destroys all 
microorganisms by using heat, pressure or chemical methods.64 When 
choosing a sterilant or disinfectant, various factors need to be considered 
for maximum efficiency. These include user acceptability, types of surfaces 
and equipment it will clean, infection rates and their mechanism of 
action.2,64 Biocidal agents have many target sites within the bacterial cell; 
they can penetrate into the cell or interact with the surface, bacterial cell 
wall and the outer membrane. They can cause reversible or irreversible 
changes and cause cell death.66 However, they must be easy to use, safe 
against human cells and should not leave any toxic residues.2 The chemical 
structure, pH and temperature of the biocide can also affect its efficiency. 
Depending on the ability of the biocide to kill bacterial spores, it is 
categorised as either a sterilant or high-, intermediate- or low disinfectant 
(as shown in Table 1.2).62,66  
 
 
Table 1.2  Examples of common disinfectants used in hospitals 
 
Biocides have been used for many years for antiseptic use, including 
ethanol, phenolics, hypochlorites and quaternary ammonium 
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compounds.67 More recently other compounds have been used, including 
chlorhexidine, glutaraldehyde and ortho-phthalaldehyde.68 Disinfectants 
are not always effective in killing all bacteria because some bacteria are 
resistant to these compounds and unproductive cleaning methods are 
frequently employed. Although disinfectants are efficacious against 
vegetative bacteria, most viruses and fungi, the majority of them are not 
active against spores or norovirus. However, aldehyde-based disinfectants 
demonstrate antibacterial activity against several pathogens and spores by 
denaturing proteins and nucleic acids.2,64,66  
Alcohol wipes have been employed on non-critical hospital surfaces and 
clinical devices to assist in reducing microbial load.39 However, in most 
cases they have resulted in cross-contamination as they can spread 
organisms rather than eradicating them on surfaces that are frequently 
touched by patients or staff. Moreover, a single wipe is used many times to 
disinfect a surface before it is discarded.2,39,64 Mops are repeatedly used to 
clean hospital floors, but they can also cause contamination if not used 
appropriately. By using a detergent solution instead of water to rinse mop 
heads, 80% of microbial burden can be reduced.15 Water can act as a 
means for bacteria to spread, thus fresh detergents are more effective and 
should be replaced every 15 minutes when in use.69 
Terminal cleaning is performed after a patient contaminated with a 
pathogen has been discharged. This includes a thorough deep clean of all 
surfaces and the removal of detachable objects, e.g. bedding and curtains. 
All medical equipment should be cleaned before and after patient use, 
regardless of how long or often it is used.39 This is vital as most clinically 
used equipment will be at a high risk of microbial contamination. Wiping 
with alcohols is a sufficient way of disinfecting stethoscopes, for example, 
but this procedure is sometimes overlooked or abandoned when staff are 
overworked.64 Given that many nurses nowadays have taken on duties 
originally carried out by doctors, it is understandable that basic cleaning 
has been overlooked compared to other professional responsibilities. It is 
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also important that the disinfectant is non-toxic towards humans, 
unaffected by organic contaminants and applied with sufficient exposure 
time.70 Therefore, better disinfection strategies need to be developed that 
are self-sufficient and can reduce microbial contamination without the 
constant requirement of manual cleaning.   
 
1.6 Alternative methods to basic cleaning 
Over 50% of hospital sites and surfaces remain untouched by conventional 
manual cleaning methods.71 Due to the continuing transmission of 
microbes in hospital environments, innovative solutions have been 
developed to improve the quality of cleaning as many surfaces remain 
unclean. New disinfection strategies are imperative as bacterial resistance 
to certain disinfectants grows, partly due to the formation of biofilms.72 
Touchless technologies can be used to overcome certain deficiencies of 
manual cleaning by eliminating human labour.73 These include fumigation 
methods74 and self-sterilising surfaces.2,39,75 
 
1.6.1 Ozone 
Ozone is a cheap, highly oxidising agent and is very effective against 
vegetative bacteria but not against fungi and bacterial spores.76 It is 
potentially toxic and corrosive towards metals and rubber, despite rapid 
dissociation into oxygen.77 Studies have shown that the use of ozone in 
laundry decontamination has reduced numbers of E. coli by 5 log1078 and C. 
difficile numbers by >4 log10 on various surfaces.76 An earlier study used 
this gaseous decontaminant in hospital rooms previously occupied by 
MRSA patients; it did not achieve any significant results and also initiated 
respiratory symptoms amongst healthcare workers.79  
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1.6.2 Steam Vapour 
Steam vapour sterilisation machines can efficaciously reduce a wide range 
of bacteria to below detection limits within 5 seconds, including P. 
aeruginosa and MRSA.14 It can be applied to various hard and soft surfaces 
without prior cleaning, reduces cleaning costs and consumes 90% less 
water without the use of harsh chemicals.80 However, there are impractical 
problems when the use of steam is applied to frequently touched surfaces 
such as doorknobs, computers, and other electrical devices.81 Moreover, 
residual moisture from the steam could be a health and safety risk for 
patients and staff, especially on exposed floor surfaces. It may also be 
difficult to use in overcrowded wards and could potentially aggravate 
breathing problems for patients or staff with respiratory conditions.82 Thus, 
steam vapour machines should only be used in well-ventilated areas and 
have been proven effective in non-clinical areas and toilets.36 Ethylene 
oxide gas is widely used for sterilising healthcare instruments and devices.2 
It is exposed to the products in a sealed chamber under vacuum and 
sterilises all accessible surfaces.83 It is highly potent against viruses, 
bacteria and fungi, but must be used carefully due to high toxicity and 
flammability.84 Hydrogen peroxide vapour (HPV) is also used to disinfectant 
clinically used materials and surfaces. It has a low toxicity and can be 
applied to most inanimate materials.2,66    
 
1.6.3 Hydrogen peroxide  
Hydrogen peroxide was first isolated in 1818 and has been used in the 
pharmaceutical industry as a popular substitute for ethylene oxide, 
chlorine dioxide and ozone.64 Several systems containing hydrogen 
peroxide have been used to disinfect hospital wards and have shown to be 
effective as HPV systems and dry aerosols.2 They are able to eradicate 
most, if not all, hospital pathogens, but are costly and have to be operated 
by trained personnel in unoccupied wards.39 Effective hydrogen peroxide 
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decontamination can take several hours to complete39,85 which proves 
difficult for today’s hospitals as most wards are overcrowded and thus, 
cannot be used in specialist units offering 24 hour care services.  
 
1.6.4 Gas Plasma 
Gas plasma is used as an alternative sterilisation method that is mainly 
targeted towards devices rather than surfaces.86 The plasma contains a 
mixture of atoms, ions, electrons, photons and radicals (including ozone, 
atomic oxygen, nitrogen oxides, superoxide and hydroxyl).2 When the 
plasma discharges, the gas enters an ionised state (via electron transfer) 
which results in antibacterial activity.86 Depending on the conditions used 
to form the plasma, there are possible types: thermal and non-thermal. 
Thermal plasmas require a higher pressure and temperature than non-
thermal plasmas.2,87 Its advantages include ease of use, low cost, does not 
require chemical products and is non-toxic to the skin.64 However, its 
bactericidal activity is greatly dependant on exposure time and bacteria cell 
density.2,64 
 
1.6.5 UV Light 
UV irradiation has been used at specific wavelengths to disinfect surfaces, 
medical devices and air.88 UV-C light has a specific wavelength of ~254 nm 
which is within the germicidal range of the electromagnetic spectrum (200 
– 320 nm).88 The effect of UV irradiation is dependent on many factors; 
exposure time, light positioning and intensity, barriers between the light 
and target material and the flow of air movement.39 It has been shown to 
significantly reduce C. difficile spores within 50 minutes89 and vegetative 
bacteria within 15 minutes, but surfaces contaminated with organic soiling 
can hinder the antimicrobial effect.62 Experts have stated that UV light 
should not be used as a replacement for manual cleaning but as a 
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supplementary method.90 UV-C technology would be expensive, and 
similarly to hydrogen peroxide, it would only be operated in an empty ward 
since UV exposure is hazardous to patients. Additionally, it is considerably 
less effective when shielded from the target surface and could potentially 
damage materials, such as polymers, if continually exposed.91 
 
1.6.6 High-intensity narrow spectrum 
High-intensity narrow spectrum (HINS) exhibits microbiocidal activity using 
a narrow bandwidth of high-intensity visible light at 405 nm.92 The 
mechanism of activity is from the photoexcitation of endogenous 
porphyrin molecules within bacterial cells (i.e. porphryinogenic bacteria) 
which produces singlet oxygen and highly reactive species lethal to 
bacteria. HINS light is harmless to humans and was reported to reduce 90% 
of surface bacterial levels of a room occupied by an MRSA-infected burns 
patient.36 
 
1.7 Antibacterial Surfaces 
Using regular cleaning regimes to control infections caused by pathogenic 
microorganisms will not completely eradicate the problem of HAIs, and in 
recent years, there has been a growing interest in the development of 
“self-sterilising” or “self-sanitising” antibacterial surfaces. They were first 
developed in 1964 but were not considered as effective controls for 
minimising the spread of bacteria until years later.39 Once a surface has 
been contaminated, a cyclical problem exists as contamination can spread 
to others in the vicinity and further assist in bacterial transmission.93 
Effective antibacterial surfaces have the potential of preventing the spread 
of infections in a hospital environment between frequently touched 
surfaces, patients and staff (Fig. 1.3). They can reduce microbial burden 
without staff having to spend hours manually cleaning surfaces.  
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There are several types of antibacterial surfaces with coatings that can 
reduce biofilm formation by killing microbes on the surface or by 
preventing bacterial adhesion.94,95  Bacterial growth can be controlled by 
three methods of action: (i) surface contact killing of bacteria by disrupting 
bacterial cell membranes,96 (ii) biocide leaching involving the release of 
cytotoxic species attaching to the bacteria,2 and (iii) anti-adhesion surfaces 
which use super-hydrophobic surfaces to prevent microbial adhesion.97  
 
Fig. 1.3 Role of antibacterial surfaces in preventing HAIs from the direct transfer of 
microorganisms. 
 
1.7.1 Biocide leaching 
Some commercially available antibacterial surfaces operate by effective 
microbiocide leaching to suppress microbial growth. Microban® is a well-
known product that releases an antimicrobial agent known as triclosan [5-
chloro-2-(2,4-dichlorophenoxy)-phenol], making the surface resistant to 
bacterial growth.93 Triclosan leaches from the surface, resulting in a non-
permanent bactericidal activity. This could potentially increase bacterial 
resistance because the active antibacterial agent is continuously leaching 
out.98 However, many liquid soap products, soap bars and toothpastes99 
contain triclosan, as well as common kitchen touch surfaces such as cling 
film and chopping boards.93 Some studies suggest that under UV light 
activation, triclosan produces dioxins that are very hazardous to 
humans.100 Surfacine is another example of biocidal leaching which 
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incorporates silver iodide as the antimicrobial agent. These surfaces can 
reduce bacterial levels by 100 CFU/in2 for up to two weeks and retains 
activity after cleaning.2 The microorganisms are killed by the biocide 
penetrating through the cell and causing cell death from an electrostatic 
interaction between the compound and the bacteria.101 
 
1.7.2 Antimicrobial polymers 
Antimicrobial polymers reduce microbial growth by either incorporating 
biocides or antibiotics on the surface or by inherently killing the 
microorganisms.102 Chitosan is widely used in the medical field due to its 
intrinsic antimicrobial ability. It is a linear polycationic hetero 
polysaccharide copolymer of β-1,4-linked D-glucosamine and N-acetyl-D-
glucosamine, obtained from partial alkaline N-deacetylation of chitin.103 
Gram-negative bacteria are more susceptible to chitosan than Gram-
positive bacteria because Gram-negative bacteria have a more negatively 
charged surface that allows chelation and electrostatic interaction between 
the polymer and bacterial cell wall.104 Gram-positive bacteria have a more 
stable cell wall structure as they contain a polyanionic lipoteichoic acid.105 
Nitrogen-containing polymers, such as quaternary ammonium compounds 
(QACs) possess antibacterial activity from an electrostatic interaction 
between the bacterial cell wall and the positively charged QAC, followed by 
denaturation of structural proteins and enzymes from the integration of 
the hydrophobic QAC tail into the bacterial hydrophobic membrane.106 
QACs with 12-14 alkyl chains are highly effective against Gram-positive 
bacteria.107 Antimicrobial polymers are suitable materials for frequently 
touched surfaces in hospitals as they can be applied to a diverse range of 
objects. 
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1.7.3 Anti-adhesive coatings 
Extremely hydrophobic or hydrophilic materials are an effective way to 
prevent microbial adhesion because the bacteria cannot colonise a surface 
to form biofilms. A way to measure hydrophobicity or hydrophilicity is by 
measuring the water droplet contact angle on a surface.108 Ideally, self-
cleaning surfaces require a contact angle less than 10o (superhydrophilic) 
or greater than 140o (superhydrophobic).109 Generally, smoother surfaces 
are much harder to colonise than rough surfaces.93 One way of preventing 
microbial adhesion is by coating the surface with a layer of poly(ethylene 
glycol) (PEG), from hydrophilic interactions with the hydrophobic bacterial 
cell membrane.102 PEG and PEG-modified surfaces are well established for 
reducing microbes and can inhibit bacterial adhesion by up to 3 log10.93 
Polymers with zwitterionic head groups can also inhibit microbial adhesion 
and biofilm formation.110 It is proposed that zwitterionic heads can 
accumulate large amounts of water, making the surface hydrophilic. This 
causes reversible reactions between the surface and bacterial cells which 
inhibit bacterial adhesion.111 These surfaces can potentially be used to coat 
catheters and other medical devices as they produce an effective barrier 
towards biofilm formation that can prevent catheter-related infections.95  
 
1.7.4 Silver-coated surfaces 
The antibacterial properties of silver have been exploited for centuries; for 
example, the Greeks and Romans used silver coins to store water.112 In the 
1900s, 1% silver nitrate solution was used to prevent blindness from eye 
infections in newborns.93 Silver ions (Ag+) can bind to thiol groups (-SH) in 
the bacteria and affect the cell wall and membrane, causing inhibition of 
cells.113 The antibacterial activity of silver is somewhat dependent on 
surface area of the particles, thus silver nanoparticles are favoured.114 
However, Ag+ ions do not confer long-term antibacterial activity because 
silver is used up in the process. Silver nanoparticles have been used to 
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inhibit environmental contamination and colonisation of bacteria on 
medical devices and catheters.115  
 
1.7.5 Copper and copper alloy surfaces 
Metallic copper surfaces have been investigated for antibacterial 
properties. Some reports have shown copper surfaces to reduce bacterial 
contamination from hospital pathogens by 7 log10 within 2 hours.39 
Another study reported that the risk of HAIs reduced by 58% in ICU rooms 
fitted with copper alloy surfaces.116 Copper is highly toxic towards bacterial 
cells; it can bind to proteins, cause oxidation stress via the production of 
hydrogen peroxide and disrupt osmotic balance in the cells.117 
 
1.7.6 Light-activated antibacterial surfaces 
Bactericidal polymers can be very effective at killing bacteria by 
incorporating light-activated antimicrobial agents (LAAAs) into the polymer 
substrate and onto the surface.93 Unlike most antibacterial agents, they do 
not target specific areas within a microorganisms and thus, avoid the 
potential problem of bacteria developing resistance towards this 
treatment.119 These antibacterial polymers kill microbes by producing 
reactive oxygen species (ROS) which are produced by the interaction of a 
photosensitiser with light119,120 (described in detail in Chapter 2).  Clinical 
studies have shown that LAAAs are able to kill bacteria, viruses and fungi 
that are on, or up to a distance of 0.65 mm from the illuminated 
antibacterial surface, due to the production of free radicals.120 There are 
two main types of antibacterial surface coatings that utilise LAAAs: (1) 
coatings containing titanium dioxide (TiO2)-based catalysts93 and (2) 
coating surfaces with a photosensitiser.93,118-120 These LAAA systems can 
significantly reduce bacterial adhesion and prevent biofilm formation of a 
wide range of hospital pathogens.120 
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1.7.6.1     Titanium oxide-based antibacterial surfaces 
TiO2 is the most widely used photocatalyst (a substance that generates 
catalyst activity using energy from light)121 with the ability to retain 
maximum antibacterial activity against pathogens during light activation. 
Unlike antibiotics or the use of silver-containing surfaces, these self-
sterilising surfaces are non-specific so organisms are unable to evolve 
resistance against them. Studies have shown a reduction of MRSA 
contamination with TiO2 treatment in a clinical environment.122 The 
mechanism (Fig. 1.4) in which this semiconductor kills the bacteria is by 
absorbing light, which then promotes an electron from the valence band 
into the conduction band; creating an electron (-) and a positive hole (+). 
The electron and hole pair creates reactions at the surface to produce 
singlet oxygen that can then interfere with the bacterial cell wall causing 
cell damage.123  
 
 
Fig. 1.4 Photo-excitation processes of TiO2. 
 
The main drawback of TiO2-based self-sterilising surfaces is that they 
require UV light activation to kill bacteria, as TiO2 has a band onset of ~3.2 
eV.124 Therefore, these surfaces would be more effective on the outside of 
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buildings where UV light is abundant rather than inside buildings where it is 
less so. For this reason, TiO2 can be modified to be photocatalytically active 
under visible light rather than UV light.93 This can be achieved by doping 
elements such as nitrogen, sulphur or carbon into the TiO2 structure.123 
Additionally, metal nanoparticles (e.g. Ag) can be coated onto the TiO2 
surface to shift the band onset so that the surface can absorb photons of 
wavelength above 385 nm and operate as a photocatalyst under visible 
light.93,123  
 
1.7.6.2     Dye-based antibacterial surfaces 
Light-activated organic dyes, known as photosensitisers, can be 
incorporated into surface coatings to reduce bacterial contamination by 
producing highly reactive radical species and/or singlet oxygen via two 
photochemical mechanisms: Type I (electron transfer) and Type II (energy 
transfer).125-130 Non-toxic photosensitisers have also been incorporated 
into catheters for preventing catheter-associated infections and have been 
reviewed extensively by Noimark et al.131 A detailed description of photo-
activated surfaces will be given in Chapter 2. 
 
1.7.7 Concerns over antibacterial surfaces 
Antibacterial surfaces are highly effective at reducing common 
microorganisms found in hospitals, but more studies need to investigate 
the bactericidal effects of these samples against more resistant bacteria, as 
well as C. difficile spores. More information needs to be provided on the 
overall cost-effectiveness of these surfaces, including their long-term 
durability and whether antibacterial activity is affected by temperature, 
humidity, organic contamination and the frequency of cleaning.  
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The increased rate of HAIs and antimicrobial resistance presents a global 
threat to the healthcare industry as many infections are becoming more 
difficult to treat. Various hospital pathogens have become resistant to 
multiple antibiotics, which greatly affects immunocompromised and elderly 
patients. There is a lack of cleanliness and hygiene that has resulted in 
contamination between patients, staff and hospital surfaces. Although 
prevention strategies are in place, alternative cleaning and disinfection 
methods are required to combat nosocomial infections. This chapter has 
detailed many alternative methods to basic cleaning and introduces the 
use of antimicrobial surfaces, in particular, light-activated antimicrobial 
surfaces. The following chapter highlights the mechanism by which these 
photo-activated surfaces operate, as well as incorporating nanoparticles 
into these surfaces for an enhanced bactericidal effect.  
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Chapter 2 
2. Photo-Activated Surfaces 
 
2.1 Introduction to Photodynamic Therapy 
The previous chapter introduced the topic of HAIs and the impact they 
have on the livelihood and wellbeing of hospitalised patients. Globally, 
hospitals are faced with many challenges, as HAIs remain a major cause of 
patient morbidity and mortality. The chapter also assessed the advantages 
and disadvantages of various cleaning and sterilising strategies that are 
already employed by hospitals and introduced new techniques to disinfect 
contaminated surfaces and medical devices. Moreover, the development 
and use of antimicrobial surfaces in hospitals was discussed as an 
efficacious approach for reducing the risk of HAIs. This chapter details the 
use of novel photo-activated surfaces to kill bacteria using a phenomenon 
known as photodynamic therapy (PDT); a multi-stage process that requires 
the presence of molecular oxygen and uses non-ionising visible light. It 
then discusses the development of light-activated polymers and introduces 
the incorporation of nanoparticles into these surfaces for an enhanced 
bactericidal response.  
Light has been used to treat diseases for many centuries, tracing back over 
4000 years to the ancient Egyptians.1 They used the combination of 
sunlight and the Amni Majus plant to successfully treat a skin disorder, 
known as vitiligo. The active ingredient of this plant (psoralen) is now used 
globally to treat psoriasis.2,3 PDT was accidentally discovered by a medical 
student named Oscar Raab in 1900 whilst studying the interaction of 
fluorescent dyes with infusoria (microscopic organisms found in fresh 
water and infusions of organic matter).4 He reported rapid destruction of a 
Paramecium species when exposing acridine dye to high intensity light.5 
Soon after, patients were being treated by this process for cancers, 
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particularly of the skin.6 Despite this breakthrough, PDT remained 
neglected for nearly 50 years but was reassessed by Lipson and Schwartz in 
1960, who revealed that photosensitising agents were capable of ablating 
tumour tissue from the body following intravenous administration.7,8 Then 
in the 1970s, Thomas Dougherty reinvigorated PDT when studying 
porphyrin compounds and helped publicise PDT worldwide by creating a 
commercially available photosensitising drug, known as ‘haematoporphyrin 
derivative’.9  
PDT is distinct from conventional phototherapy which only uses light, and 
requires the combination of a photosensitiser, molecular oxygen and light 
tuned to a wavelength that is efficiently absorbed by the photosensitiser. 
PDT is commonly used to destroy cancerous tissues by using a 
photosensitiser that is activated by light at a specific wavelength, most 
commonly in the red or near-infrared where absorption by haemoglobin 
and other tissue chromophores is weak.10 Porphyrins and phthalocyanines 
were the first photosensitive molecules identified in the mid-nineteenth 
century. Porphryins typically contain four pyrrole rings connected by 
methine bridges in a cyclic formation and phthaloycanines are connected 
by aza bridges.11 As well as tetrapyrrole-based photosensitisers, non-
tetrapyrrole-based photosensisiters are also used, which can be xanthene- 
or phenothiazine-based.12 Examples of photosensitisers used in PDT (Fig. 
2.1) include PhotofrinTM, a purified form of haematoporphyrin derivative, 
methylene blue (MB), toluidine blue O (TBO), crystal violet (CV) and Rose 
Bengal (RB).  One major advantage of PDT is that photosensitisers can be 
administered in a number of ways, such as injected, applied to the skin, or 
used as a device or surface coating.13 Additionally, it avoids the potential 
development of microbial resistance as PDT operates via non-specific 
mechanistic pathways14 (as described in section 2.1.2). 
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Fig. 2.1 Chemical structures of tetrapyrrole based and non-tetrapyrrole based 
photosensitisers used in PDT. 
 
PhotofrinTM has successfully been used in clinical practice to treat a range 
of tumours and viral infections, especially human papilloma virus (HPV), 
when activated by red light at 630 nm.15,16 Few clinical trials have been 
carried out to show the effect of PDT in localised bacterial infections, but 
one study demonstrated a positive clinical response in patients with brain 
abscesses after activating hematoporphyrin for 5 minutes.14,17 A clinically 
approved application of antimicrobial PDT is treating oral infections. In 
dentistry, one of the most common bacterial diseases for humans is 
periodontal disease, which is a chronic inflammatory condition of the gum 
and bone support surrounding the teeth.17 To treat this disease, the 
PhotofrinTM 
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photosensitiser is injected in the target area and light is delivered to the 
area using a narrow fibre optic tip. PDT with TBO and a 660 nm laser was 
effective in treating patients with aggressive periodontitis.16 Furthermore, 
PDT is used in the sterilisation of root canals in children’s primary teeth 
with necrotic pulps.18    
 
2.1.1 Photochemistry 
 
Fig. 2.2     Modified Jablonski diagram displaying the electronic states (S0, S1, Sn, T0, T1, Tn) 
of a photosensitiser after the absorption of a photon. Non-radiative transitions are 
labelled as follows: internal conversion (IC), intersystem crossing (ISC), vibrational 
relaxation (VR). Diagram also shows the production of singlet oxygen (1O2) via resonant 
electronic energy transfer. 
 
When a chromophore (part of a molecule responsible for colour) absorbs a 
photon in the form of light energy, an electron is promoted into a higher-
energy molecular orbital, and the chromophore is excited from the ground 
state (S0) into a short-lived, electronically excited state (Sn), generally a 
singlet state with no net electronic spin.19,20 The chromophore in its excited 
state can lose energy by decaying rapidly to populate their lowest 
vibrational levels (S0 or S1) by non-radiative and radiative transitions 
(illustrated in Fig. 2.2).21  
 42 
2.1.1.1 Non-radiative transitions 
Vibrational relaxation (VR) is a non-radiative transition that occurs when a 
molecule in a high vibrational level of an excited state (Sn) rapidly falls to 
the lowest vibrational level of this state.22 It only occurs between levels of 
the same vibrational progression.22,23 Internal conversion (IC) occurs when 
a molecule falls from an excited singlet state (Sn or S1) to a lower or ground 
state (S1 or S0). Intersystem crossing (ISC) is a spin-forbidden process in 
quantum mechanics due to changes in electron spin; from S0 or S1 
(antiparallel) to an excited triplet state (T1; parallel).24 
 
2.1.1.2 Radiative transitions 
Fluorescence (S1  S0) is a radiative transition that results from decay of 
the excited singlet state (S1) to the ground state (S0). The lifetime of this 
transition is very short (10-9 – 10-6 seconds) since it is considered an 
“allowed” transition (same spin states: either S  S or T  T).8 
Alternatively, the singlet state electron (S1) can undergo ISC and populate 
the lower-energy first triplet state (T1); a spin-forbidden process.25-27 This 
excited electron can then undergo another spin-forbidden transition by 
depopulating the excited triplet state (T1) and decaying to the ground state 
(S0). This process is known as phosphorescence and has a much longer 
lifetime than fluorescence (10-3 – 1 second) because it undergoes a spin-
forbidden transition (T1  S0).25-27 
 
2.1.2 Mechanism of action 
PDT is a photochemical process that uses non-thermal power densities.8 
After the absorption of light (photons) the photosensitiser (PS) is 
transformed from its ground singlet state (S0) to the relatively long-lived 
electronically excited triplet state (T1), via ISC from the short-lived excited 
singlet state (S1).28 The triplet state can undergo two different reactions. 
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The first is a direct reaction between the excited singlet state or triplet 
photosensitiser (1PS* [S1]; 3PS* [T1]) with oxygen or a substrate, resulting in 
the transfer of electrons to form radicals and other reactive oxygen species 
(ROS), which is known as the Type I process.29 Alternatively the triplet state 
photosensitiser (3PS* [T1]) can transfer its energy directly to ground state 
triplet oxygen (3O2) to form excited state singlet oxygen (1O2), which is 
known as the Type II process.30 These photochemical pathways are 
summarised in Fig. 2.3(a). 
In a Type I process, an electron is transferred from the substrate to the 
excited state photosensitiser (PS*), which generates a substrate radical 
cation (Subs.+) and a photosensitiser radical anion (PS.-).8,30 Further 
reactions with oxygen produce a complex mixture of ROS (shown in Fig. 
2.3(b)). Only when the photosensitiser is in its excited state (3PS*) can it 
interact with molecular oxygen (3O2; T1) to produce singlet oxygen (1O2; S1), 
as it is a spin-allowed transition.30,31 This Type II scheme is shown in Fig. 
2.3(b).  
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Fig. 2.3 (a) Simplified Jablonksi diagram displaying the processes involved in photodynamic 
therapy when a photo-excited photosensitiser undergoes energetic transitions after the 
absorption of a photon. The photosensitiser in its excited singlet state can undergo 
radiative decay (fluorescence) or non-radiative decay via internal conversion, or convert 
to the excited triplet state via intersystem crossing. The triplet state molecule can decay 
radiatively by phosphorescence, non-radiatively via internal conversion, or interact with 
molecular oxygen via resonant energy transfer (Type II process) or other substrate 
molecules via electron or proton transfer (Type I process). (b) Common reactions involved 
in Type I and Type II processes. 
 
(a) 
(b) 
TYPE I Process 
PS* + Substrate  PS.- + Substrate.+ox 
PS.- + O2  PS + O2.- 
PS* + O2  PS.+ + O2.- 
2O2.- + 2H+  3O2 + H2O2 
O2.- + Fe3+  3O2 + Fe2+ 
Fe2+ + H2O2  Fe3+ + OH. + OH- 
O2.- + OH.  1O2 + OH- 
 TYPE II Process 
3PS* + 3O2  1PS + 1O2 
1O2 + Substrate  Oxidative damage 
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Both Type I (electron transfer) and Type II (energy transfer) mechanistic 
pathways can occur simultaneously but the ratio of these processes are 
dependent on the type of photosensitiser and the concentration of 
substrate and oxygen.32 The photosensitiser requires a good triplet state 
quantum yield and a long triplet state lifetime in order to promote Type I/II 
processes.11 The quantum yield is defined by the efficiency of a 
photochemical process,33 i.e. the number of molecules undergoing a 
process for each quantum of radiation energy absorbed.30 Superoxide 
anion (O2.-) is generally produced via a Type I pathway involving electron 
transfer. Superoxide is relatively ineffective at causing oxidative damage on 
its own compared to singlet oxygen, but it can undergo dismutation to 
produce oxygen and H2O2, (as shown in Fig. 2.4) which can pass through 
bacterial cell membranes to cause oxidative damage.29  
 
 
Fig. 2.4 Superoxide dismutation reaction. 
 
O2.- can also act as a reducing agent to produce ROS by a Fenton reaction 
process discovered over 100 years ago.34 Superoxide donates an electron 
to reduce metal ions (e.g. ferric ion or Fe3+) that catalyses the conversion of 
H2O2 into highly reactive hydroxyl radicals (.OH).35 The Fenton reaction is 
important in biological systems because the cells contain small amounts of 
metal (e.g. iron or copper) which can facilitate this process.36 The reduced 
metal ions, e.g. ferrous Fe2+ ions, induce the decomposition of H2O2 to 
produce .OH and a hydroxide ion (OH-). Moreover, superoxide anions can 
react with the hydroxyl radical to produce highly reactive singlet oxygen (a 
secondary process).35,36  
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Singlet oxygen and hydroxyl radicals are extremely reactive and have very 
short half-lives, so only cells that are in close proximity to the 
photosensitiser are directly affected by PDT.30 Although singlet oxygen has 
a net spin of zero, the highest energy electrons are in degenerate states 
(unpaired), therefore, it is highly reactive.37 The half-life of singlet oxygen 
in biological systems is < 40 ns and the radius of action of singlet oxygen is 
in the order of < 20 nm.38 It attacks unsaturated bonds in particular which 
are most vulnerable (i.e. aromatic compounds, amino acids, unsaturated 
lipids).39,40  
Photosensitisers can also undergo degradation upon light exposure, 
leading to a process known as ‘photobleaching’ or ‘photodegradation’.30 
Photobleaching occurs when singlet oxygen or ROS produced by light 
activation react with the photosensitive molecule resulting in its oxidation 
thereby decreasing its photosensitisation efficiency, unless there is a 
photoactive product with comparable absorbance characteristics.41   
For clinical use photosensitisers should exhibit minimal toxicity towards 
mammalian cells42 and absorb light in the red or far-red wavelength range 
to penetrate tissue.30 They should also be targeted appropriately so that 
the treatment is pain-free.16 Absorption bands at wavelengths greater than 
800 nm generally entails that the triplet state will have insufficient energy 
for the photosensitiser to transfer energy to oxygen to form singlet oxygen 
(energy threshold of 94 kJ/mol).30  
PDT is particularly advantageous for antimicrobial application because 
there is a low risk of developing bacterial resistance.43 When illuminated, 
ROS generated from the photosensitiser can attack the bacteria at multiple 
sites at a cellular level.29 Although bacterial cells have many natural 
defences against ROS, the level of redox imbalance caused by PDT is usually 
greater than the level of protection given by enzymes and molecular 
antioxidants within the cell.29 Bacterial cells are capable of defending 
themselves against H2O2 and superoxide anion radicals, but cannot 
naturally deactivate singlet oxygen or hydroxyl radicals.44  
 47 
A positively charged photosensitiser is more effective at inactivating 
bacteria and even spores, as they are able to interact with negatively 
charged bacterial cell walls.12 Gram-positive bacteria were shown to be 
more susceptible to PDT compared to Gram-negative bacteria, presumably 
as a result of differences in their cell wall structures (Fig. 2.5).45 The 
photosensitiser is able to penetrate through a Gram-positive bacteria cell 
wall as it has a single thick peptidoglycan layer,46 whereas Gram-negative 
bacteria consist of a thinner peptidoglycan later with an inner and outer 
membrane.12 The outer membrane can prevent binding and penetration of 
the photosensitiser.47  
 
2.2 Antibacterial Action of Nanoparticles 
2.2.1 Use of nanoparticles in a clinical environment 
Conventional antibiotic treatments for reducing HAIs are becoming less 
effective against multi-drug resistant bacteria. Advances in nanoscience 
and nanotechnology have resulted in novel nano-sized materials which 
have the potential of replacing antibiotics within hospitals due to their 
distinct functional properties.48 In particular, the bactericidal effect of 
metal or metal oxide nanoparticles is of particular interest since they can 
be immobilised or coated onto surfaces for various applications, such as 
antibacterial surfaces,49 medical devices,50 food processing51 and water 
treatment.52  
Due to their high surface area-to-volume ratio, nanoparticles exhibit 
different biological properties (e.g. accumulation within the cell tissue),53 
chemical properties (e.g. increased reaction rate)54 and physical properties 
(e.g. increased absorption or diffusion rates)55 compared to the bulk 
material. It has been extensively reported in the literature that smaller 
nanoparticles (< 100 nm) exhibit better antibacterial activity.56-58 The 
bactericidal mechanism of nanoparticles is specific to a particular bacterial 
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species, i.e. the antibacterial efficacy is dependent on the bacterial cell 
structure.57  
The bacterial cell wall is intended to protect the cell from mechanical 
damage and osmotic rupture by providing strength, shape and rigidity.59 As 
previously described, the bacterial cell wall can either be categorised as 
Gram-positive or Gram-negative.60 Gram-negative bacterial cell wall 
structures are more chemically and structurally complex than Gram-
positive. The outer membrane of Gram-negative bacteria contain 
lipopolysaccharides which increase the overall negative charge of cell 
membranes and maintain structural integrity of the bacteria61 (Fig. 2.5). 
Furthermore, Gram-negative bacteria are more resistant to hydrophobic 
compounds (e.g. detergents).62 Similarly to photosensitisers, the bacterial 
cell wall structure plays a crucial role in determining the ability of 
nanoparticles to penetrate into the cell.63 
 
 
Fig. 2.5 Gram-positive and Gram-negative bacterial cell wall structure. 
 
Additional factors can influence the susceptibility of bacteria to 
nanoparticles, such as the type of nanoparticle64 and the bacterial growth 
rate.65 Some studies have shown that E. coli is more susceptible to CuO 
nanoparticles than S. aureus48 and it has been reported that the 
antibacterial activity of Ag nanoparticles is greater than Cu nanoparticles 
against both Gram-positive and Gram-negative bacteria.66 Fast-growing 
bacteria are more susceptible to nanoparticles than slow-growing bacteria, 
Gram-positive Gram-negative 
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possibly because the tolerance of slow-growing bacteria is related to the 
expression of stress-response genes.67 
 
2.2.1.1  Antibacterial mechanism of nanoparticles 
The exact antibacterial mechanism of nanoparticles is not completely 
understood. There are a number of ways in which nanoparticles are 
reported in the literature to kill bacteria, e.g. disruption/penetration of the 
cell,58 electrostatic interaction,57 or generating ROS, causing permanent 
damage and eventually cell death (summarised in Fig. 2.6).68 ROS 
generation is considered the most effective means of nanoparticle 
bactericidal activity as it produces severe oxidative stress causing DNA 
damage.69 When ROS production is activated by UV or visible light, the 
toxicity of nanoparticles is photocatalytic (e.g. TiO2).70 
 
 
Fig. 2.6 Different possible mechanisms of toxicity of nanoparticles against bacteria, 
including: reactive oxygen species (ROS) production, ion release, protein and DNA damage 
and disruption of the cell membrane.  
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Various metal and metal oxide nanoparticles have been studied for their 
antibacterial activity which may find applications in the medical field. These 
include silver, gold, iron, titanium dioxide, copper, zinc oxide and 
magnesium oxide. Silver has been exploited for its antibacterial properties 
for many years and is used in a range of applications such as wound 
dressing,71 disinfecting water72 and for coating medical devices.73 The 
antibacterial activity of silver nanoparticles (Ag NPs) is size-dependent74 
and operates via ROS production causing structural changes in the cell 
membrane and ultimately cell death.75 However, the main proposed 
mechanism of action of Ag NPs is considered to be the release of silver 
ions.76 Ag NPs have shown to be very effective in preventing biofilm 
formation of E. coli and S. aureus77 and exhibit no significant cytotoxicity 
towards mammalian cells.78  
Gold nanoparticles (Au NPs) have limited bactericidal effects on their own 
but when they are bound to antibiotics, such as ampicillin and vancomycin, 
they demonstrate an enhanced activity of the antibiotic against Gram-
positive and Gram-negative bacteria.79 Titanium dioxide is the most 
commonly studied antibacterial metal oxide nanoparticle and was first 
discovered to reduce levels of E. coli in 1985.58 The main bactericidal 
mechanism of TiO2 nanoparticles is the production of ROS in the presence 
of UV light (Fig. 1.4, Chapter 1).68 Various studies have focused on 
activating TiO2 with visible light by metal doping (e.g. Ag, Fe3+, Cd or 
NiO).72,80-82 
 
2.2.2 Copper nanoparticles 
Metallic copper has been widely used as an antibacterial surface agent, 
though only a few studies have reported the antibacterial effects of copper 
nanoparticles (Cu NPs). Metallic nanoparticles are reported to exhibit 7 – 
50 times less toxicity towards mammalian cells than their ionic forms.83 
Copper is cost effective to produce and has been used for centuries to 
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sterilise liquids, textiles and human tissue.84 The availability of copper has 
made it a better alternative to other expensive noble metals, e.g. silver and 
gold.85 Cu NPs have shown a high antibacterial effect against P. aeruginosa, 
S. aureus, E. coli, viruses and fungi,86 but a low toxicity against humans 
which makes them appropriate for creating wound healing products87 and 
for impregnation into antibacterial surfaces in hospitals.88 
They have been prepared using a range of methods, such as thermal 
reduction,89 chemical reduction, vacuum vapour deposition and microwave 
irradiation methods.90 These methods use oxygen-free conditions to 
synthesise the nanoparticles as they rapidly oxidise to Cu2+ ions in air or 
aqueous media.72 Thus, it is vital that a method is developed which can 
stabilise Cu NPs to prevent oxidation and agglomeration. Nanoparticles 
readily aggregate because they have a high surface energy that prevents 
effective dispersion into solutions or polymer matrices.91 Alternative 
methods have been used to synthesise Cu NPs in the presence of polymers 
(e.g. chitosan,92 polyethylene glycol93) or surfactants (e.g. cetyl trimethyl 
ammonium bromide) as stabilisers to form coatings around the 
nanoparticle surface.94 
The exact bactericidal mechanism of Cu NPs is not fully understood. Their 
small size and high surface-to-volume ratio allows a close interaction with 
bacterial cell membranes to alter their permeability and cause irreversible 
cell damage.58 Moreover, they can generate ROS that cause severe 
oxidative damage to the cell structure.95 Cu2+ ions can be released from the 
nanoparticle surface that are adsorbed on the cell membrane from 
electrostatic interaction, causing DNA damage in the bacteria and 
ultimately cell death.96  
 
2.2.3 Magnesium oxide nanoparticles 
Magnesium oxide nanoparticles (MgO NPs) are advantageous compared to 
other bactericidal agents because they are odourless, non-toxic towards 
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human cells at low concentrations, and can be synthesised from 
economically and commercially available precursors and solvents.58 They 
are multi-functional and can be used in catalysis, catalyst supports,79 
superconductors and lithium ion batteries, and removing pathogenic 
microorganisms from toxic wastewater.97 In medical applications, MgO NPs 
have been used for bone regeneration,98 treating heartburn and sore 
stomachs, and more recently they have been used in tumour treatment.99 
MgO NPs have a wide band gap and exhibit antibacterial activity without 
photo-activation (unlike TiO2).97 It has been reported that the size and 
shape of MgO NPs gives them a high surface reactivity as they contain a 
high concentration of edge/corner sites and structural defects on the 
surface.99 Some studies suggest that Mg2+ ions can cause cell death when 
released into solution,72,100 whilst others have found no inhibition of E. coli 
or S. aureus from ion release.79 It has been proposed that active superoxide 
ions are generated on the surface of metal oxides, such as MgO NPs, which 
react with peptide linkages in bacteria cell walls and cause disruption. An 
increase in the production of superoxide ions is caused by an increase in 
surface area of the nanoparticles.97 
Many methods have been used to synthesise MgO NPs, including sol-gel, 
chemical vapour deposition and thermal evaporation.101 The sol-gel 
method is very common for producing MgO NPs because it prepares 
controlled homogenous particles at a low cost.91 Additionally, magnesium 
fluoride nanoparticles (MgF2 NPs) can prevent biofilm formation of 
common bacterial pathogens such as E. coli and S. aureus.79 MgF2 NPs 
attach and penetrate into the bacterial cells; causing disruption in the 
membrane potential, inducing membrane lipid peroxidation and 
interacting with chromosomal DNA.62,79 
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2.2.4 Zinc oxide nanoparticles 
Zinc oxide nanoparticles (ZnO NPs) are relatively cheap102 and exhibit 
effective size-dependent antimicrobial activity against many bacteria, 
viruses and fungi, including E. coli, S. aureus, MRSA and Klebsiella 
pneumonia.68 The antibacterial activity of ZnO NPs has attracted much 
biomedical interest as the nanoparticles show toxicity towards bacteria but 
exhibit minimal effects on mammalian cells. They are widely used for 
bioimaging,103 drug delivery,103,104 and as effective bactericidal agents 
against food-borne pathogens in food packaging.105 ZnO NPs have a wide 
band gap (3.3 eV) in the near-UV region, which affects the electrical 
conductivity and optical properties.106 They have a high optical absorption 
in the UV region and are consequently used as a UV protector in 
cosmetics.107 
ZnO is highly photocatalytic and is more biocompatible than TiO2.108 It can 
strongly absorb UV light which enhances the conductivity and causes a 
better interaction between the bacteria and nanoparticles.107 There are 
many proposed mechanisms of the antibacterial activity of ZnO NPs, 
including the disruption of bacterial cell membranes107 and photo-oxidative 
stress induced by ROS generation.109 Some reports suggest that ZnO NPs 
generate hydroxyl and superoxide anion radicals under UV or visible light 
activation.69 A recent study reported that the antibacterial activity of ZnO 
NPs is partially due to Zn2+ release. These experiments were conducted in 
the dark so there was minimal photoactivated ROS generation.68 Some 
studies suggest that ZnO NPs are less toxic towards Gram-positive bacteria 
due to the presence of a thicker peptidoglycan layer,57 but many other 
studies contradict this, demonstrating a lower susceptibility towards Gram-
negative bacteria presumably due to the outer cell membrane.57,107 
The toxicity of ZnO NPs is dependent on their morphology, which is 
determined by synthetic conditions.110 Therefore, optimal antibacterial 
response of these nanoparticles can be obtained by controlling parameters 
such as solvent type, precursor type, temperature and pH.107 The surfaces 
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of ZnO NPs contain many defects that are potential reactive surface sites. It 
has been suggested that the abrasive surface of ZnO is responsible for its 
antibacterial properties.111 ZnO NPs were coated onto silicone wafers and 
incorporated into polyvinyl chloride (PVC) to study their effect against 
biofilm formation.107 The results indicated 20 - 50% reduction of biofilm 
growth against E. coli and S. aureus.57,107   
 
2.3 Dye and nanoparticle-incorporated polymers 
Aqueous solutions of photosensitisers are highly effective for killing 
hospital pathogens following light activation via the formation of oxygen-
derived, cytotoxic ROS.112 In cellular environments, these ROS can result in 
cell death and destruction of tissues.30 Photosensitisers are taken up into 
cells all over the body and are harmless in the absence of light (and usually 
oxygen), where they have no effect on healthy tissue.11 Preferably, light 
activation should be controlled so that photoactivation only occurs when a 
higher concentration of the photosensitiser is present in the diseased 
tissue and does not cause damage to surrounding, non-cancerous cells.113 
When exposed to bacteria, photosensitisers are very effective at killing the 
bacteria following light exposure, which has led to the idea of coating 
photosensitisers onto polymers since ROS can migrate from the polymer to 
the bugs. By coating the polymer with the photosensitiser, the 
photosensitiser then becomes less harmful to surrounding tissue/skin 
compared to aqueous solutions of the dye where the dye is able to enter 
cells.  
The ROS generated are unlikely to cause bacterial resistance, unlike 
antibiotics, as they attack microorganisms by multiple pathways rather 
than having a specific mode of attack.112,113 At concentrations lethal to 
bacteria, photosensitisers exhibit minimal toxicity against mammalian cells 
following light activation.114 Various metal and metal oxide nanoparticles 
demonstrate significant antibacterial activity against bacteria with or 
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without light activation.79,115 One possible mechanism of action of these 
nanoparticles is the generation of ROS, but they can also kill bacteria by 
electrostatically interacting with the cell membrane from the leaching of 
ions and causing damage by penetrating through the cell membrane.116 It is 
possible to further enhance the antibacterial properties of photosensitisers 
and nanoparticles by combining them together in polymers to produce 
light-activated antibacterial surfaces.112-114 
 
2.3.1 Polymer types 
The material of antibacterial surfaces or medical devices in hospitals should 
be biocompatible and perform its intended function without causing 
unwanted side effects. It is important to consider physical properties of the 
material (i.e. surface roughness and rigidity)117 as well as chemical 
properties (allergenic or toxic).88 For invasive medical devices, such as 
catheters, the material must not cause any side effects to the body that 
will alter its primary function.118-119 
 
2.3.1.1 Polyvinyl chloride 
Polyvinyl chloride (PVC) is produced by addition polymerisation of vinyl 
chloride monomer. The pure plastic is relatively hard and rigid, thus, 
chemicals (e.g. plasticisers) are added to make PVC more soft and 
pliable.120 As the plasticisers are not chemically bound to the polymer, they 
can induce acute inflammatory reactions in vivo if they leach.121 PVC 
polymers have been commercially available for around 50 years and are 
considered as a ‘mature product’. Recently, novel materials have been 
introduced, including PVC alloys and ultra-high molecular weight PVC 
polymers that do not require additional plasticisers.122 
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2.3.1.2 Silicone 
Silicone, also known as polydimethylsiloxane (PDMS), is a widely used 
biomaterial and has been used as a medical device coating for many years. 
It is durable, hydrophobic, chemically and thermally stable and has a low 
surface tension.123 Silicone remains unaffected by repeated autoclaving 
and can also be dry-heat sterilised.124 Studies comparing silicone and PVC 
catheters found that silicone catheters performed much better and 
maintained their physical properties and flexibility over time.125 However, 
silicone is more expensive than other materials such as latex and PVC.124 
 
2.3.1.3 Polyurethane 
In Western Europe, thousands of tonnes of polyurethane products are 
manufactured each year for medical device applications.126 They are used 
for surgical prostheses, catheters, artificial heart, kidney and blood vessels 
and are replacing silicone in maxillofacial surgery.127 Moreover, 
polyurethane elastomers are used in formulating haemostatic coatings and 
biomedical adhesive systems.122 More flexible polyurethane foams are 
used in producing bandages, surgical dressings and absorbent materials for 
general hospital practice.128 This polymer is biocompatible and has 
replaced silicone in some catheters as it can be more comfortable for 
patients.124 
  
2.3.2 Overview of the research at the Materials Research Centre, UCL 
Self-sterilising antibacterial surfaces can assist in significantly reducing 
HAIs, as basic cleaning methods are ineffective against emerging multi-drug 
resistant bacteria. The Materials Research Centre at University College 
London (UCL) has developed several photo-activated surfaces and tested 
them against a range of Gram-positive and Gram-negative bacteria under 
different lighting conditions (e.g. laser, UV, visible light and in the dark).113 
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Some materials have been designed to combat catheter-associated 
infections, which account for a large proportion of healthcare infections.129-
133 These studies demonstrate that the incorporation of a photosensitiser 
into a polymer results in highly efficacious kill of pathogens, with a 
potential to prevent biofilm formation. Metal-based nanomaterials and 
photosensitisers have been incorporated into polymers using a simple, 
easily up-scalable ‘swell-encapsulation-shrink’ method.112,129 This 
preparative route is effective, low maintenance, and does not require any 
complicated synthetic methods of attachment.114 It is described in more 
detail in Chapters 3-6.   
Earlier studies conducted by Piccirillo et al127,128 showed lethal 
photosensitisation of E. coli and Staphylococcus epidermidis (S. 
epidermidis) with TBO- and MB-incorporated silicone polymers irradiated 
with 634 nm and 660 nm light, respectively. Further investigations carried 
out by Perni et al134 demonstrated a 2 log10 reduction in MRSA and S. 
epidermidis using indocyanine green-containing polyurethane when 
exposed with a laser light from near-infrared spectrum (808 nm). Following 
this, Perni et al133 examined the antibacterial activity of silicone against E. 
coli and S. epidermidis exposed to laser light (660 nm), showing that they 
were both considerably affected by the presence and size of Au NPs. 
Noimark et al130 established that 2 nm sized Au NPs were most effective in 
reducing bacterial numbers under fluorescent lighting. They demonstrated 
an enhancement in MB triplet state production with 2 nm Au NPs using 
time-resolved electron paramagnetic resonance (EPR) spectroscopy, 
indicating a greater production of ROS in these co-doped materials than 
with MB alone. Furthermore, they revealed exceptionally effective 
antibacterial activity of silicone containing CV and Au NPs against Gram-
positive and Gram-negative bacteria upon irradiation with a low power 
laser (635 nm) for short time periods. More significantly, bacterial kill was 
achieved in the dark.129 Bovis et al135 used 660 nm laser light to confirm 
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both Type I and Type II mechanisms were occurring within photo-activated 
silicone containing MB and Au NPs.  
Following this, novel multi-dye antibacterial polymers were prepared by 
Noimark et al136 using silicone incorporated with CV, MB and 2 nm Au NPs 
and activated by white light emitting ~3,750 lux. Lethal photosensitisation 
of S. epidermidis and E. coli occurred within 3 hours and 6 hours, 
respectively (≥ 4 log10 reduction). Moreover, potent antimicrobial activity 
against both bacteria was shown within 18 hours in the dark. Most 
recently, Noimark et al137 and Ozkan et al138 introduced ZnO NPs into 
silicone-based systems. ZnO NPs combined with CV displayed lethal 
bactericidal effects against E. coli and S. aureus when activated by white 
light emitting ~3,750 – 10,500 lux intensity. 
 
2.4 Research aims 
This thesis focuses on photo-activated surfaces incorporated with 
nanoparticles and/or crystal violet dye. These antibacterial surfaces will be 
activated by white light and tested in the dark to determine their efficacy 
against a wide range of hospital-associated bacteria. Polyurethane was 
used as the main polymer in this thesis since it is replacing silicone for 
medical applications as detailed above and therefore, represents an 
advance on the previous studies described in section 2.3.2. The thesis 
describes the following studies: 
(a) Investigating the antibacterial activity of biocompatible copper 
nanoparticles impregnated into two widely used polymers: silicone 
and polyurethane, to understand the differences in bacterial 
reduction without a photosensitiser (i.e. dark kill). For the first time, 
two polymers are compared and non-toxic copper nanoparticles 
will be synthesised via a green method. 
(b) Incorporating a well-known biocidal disinfectant used in hospitals 
into a polymer and studying the efficiency of the ‘swell-
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encapsulation-shrink’ method compared to coating the material 
with the antibacterial agent. Looking at the activity of a biocide for 
the first time in our research group to see its efficiency when 
incorporated into a polymer rather than in solution form. 
(c) An investigation into the effects of ZnO nanoparticle size and 
capping ligand on the antibacterial activity of crystal violet when 
incorporated into polymers under varied white light intensity and in 
the dark.  
(d) A study into the mechanism of the polymeric systems to see how 
ZnO nanoparticles enhance bactericidal properties of the 
photosensitiser, an aspect which has not previously been 
investigated before in our research group. Mechanistic studies will 
focus on Type I and Type II inhibitors.  
(e) Advancements of a protocol used for antimicrobial testing was 
developed that provided a closer simulation of real-world 
conditions and also tested the new materials against wild strains of 
clinically-relevant bacteria and C. difficile endospores rather than 
laboratory strains, which only have been tested in previous work. 
By making these changes and studying the best-performing 
antibacterial polymers against actual clinical strains, evidence is 
presented which suggests that these surfaces are potentially 
appropriate to be used in healthcare applications by reducing the 
spread of bacterial contamination and minimising the risk of HAIs. 
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Chapter 3 
3. Silicone and Polyurethane-Encapsulated 
Copper; Antimicrobial Polymers without White 
Light Activation 
 
3.1 Introduction 
Hospital-acquired infections (HAIs) are the most common complication in 
healthcare and are attained by patients during medical treatments and 
procedures. They are a result of severely contaminated hospital surfaces 
and medical devices, and poor adherence towards cleanliness and basic 
hand washing by patients, staff and visitors. Patients who acquire these 
infections can be hospitalised 2.5 times longer than those who are 
uninfected, resulting in additional hospital costs of up to £3,000.1 Over the 
last century, new antibiotics have been developed to combat infections 
that are caused by common microorganisms found in hospitals. 
Consequently, bacteria have evolved resistance mechanisms that pose a 
major threat to patients, contributing towards morbidity and mortality.2 
Carbapenem-resistant Enterobacteriaceae (CRE) are extremely problematic 
for immunocompromised and catheterised patients as treatment options 
are limited.3 Methicillin-resistant Staphylococcus aureus (MRSA) 
contaminates around 75% of patient rooms and 42% of those who touch a 
surface contaminated with MRSA will become contaminated themselves, 
despite not having direct contact with a patient. It can cause minor skin 
infections but also more serious problems, such as infected wounds or 
pneumonia.4  
Numerous prevention strategies have been developed to reduce the 
incidence of HAIs. Novel methods, including the use of hydrogen peroxide 
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mist and ultra violet (UV) light have been shown to reduce microbial 
burden, but are unsuccessful in significantly reducing the rates of HAIs.5 
Metallic copper exhibits intrinsic broad-spectrum antimicrobial activity 
against commonly found bacteria in healthcare.6 Studies showed that 
patients cared for in intensive care units (ICUs) with copper alloy surfaces 
(e.g. pipes, bed rails and pushplates) had a much lower rate of MRSA and 
vancomycin-resistant Enterococcus (VRE) colonisation than patients 
treated in standard hospital wards.5 However, metallic copper has a limited 
range of applications within hospital environments as it can only be applied 
to hard surfaces such as taps, bedrails, overbed tables and visitors chair 
arms.7  
Copper nanoparticles (Cu NPs) have gained particular attention due to their 
availability and cost effectiveness compared to other noble metals, such as 
silver and gold.8 They display bactericidal activity against a wide range of 
Gram-positive and Gram-negative bacteria, such as Escherichia coli (E. coli) 
and S. aureus.9 There are only a few studies in the literature that report the 
antibacterial mechanism of Cu NPs. Ruparelia et al and Raffi et al suggested 
that an interaction between Cu2+ and DNA/protein causes a disruption of 
bacterial structures and their biochemical processes.10 Additionally, Wu et 
al found an increased concentration of Cu ions from the antibacterial Cu 
agent caused 99% killing of bacteria.11 Excess copper causes a reduction in 
bacterial membrane integrity, leading to desiccation and eventually, cell 
death.12 Moreover, an increased concentration of copper inside the 
bacterial cell can form H2O2 via oxidative stress (the Fenton reaction).13 
There are very few reports on synthesising Cu NPs using a “green method” 
with a low environmental impact. For hospital applications, it is imperative 
that these nanoparticles are synthesised from nontoxic chemicals, solvents 
and renewable materials.14-16 
Despite their bactericidal efficacy, Cu NPs suffer from rapid oxidation upon 
air exposure. Cu oxidises to CuO and Cu2O and converts to Cu2+ during 
preparation and storage, causing difficulty in synthesising Cu NPs in 
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ambient conditions.8 Therefore, alternative synthetic routes have been 
developed to form coatings on nanoparticle surfaces, as well as the use of 
polymers and surfactants as stabilisers.8,17 Another method of preventing 
oxidation of Cu NPs is by incorporating them into polymeric materials for 
use as antibacterial surfaces in preventing HAIs.18 Such materials include 
polyvinyl chloride, silicone and polyurethane.19-21  
This chapter details the antibacterial activity of environmentally benign Cu 
NPs (~2.5 nm in size) when incoporated into two widely used polymers, 
medical grade silicone and polyurethane sheets. These novel bactericidal 
surfaces were tested against E. coli ATCC 25922 as a representative Gram-
negative bacterium, and an epidemic strain of MRSA (EMRSA-16; S. aureus 
NCTC 13143), one of two clones known to predominate in the UK (Public 
Health England),22 as a representative Gram-positive bacterium. Silicone-
encapsulated copper and polyurethane-encapsulated copper both 
demonstrated highly significant antibacterial activity in the dark, i.e. 
without UV or white light activation, against both bacteria within only a 
few hours. Moreover, both modified polymer surfaces mostly remain 
unstained after encapsulation, which should prove commercially appealing. 
   
3.2 Experimental 
3.2.1 Chemicals and Reagents 
The reagents used to synthesise Cu NPs were commercially supplied by 
Sigma-Aldrich Chemical Co. Copper (II) chloride dihydrate (CuCl2.2H2O) was 
used as a precursor for nanoparticle formation and L-ascorbic acid acted as 
a capping agent and a reducing agent.23 Medical grade flat silicone sheets 
with a thickness of 1.0 mm were purchased from NuSil (Polymer Systems 
Technology Ltd) and medical grade polyurethane sheets with a thickness of 
0.8 mm were purchased from American Polyfilm Inc. (Branford, CT, USA). 
Deionised water (resistivity 15 MΩ cm) was used throughout all synthetic 
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work carried out and acetone (Sigma-Aldrich, UK) was used to prepare 
modified polymer substrates via the “swell-encapsulation-shrink” method.  
 
 
 
Fig. 3.1 Chemical structures of silicone and polyurethane. 
 
3.2.2 Synthesis of Copper Nanoparticles 
Nanosized copper particles were prepared using a method adapted by 
Xiong et al.24 An aqueous solution of CuCl2.2H2O (0.2 M) in water was 
heated to 70 oC with constant magnetic stirring, followed by dropwise 
addition of an aqueous solution of L-ascorbic acid (0.6 M) in water. The 
reaction mixture was kept at 70 oC and sealed for 3 h until a dark 
orange/brown solution was obtained.  
 
3.2.3 Material Preparation 
3.2.3.1 Polymer System Optimisation – Organic Solvent Concentration 
1 cm2 polyurethane polymer square sheets were immersed in the following 
acetone : water ratios – 0:1, 1:1, 9:1 and 1:0. They were allowed to swell 
for 24 h in the dark, removed, air-dried overnight, and subsequently 
washed and towel-dried.  
 
n 
(a) 
(b) 
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Fig. 3.2 Schematic diagram illustrating the preparation of copper nanoparticles (Step 1) 
and encapsulating them into 1 cm2 polymer squares for antibacterial testing (Step 2).  
 
3.2.3.2 Polymer Samples Prepared for Antibacterial Testing 
The following modified silicone and polyurethane samples (1 cm2) were 
prepared for antimicrobial testing: 
(a) Polyurethane-encapsulated copper (Cu-polyurethane) and silicone-
encapsulated copper (Cu-silicone) polymer samples were prepared 
using a ‘swell-encapsulation-shrink’ method adapted from Perni et 
al.25 They were immersed in a 9:1 acetone/water swelling solution 
which contained Cu NPs for 24 h.  They were then removed from 
solution, air-dried overnight and washed with distilled water (as 
summarised in Fig. 3.2).  
(b) Control silicone and polyurethane samples were prepared by using 
a 9:1 acetone/water solution for 24 h in the dark. They were 
removed from the solution, air-dried overnight and washed with 
distilled water.  
 
3.2.4 Material Characterisation 
3.2.4.1 Characterisation of Copper Nanoparticles 
An aqueous suspension of Cu NPs was drop-cast onto a 400 Cu mesh lacey 
carbon film TEM grid (Agar Scientific Ltd) and imaged using a Jeol 2100 high 
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resolution transmission electron microscope (HR-TEM) with a LaB6 source, 
operating at an acceleration voltage of 200 kV with an Oxford Instruments 
XMax EDS detector running AZTEC software. The TEM images were 
analysed using ImageJ software and energy-dispersive X-ray (EDX) spectra 
were obtained. 
 
3.2.4.2 Characterisation of Modified Polymer Samples 
A Perkin Elmer Fourier transform Lambda 950 UV-Vis spectrometer (350 – 
550 nm range) was used to measure the absorption spectra of all modified 
polymer samples. X-ray photoelectron spectroscopy (XPS) analysis was 
performed using a Thermo Scientific K-Alpha spectrometer to detect 
copper as a function of polymer depth, and all binding energies were 
calibrated to the carbon 1s peak at 284.5 eV. Scanning electron microscopy 
(SEM) of the modified polymer samples was carried out using secondary 
electron imaging on a Jeol 6301 field emission instrument with an 
acceleration voltage of 5 kV. Equilibrium water contact angle 
measurements (~5.0 µL) were measured to determine the differences in 
surface hydrophobicity of treated polymer samples. Contact angle 
measurements were averaged from over 10 measurements using a droplet 
of deionised water dispensed by gravity from a gauge 30 needle. 
 
3.2.5 Antibacterial Activity 
3.2.5.1 Microbiology Assay 
The following 1 cm2 polyurethane and silicone samples were prepared: (i) 
control (solvent treated) and (ii) polymer-encapsulated copper. The 
antibacterial activity of these samples was tested against E. coli ATCC 
25922 and an epidemic strain of MRSA, (EMRSA-16; S. aureus NCTC 13143), 
which is representative of one of the two types of MRSA that dominate in 
UK hospitals.22 These organisms were stored at -70 ○C in Brain-Heart-
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Infusion broth (BHI, Oxoid) containing 20% (v/v) glycerol and propagated 
onto either MacConkey agar (MAC, Oxoid) in the case of E. coli or Mannitol 
Salt agar (MSA, Oxoid) in the case of S. aureus for a maximum of 2 
subcultures at intervals of 2 weeks.  
BHI broth was inoculated with 1 bacterial colony and cultured in air at 37 
oC for 18 h with shaking, at 200 rpm. The bacterial pellet was recovered by 
centrifugation, (20 oC , 2867.2 g, 5 min), washed in PBS (10 mL), centrifuged 
again to recover the pellet (20 oC, 2867.2 g, 5 min), after which the bacteria 
were finally re-suspended in PBS (10 mL). The washed suspension was 
diluted 1,000-fold to obtain an inoculum of ~106 cfu/mL. In each 
experiment, the inoculum was confirmed by plating 10-fold serial dilutions 
on agar for viable counts. Triplicates of each polymer sample type were 
inoculated with 25 µL of the inoculum and covered with a sterile cover slip 
(2.2 cm2). The samples were then incubated in the dark for up to 6 h and 3 
h for the modified silicone and polyurethane samples, respectively.   
After incubation, the inoculated samples and coverslips were added to PBS 
(450 µL) and mixed using a vortex mixer. The neat suspension and 10-fold 
serial dilutions were plated on agar for viable counts and incubated 
aerobically at 37 ○C for 24 h (E. coli) or 48 h (S. aureus). To examine the 
stability of the modified polymer squares, their antibacterial activity was 
re-tested against both bacteria after 30 days and 90 days storage at room 
temperature in air.  
 
3.2.5.2 Statistical Significance 
The experiment was repeated three times and the statistical significance of 
the following comparisons was analysed using the Mann-Whitney U test: (i) 
control polymer vs. inoculum; (ii) Cu NP-incorporated vs. control polymer. 
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3.2.5.3 Further Antimicrobial Testing for Mechanistic Evaluation 
Bovine serum albumin (BSA, 0.03%)26 and superoxide dismutase (SOD, 55 U 
mL-1),27 purchased from Sigma-Aldrich, UK, were added to the E. coli 
suspension and exposed to both polymers as described in section 3.2.5.1. 
The BSA and SOD solutions were filter sterilised using a 0.2 µm syringe 
filter (VWR, UK). BSA was added to simulate contamination in a hospital 
setting with organic material, as well as acting as a scavenger of reactive 
oxygen species (particularly singlet oxygen),18,26,28 and SOD was added as 
an inhibitor of superoxide anions in radical formation.27,29 The inhibitors 
were added to the bacterial suspension and exposed to the polymer as 
described above in section 3.2.5.1. 
 
3.3 Results and Discussion 
3.3.1 Material Characterisation 
3.3.1.1 Characterisation of Copper Nanoparticles 
A facile and environmentally friendly method was used to synthesise Cu 
NPs by gently heating an aqueous solution of copper (II) chloride dihydrate 
and adding L-ascorbic acid dropwise to the solution. The dispersion 
became colourless upon the addition of L-ascorbic acid and gradually 
turned to yellow, orange and finally dark orange/brown. Narrow size 
control of the nanoparticles was achieved by using the anti-oxidant, L-
ascorbic acid, which acted as both the reducing and capping agent by 
encapsulating Cu2+ ions and reducing them into Cu(0).24 The resulting 
oxidation products then adsorb onto the surface of Cu NPs, preventing the 
particles from additional growth.  
HR-TEM images showed the Cu NPs to be monodisperse, crystalline and 
mainly spherical (Fig. 3.3(a)). Size analysis indicated an average size 
diameter of 2.5 ± 0.7 nm. There was some aggregation of nanoparticles as 
clusters of ~10 nm in diameter was observed, but generally the images 
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displayed shape uniformity and a narrow size distribution (Fig. 3.3(b)). EDX 
elemental composition analysis demonstrated minimal oxidation of the 
nanoparticles and a strong presence of Cu (Fig. 3.4). 
 
           
 
Fig. 3.3 (a) HR-TEM images of Cu NPs. (b) Cu NP size distribution determined by HR-TEM.   
 
 
Fig. 3.4 EDX spectrum of Cu NPs.  
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3.3.1.2 Characterisation of Modified Polymer Samples 
The nanoparticles were incorporated into both polyurethane and silicone 
by using a simple and efficient ‘swell-encapsulation-shrink’ method (Fig. 
3.2). This method has proven to be highly efficacious at introducing 
antibacterial functionality to polymers by impregnating a wide range of 
small nanoparticles into their matrices.25,26,30-33 Previous studies have 
shown that the extent of polymer swelling is greatly affected by the type of 
organic solvent used.30,34 However, as the Cu NPs were suspended in 
water, the choice of organic solvents was limited. Perni et al25 
demonstrated that acetone is very effective at encapsulating gold 
nanoparticles via this preparative route by using a 9:1 ratio of 
acetone/water suspension containing the nanoparticles. To confirm this, 1 
cm2 polyurethane squares were immersed into solutions containing the 
following ratios of acetone/water: 0:1, 1:1, 9:1 and 1:0 for 24 h. Once 
removed, they were immediately measured to determine the extent of 
swelling. As shown in Table 3.1, a 1:1 ratio of acetone/water only allowed 
22% of swelling, whereas a 9:1 ratio caused 50% swelling (only 5% less than 
using acetone alone). Moreover, a 9:1 ratio did not cause the polymer to 
deform or bend. Therefore, a 9:1 acetone/water ratio was used to swell-
encapsulate Cu NPs into both polymers for 24 h to maximise the extent of 
polymer swelling and encapsulation of nanoparticles throughout the 
polymer bulk. 
 
Table 3.1  Extent of polymer swelling (%) after immersing 1 cm2 polyurethane samples in 
different ratios of acetone and water.  
Acetone : water 
ratio 
Extent of polymer 
swelling (%) 
0:1 0 
1:1 22 
9:1 50 
1:0 55 
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In the interest of aesthetics, Cu NP incorporation into the polymers 
resulted in a limited change in colouration. This is advantageous as 
previous studies carried out by our research group have used polymers 
with distinct colouration upon addition of photosensitisers to achieve their 
antibacterial functionalities.25,26,30-33  As shown in Fig. 3.5, the slight 
colouration of polyurethane may be attributed to a significantly greater 
extent of swelling under these conditions. However, this results in an 
increased uptake of Cu NPs, which subsequently anticipates an 
enhancement in antibacterial efficacy. UV-vis absorbance spectroscopy 
displayed a stronger absorbance signal for Cu-polyurethane compared to 
Cu-silicone and the control polymers (Fig. 3.6), giving evidence of a greater 
uptake of Cu NPs in polyurethane compared to silicone. Additionally, when 
immersed in a 9:1 ratio of acetone : water, polyurethane swelled up to 50% 
of its original size compared to silicone, which only swelled 30% more than 
its original size. Thus, this also suggests that Cu-polyurethane, which is 
slightly more coloured than Cu-silicone, contains a higher concentration of 
Cu NPs.  
 
                                               
Fig. 3.5 Modified polymer samples for antibacterial testing (1 cm2): (a) polyurethane 
control; (b) polyurethane-encapsulated copper; (c) silicone control; (d) silicone-
encapsulated copper.  
 
(a)    (b)        (c)           (d) 
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Fig. 3.6 UV-vis absorbance spectra of polyurethane control, Cu-polyurethane, silicone 
control and Cu-silicone, measured in the range 350 – 550 nm. 
 
XPS analysis was used to examine the diffusion of Cu NPs through the 
polymer bulk and on the surface (sputtered 50 s).  For all polyurethane 
samples, peaks attributed to the presence of C (1s), O (1s) and N (1s) were 
found and for all silicone samples, peaks attributed to the presence of C 
(1s), O (1s) and Si (2p) on the surface were observed (data not shown). The 
presence of Cu was detected on the polyurethane surface and within the 
substrate as a peak correlating to Cu (2p) was observed at 952.3 eV (Fig. 
3.7(a) and (b)). A peak was also evident at 932.4 eV which confirmed the 
presence of Cu in CuO, indicating some oxidation of the Cu NPs. Fig. 3.7(c) 
and (d) showed there was a limited amount of Cu detected on the silicone 
surface, but a significant amount of Cu NPs incoporated in the silicone bulk. 
Peaks in the Cu (2p) region indicated this for Cu and CuO (952.3 eV and 
933.1 eV, respectively). SEM images shown in Fig. 3.8 indicated there was 
no physical change in the surface appearances of polyurethane and silicone 
after encapsulating Cu NPs. XPS data showed a higher content of Cu on the 
polyurethane surface compared to the silicone surface, but both polymers 
showed similar Cu content within the polymer matrices (Fig. 3.7).  
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Fig. 3.7 Cu (2p) region XPS spectra for: (a) Cu-polyurethane surface; (b) Cu-polyurethane 
sputtered 50 s; (c) Cu-silicone surface; and (d) Cu-silicone sputtered 50 s.  
 
 
Fig. 3.8 SEM imaging of the following modified polymer squares: (a) polyurethane 
control; (b) polyurethane-encapsulated copper; (c) silicone control; (d) silicone-
encapsulated copper.   
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Water contact angle measurements were carried out on all modified 
polymer samples to investigate any changes in wetting properties after 
encapsulation of Cu NPs. Both control polyurethane and silicone polymers 
present a hydrophobic surface35,36 prior to incorporating the nanoparticles. 
 
3.3.2 Antibacterial Activity 
The antibacterial activity of the modified polymer samples was tested 
against two hospital pathogens as representative Gram-positive and Gram-
negative bacteria: an epidemic strain of MRSA (EMRSA-16; S. aureus NCTC 
13143) and E. coli ATCC 25922. Fig. 3.9 illustrates the bactericidal activity of 
modified polymers against S. aureus NCTC 13143. Following 1 h of 
incubation (Fig. 3.9(a)), the control polyurethane sample did not display 
any significant kill of S. aureus, whereas Cu-polyurethane resulted in a 
~0.75 log reduction in bacterial numbers (P < 0.001). After increasing the 
exposure time to 2 h (Fig. 3.9(b)), Cu-polyurethane demonstrated highly 
significant bactericidal activity reducing the bacterial numbers to below the 
detection limit of 100 cfu/mL (≥4 log reduction; P < 0.001). The strain of 
EMRSA-16, S. aureus NCTC 13143, was also exposed to silicone and Cu-
silicone for longer time periods. After 4 h of incubation (Fig. 3.9(c)), control 
silicone did not exhibit significant kill of the bacteria, but Cu-silicone caused 
~1 log reduction. By increasing the incubation time to 5 h, Cu-silicone 
reduced bacterial numbers to below the detection limit, proving to be 
highly active against S. aureus NCTC 13143 (≥4 log; P < 0.001). 
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Fig. 3.9 Viable counts of S. aureus NCTC 13143 after incubation on modified polyurethane 
squares for:  (a) 1 h and (b) 2 h, and modified silicone squares for: (c) 4 h and (d) 5 h. All 
samples were incubated at 20oC in the dark. Control samples are solvent treated. * 
indicates bacterial numbers reduced below the detection limit of 100 colony forming 
units/mL (cfu/mL). 
The bactericidal activity of the modified polymers was then tested against a 
Gram-negative bacterium, E. coli, using the same conditions but for an 
extended period of time (Fig. 3.10). Following 2 h of bacterial contact, 
polyurethane displayed no significant antibacterial activity (Fig. 3.10 (a)), 
whereas Cu-polyurethane caused ~0.5 log reduction of E. coli. After 3 h 
(Fig. 3.10(b)), Cu-polyurethane demonstrated efficacious bactericidal 
activity against E. coli (≥4 log; P < 0.001). Following a 4 h incubation, Cu-
silicone resulted in ~0.5 log reduction of E. coli (Fig. 3.10 (c)). However, by 
(a) (b) 
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increasing the incubation time to 5 h, Cu-silicone caused ≥4 log reduction in 
the numbers of E. coli (P < 0.001). 
 
 
 
Fig. 3.10 Viable counts of E. coli ATCC 25922 after incubation on modified polyurethane 
squares for: (a) 2 h and (b) 3 h, and modified silicone squares for: (c) 4 h and (d) 6 h. All 
samples were incubated at 20oC in the dark. Control samples are solvent treated. * 
indicates bacterial numbers reduced below the detection limit of 100 colony forming 
units/mL (cfu/mL). 
 
Table 3.2  Summary of the antibacterial activity of Cu-polyurethane and Cu-silicone in the 
dark against S. aureus NCTC 13143 and E. coli ATCC 25922. Bacterial reduction is given in 
log form. 
Bacterial strain Cu-polyurethane Cu-silicone  
S. aureus NCTC 
13143 
0.75 log (1 h) 
≥4 log (2 h) 
1 log (4 h) 
≥4 log (5 h) 
E. coli ATCC 
25922 
0.5 log (2 h) 
≥4 log (3 h) 
0.5 log (4 h) 
≥4 log (6 h) 
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In the experiments described above, 2.5 nm Cu NPs were synthesised with 
L-ascorbic acid as a reducing and capping agent and impregnated into flat 
medical grade 1 cm2 polyurethane and silicone squares. To ensure that the 
capping agent itself was not responsible for the antibacterial properties of 
the modified polymers, unbound L-ascorbic acid was incorporated into the 
polymers and tested for bactericidal activity when tested against S. aureus 
NCTC 13143 and E. coli ATCC 25922 using the same microbiological 
conditions described above. It should be noted that L-ascorbic acid is 
reported in literature as a scavenger of ROS in the light,37-39 which would 
cause a reduction in bacterial kill if ROS production is a mechanism 
responsible for the bactericidal activity of polyurethane-encapsulated 
copper.  
Xiong et al reported that the Cu NP solution was stable even after 2 
months of storage.24 To investigate the stability of the nanoparticles 
incorporated into both polymers, their bactericidal activity was assessed 
after 30 days and 90 days after their preparation. After 90 days, the 
samples still remained active (Fig. 3.11), exhibiting similar levels of 
bacterial kill as shown for the freshly prepared polymers displayed in Fig. 
3.9 and 3.10.  
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Fig. 3.11 Viable counts of S. aureus NCTC 13143 after incubation on modified polyurethane 
squares for (a) 2 h and modified silicone squares for (b) 5 h after 90 days from 
preparation. Viable counts of E. coli ATCC 25922 after incubation on modified 
polyurethane squares for (c) 3 h, and modified silicone squares for (d) 6 h after 90 days 
from preparation. All samples were incubated at 20oC in the dark. Control samples are 
solvent treated. * indicates bacterial numbers reduced below the detection limit of 100 
colony forming units/mL (cfu/mL). 
 
The ‘swell-encapsulation-shrink’ method proves to be highly effective for 
impregnating small Cu NPs into two widely used polymers. It is an efficient 
and easily upscalable preparative route that allows the incorporation of 
nanoparticles within polymeric materials compared to other methods, such 
as covalent attachment.40,41 Furthermore, encapsulating nanoparticles 
within the polymer matrix minimises particle loss by wiping or washing the 
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surface. For the first time, Cu NPs are impregnated into polymers for 
antibacterial surface applications. There are many reports that 
demonstrate the lethal activity of copper alloys used for pipes, bed rails 
and other hard surfaces,7,41 but these novel polymeric surfaces have the 
potential of being used for a much wider range of surfaces and medical 
devices due to their flexibility and biocompatibility.19-21  
A proposed mechanism for the antibacterial activity of copper 
incorporated into the polymers is by nanoparticle leaching from the 
polymer into the surrounding bacterial suspension.18 A high concentration 
of copper ions can leach into the suspension and the Cu surface can 
interact with the bacterial cell wall; causing membrane rupture which 
weaken the cells through the loss of vital nutrients and water, eventually 
causing cell death.42 Additionally, Cu NPs can produce reactive oxygen 
species (ROS), causing progressive oxidative damage and cell death.43 
Therefore, to gain a better understanding of the bactericidal mechanism 
involved within this system, superoxide dismutase (SOD, 50 U mL-1) was 
used to eliminate superoxide anions in radical formation.27,29 SOD was 
added to the antibacterial tests against E. coli and neither Cu-polyurethane 
nor Cu-silicone displayed any reduction in bactericidal activity, indicating 
that superoxide radicals are not responsible for the lethal activity observed 
from the Cu NPs (data not shown).  
BSA was also added to the antibacterial protocol (without SOD) and no 
significant change in antibacterial activity of Cu-polyurethane or Cu-silicone 
was observed against E. coli using the same time conditions described 
above (data not shown). These results signify that the antibacterial activity 
of these polymeric surfaces is retained even in the presence of organic 
matter, which suggests that it could be effective in environments where it 
is contaminated with lipids, for example, that come from hands. It also 
suggests that singlet oxygen, a major ROS, is also not responsible for the 
bactericidal activity. This is highly advantageous and differs from 
experiments involving the incorporation of photosensitisers (described in 
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Chapter 5) where a substantial reduction in bacterial kill is observed upon 
addition of BSA to the system. An additional advantage is that compared to 
previous polymeric antibacterial samples investigated at the Materials 
Research Centre at University College London (UCL), these copper-
containing surfaces do not require light to activate their bactericidal 
properties. The average light intensity in hospitals is reported to range 
between 1,000 lux in an accident and emergency (A & E) examination room 
to 10,000-100,000 lux in an operating theatre (detailed in Table 3.3).44 
However, actual light intensity measurements in some hospital wards are 
as low as ~200 lux (Prof. P. Wilson, UCLH, personal communication). Cu-
polyurethane and Cu-silicone bactericidal surfaces eliminate the concern 
associated with variable light intensities of different areas in hospitals by 
possessing lethal activity in the dark. 
 
Table 3.3  Average light intensities in common hospital surroundings in the UK.44 
Hospital environment Light intensity / lux 
Ward corridors ≥ 200 
A & E examination room 1,000 
Pathology laboratory 8,000 
Operating theatre 10,000 – 100,000 
 
These bactericidal surfaces have been prepared without altering the 
appearance of the materials. Aesthetically, a material that is not brightly 
coloured and rapidly reduces bacterial contamination is appealing for 
frequently touched surfaces in hospital environments. As shown in Fig. 3.9 
and 3.10, the antibacterial activity of surfaces are polymer dependent, 
demonstrating that Cu-polyurethane was more efficient at reducing both S. 
aureus NCTC 13143 and E. coli ATCC 25922 at shorter incubation times. 
Compared to polyurethane alone, Cu-polyurethane undergoes a slight 
change in colour and has a greater increase in hydrophobicity than shown 
by the incorporation of Cu into silicone.  As polyurethane swells more than 
silicone, a greater concentration of nanoparticles is incorporated into 
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polyurethane which results in a greater antibacterial effect from Cu-
polyurethane than Cu-silicone. This is also responsible for the change in 
appearance and hydrophobicity of the different polymer types. XPS data 
also suggests that more Cu is present on the surface of polyurethane than 
silicone, which may explain why Cu-polyurethane reduces bacterial 
numbers more effectively than Cu-silicone; it contains more free copper on 
the surface which can potentially leach from the surface and kill bacteria 
before they can interact with Cu NPs incorporated into the polymer 
substrate.  
Further experiments were carried out to determine whether Cu NPs 
leached into a solution by immersing the modified polymer samples into 
PBS for up to 2 weeks. After 2 weeks, the samples were removed from the 
solution and the solution itself was tested for antibacterial activity. The 
results indicated no bactericidal activity from the surrounding solution, 
suggesting a low level of Cu NPs present in the solution (data not shown). 
This study suggests that the bactericidal activity of Cu-incorporated 
polymers is not due to Cu ions leaching into the bacterial solution but from 
the combination of other possible mechanisms.  
 
3.4 Conclusion 
An easily reproducible “green strategy” was used to synthesise cost 
effective and monodisperse Cu NPs (~2.5 nm in size). The synthetic 
reagents used are non-toxic and environmentally friendly showing that 
these nanoparticles have biomedical applications24 unlike other Cu NPs 
reported in the literature.45,46 These nanoparticles are uniform in shape 
and have a narrow size distribution. They have been incorporated into 
polyurethane and silicone, two commonly used polymers in hospitals used 
for medical devices which can also be used to coat surfaces such as 
mousepads, keyboards and other electronic devices such as iPads and 
tablets.  
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These antibacterial surfaces have proven to be stable materials after 90 
days, demonstrating significant bactericidal activity against E. coli and a 
strain of EMRSA-16, one of two clones known to predominate in the UK.22 
Cu-silicone demonstrated efficacious antibacterial activity against both S. 
aureus and E. coli, by reducing bacterial numbers to below the detection 
limit within 5 h and 6 h, respectively. However, Cu-polyurethane reduced 
numbers of S. aureus and E. coli to below the detection limit within only 2 
h and 3 h, respectively, demonstrating a greater bactericidal effect than 
Cu-silicone. Upon the addition of organic contaminant to mimic organic 
material deposition by hand touching, the antibacterial activity of the 
samples did not change. The exact mechanism for the antibacterial activity 
of these polymeric systems has not been determined, however, the results 
from this investigation suggests it is due to a combination of electrostatic 
interaction between the copper surface and bacterial membrane and the 
leaching of copper ions, and less likely due to the production of ROS (as L-
ascorbic acid is a potential scavenger of ROS).  
These novel, highly effective antibacterial materials are easy to synthesise 
and exhibit lethal antibacterial activity against Gram-positive and Gram-
negative bacteria. Polyurethane-encapsulated Cu demonstrates greater 
bactericidal activity than Cu-silicone, however, Cu-silicone remains 
completely unchanged visually after the addition of copper, which may 
prove more commercially attractive for use as protective covers for 
keyboards and electronic tablets. These materials differ from previous 
studies that focus on light activation to achieve bacterial kill. Thus, this 
chapter presents self-sterilising materials with a strong potential to reduce 
the incidence of HAIs in a clinical environment. 
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Chapter 4 
4. Polyurethane-Encapsulated Glutaraldehyde; 
Antimicrobial Polymer without White Light 
Activation 
 
4.1 Introduction 
Much progress has been made in recent years in minimising the risk of 
hospital-acquired infections (HAIs), but as many bacterial pathogens 
become resistant to multiple antibiotics, we need to evaluate existing 
methods and find new and better ways of preventing these sometimes life-
threatening infections. In particular, genera of Enterobacteriaceae (a family 
of Gram-negative bacteria), which are normally found in the human 
intestine,1 exhibit multiple antibiotic resistances and present a major 
threat to healthcare  worldwide.2  Various control measures can be 
implemented to reduce the spread of HAIs, including improvements in 
hand washing, the use of disposable equipment and medical devices, and 
isolating patients with appropriate ventilation.3 Regular and effective 
cleaning regimes for hospitals is mandatory as unproductive cleaning can 
assist in transferring bacteria between healthcare personnel, patients and 
surfaces.4   
Chapter 3 introduced novel antibacterial surfaces made by encapsulating 
nanosized copper particles into medical grade polyurethane and silicone 
sheets. The results showed that polyurethane was able to swell more 
effectively, suggesting that a greater concentration of antibacterial agent 
was likely to be incorporated into polyurethane compared to silicone. Thus, 
for the remaining chapters, all antibacterial surfaces investigated are 
prepared from polyurethane, which has shown to exhibit effective 
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bactericidal activity within short exposure times. In this chapter, 
glutaraldehyde, a well-known disinfectant in hospitals, is impregnated into 
polyurethane at a low concentration to minimise toxicity. These surfaces 
are tested against Gram-positive and Gram-negative bacteria and their 
antibacterial activity over time is examined. 
Biocides are extensively used in healthcare for sterilising medical devices 
and heat sensitive equipment, preserving pharmaceutical products, and 
disinfecting contaminated surfaces and water.5 They are extremely 
effective in controlling HAIs because they can inhibit or kill some of the 
most clinically relevant bacteria.6 They can target different locations on the 
bacteria by interacting with the cell wall and outer membrane, or 
penetrating the cell and causing cell death.7 However, due to insufficient 
cleaning protocols, most disinfectants almost never clean 100% of the 
targeted surface sufficiently.8 When choosing a disinfectant, there are 
many factors to be considered, such as compatibility with instruments and 
medical devices, types of surfaces, and compliance with health and safety 
regulations.9 It must be easy to use and not leave any toxic residues.10  
Glutaraldehyde is a saturated dialdehyde (Fig. 4.1) that is commonly used 
in hospitals as a chemical sterilant and disinfectant.11 It can inactivate a 
wide range of pathogens, including Staphyloccocus aureus (S. aureus), 
methicillin-resistant S. aureus (MRSA), Klebsiella pneumoniae, 
Pseudomonas aeruginosa (P. aeruginosa) and Escherichia coli (E. coli).8,11,12 
The antibacterial activity of glutaraldehyde is due to the alkylation of 
hydroxyl, carbonyl and amino groups which affects DNA, RNA and protein 
synthesis.13 In addition to this, Maillard et al reported a strong binding of 
glutaraldehyde to the outer membrane of E. coli and inhibition of 
membrane transport in other Gram-negative bacteria.14   
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Fig. 4.1 The chemical structure of glutaraldehyde. 
 
Glutaraldehyde is active in mildly alkaline conditions (pH 7.5 – 8.5) and is 
not biocidal against bacteria when in acidic aqueous conditions.15 At a 
higher pH there are more reactive sites formed at the surface (e.g. more 
free hydroxyl, carbonyl groups) which lead to a faster bactericidal effect.11 
Studies have shown that >2% glutaraldehyde solution (buffered to pH 7.5 – 
8.5) effectively killed vegetative bacteria, such as S. aureus, E. coli and P. 
aeruginosa within 2 minutes, Mycobacterium tuberculosis, viruses and 
fungi within 10 minutes and Bacillus and Clostridium spores within 3 
hours.11  However, some studies have found no significant difference 
between the bactericidal effects of alkaline and acidic solutions of 
glutaraldehyde.12,15 It is widely used in hospitals because it is non-corrosive 
towards rubber, plastic, thermometers and endoscopic equipment9,16 and 
it still has significant microbicidal activity in the presence of organic matter 
(20% bovine serum).9,11,15 
There is no evidence for carcinogenic activity, but at high concentrations, 
glutaraldehyde is considered toxic and a strong irritant.17 Glutaraldehyde 
has many uses besides from being a commonly used disinfectant in 
healthcare environments, thus the recommended concentration for each 
application differs (Table 4.1).9,11 In hospitals, 1 – 2% aqueous 
glutaraldehyde solution is used, which is then activated by an alkaline 
buffer (e.g. sodium bicarbonate).18 On the other hand, 10 – 50% 
glutaraldehyde is used for water treatment and up to 0.1% as a 
preservative for cosmetics in Europe (not allowed in aerosols or sprays).19 
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However, one major drawback of glutaraldehyde in aqueous solution is 
that it loses bactericidal activity after approximately 14 days because the 
molecule begins to polymerise by Aldol condensation.20 When 
polymerisation occurs, the active sites (aldehyde groups) are blocked and 
biocidal activity is reduced.21 
 
Table 4.1 Concentration (%) of aqueous glutaraldehyde solution used in various 
industries.18,19 
Glutaraldehyde Use Concentration 
Healthcare industry 1 – 2% 
Water treatment 10 – 50% 
Biocide in pulp & paper industry 10 – 50% 
Retail cleaning agent 0.05 – 0.1% 
Animal health 0.1 – 0.3% 
Microscopy/histology 1.5 – 6% 
Cosmetics 0.1% 
 
 
The biocidal activity of glutaraldehyde in solution is well recognised, but 
the incorporation of the biocide into polymers as antibacterial surfaces for 
hospitals has not yet been examined. In this chapter, novel materials are 
prepared by encapsulating glutaraldehyde into polyurethane and 
compared with materials prepared from simply coating the biocide on to 
the polymer surface. The antibacterial activity of these materials is 
assessed against S. aureus 8325-422 and E. coli ATCC 25922 to test the 
efficiency of the ‘swell-encapsulation-shrink’ method against two hospital 
pathogens. The stability of glutaraldehyde in the polymer is examined after 
15 and 30 days of preparation. 
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4.2 Experimental 
4.2.1 Chemicals and Reagents 
Glutaraldehyde solution grade II (containing ~3% w/v glutaraldehyde in 
water) was purchased from Sigma-Aldrich Chemical Co.  Medical grade flat 
polyurethane sheets (thickness 0.8 mm) were purchased from American 
Polyfilm Inc. (Branford, CT, USA). Acetone (Sigma-Aldrich, UK) was used to 
prepare polyurethane-encapsulated glutaraldehyde and deionised water 
(resistivity 15 MΩ cm) was used throughout all synthetic work. 
 
4.2.2 Material Preparation 
Glutaraldehyde solution grade II (~3% w/v glutaraldehyde in water) was 
diluted by a factor of 100 (~0.03% w/v glutaraldehyde in water).  
The following polymer samples (1 cm2) were prepared for antibacterial 
testing: 
(a) Polyurethane-encapsulated glutaraldehyde samples were prepared 
using the ‘swell-encapsulation-shrink’ method. They were 
immersed into a 1:1 acetone/glutaraldehyde solution in water for 
24 h (containing ~0.015% w/v glutaraldehyde). They were removed 
from solution, air-dried overnight and washed with distilled water 
(as shown in Fig. 4.2). 
(b) Glutaraldehyde-coated polyurethane samples were prepared by 
using a 1:1 ratio of water/glutaraldehyde solution in water for 24 h 
(no swelling solution, containing ~0.015% w/v glutaraldehyde). 
They were removed from solution, air-dried overnight and then 
washed with distilled water. 
(c) Control polyurethane samples (for polymer-encapsulated 
glutaraldehyde) were prepared by using 1:1 acetone/water solution 
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for 24 h. They were washed, air-dried overnight and washed with 
distilled water.   
(d) Control polymer samples (for glutaraldehyde-coated samples) were 
prepared by immersing them in water for 24 h, removed and air-
dried overnight.   
 
 
Fig. 4.2 Schematic diagram showing the preparation of polyurethane-encapsulated 
glutaraldehyde squares (1 cm2) for antibacterial testing. 
 
4.2.3 Material Characterisation 
Infrared absorbance spectra of modified polyurethane samples were 
measured using a Brüker Platinum ATR with an accumulation of 16 scans 
per sample (range 4000 – 400 cm-1). X-ray photoelectron spectroscopy 
(XPS) was carried out using a Thermo Scientific K-Alpha spectrometer to 
classify the different elements present as a function of polymer depth on 
all polymer samples. All binding energies were calibrated to C (1s) at 284.5 
eV.  Equilibrium water contact angle measurements were obtained for all 
samples using a FTA 1000 Drop Shape Instrument. The average contact 
angle was measured over ≥10 measurements using a droplet of deionised 
water (~5.0 µL) dispensed by gravity from a gauge 30 needle. A camera was 
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attached to the side in order to photograph the samples and the data were 
analysed using FTA32 software.  
4.2.4 Antibacterial Activity 
The following polymer samples (1 cm2) were prepared: (i) control samples 
(solvent treated and water treated), (ii) polyurethane-encapsulated 
glutaraldehyde and (iii) polyurethane coated with glutaraldehyde. The 
antibacterial activity of these samples was tested against S. aureus 8325-
422 and E. coli ATCC 25922. BHI broth (10 mL) was inoculated with 1 
bacterial colony and cultured in air (37 oC, 200 rpm, 18 h). The bacterial 
pellet was recovered by centrifugation, (20 oC , 2867.2 g, 5 min), washed in 
PBS (10 mL), centrifuged again to recover the bacteria (20 oC, 2867.2 g, 5 
min) and finally the bacteria were re-suspended in PBS (10 mL). The 
washed bacterial suspension was diluted 1000-fold to achieve an inoculum 
of ~106 cfu/mL. In each experiment, the inoculum was confirmed by plating 
10-fold serial dilutions on agar for viable counts. Triplicates of each 
polymer sample type were inoculated with 25 µL of the inoculum and 
covered with a sterile cover slip (2.2 cm2). The samples were incubated for 
up to 2 h (dark conditions). After incubation, the inoculated samples and 
cover slips were added to PBS (450 µL) and mixed thoroughly using a 
vortex mixer. The neat suspension and 10-fold serial dilutions were plated 
on agar for viable counts and incubated aerobically at 37 ○C for 48 (S. 
aureus) or 24 hours (E. coli). 
 
4.2.4.1 Statistical Significance 
The antibacterial experiments were repeated three times and the statistical 
significance of the following comparisons was analysed using the Mann-
Whitney U test: (i) control polymer vs. inoculum; (ii) polyurethane-
encapsulated glutaraldehyde vs. control polymer; (iii) polyurethane coated 
with glutaraldehyde vs. control polymer. 
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4.3 Results and Discussion 
4.3.1 Material Preparation 
Glutaraldehyde solution grade II was purchased from Sigma-Aldrich 
Chemical Co., containing 3% w/v glutaraldehyde in water. This solution was 
diluted by a factor of 100 to contain only ~0.03% w/v glutaraldehyde. By 
diluting the solution, the pH naturally increased from ~pH 3 to ~pH 8 and 
contained a low concentration of the biocide to minimise potential toxicity 
towards patients, visitors and staff in a clinical setting. Even though a 
concentration of up to 2% glutaraldehyde is acceptable within hospitals,15 
the application of these antibacterial surfaces differs from using the 
biocide solution to sterilise medical equipment and devices.9,15 The 
application for these polymer-encapsulated glutaraldehyde surfaces would 
be for frequently touched surfaces in a hospital (e.g. keyboard and 
electronic device covers), whereas glutaraldehyde solution used as a 
disinfectant is only handled by trained staff at specific times throughout 
their daily cleaning regime.8 The diluted biocidal solution (~0.03%) was 
further diluted by half (~0.015%) to prepare the modified polyurethane 
samples.  
To prepare the glutaraldehyde incorporated polymer samples, the biocidal 
solution was prepared in a 1:1 mix of acetone and glutaraldehyde solution 
in water for up to 24 hours at room temperature and pressure. This 
method of swell-encapsulation (as shown in Fig. 4.2) ensures uniform 
coating and incorporation of the biocide into the polymer substrate and 
across the surface. To prepare the glutaraldehyde-coated samples, the 
dilution was simply performed in pure water to obtain the same 
concentration of the biocide as the polyurethane-encapsulated 
glutaraldehyde samples.  These polymer squares were immersed into a 1:1 
mix of water and aqueous glutaraldehyde solution for up to 24 hours and 
then removed, washed and towel-dried.  
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4.3.2 Material Characterisation 
Infrared absorbance spectroscopy was obtained for all modified polymer 
samples (Fig. 4.3). The spectra demonstrated that neither encapsulating 
the biocide into the polymer nor coating the polymer with the biocide 
caused any chemical change of the polymer substrate. It also showed that 
there were no significant changes between the treated and untreated 
polyurethane samples. This can be attributed to the low concentration of 
glutaraldehyde used in the experiments and also due to strong absorbance 
bands of the polymer. XPS was used to determine the efficacy of swell-
encapsulating glutaraldehyde into the polymer (Fig. 4.4). XPS depth profile 
data (after samples were sputtered for 50 seconds) indicated that the 
carbon content did not decrease with polymer depth, but nitrogen and 
oxygen content did decrease with polymer depth across all polymer types 
tested, and therefore cannot be attributed to the presence of 
glutaraldehyde.  All modified polymer surfaces showed characteristic peaks 
corresponding to the presence of carbon (284.5 eV), nitrogen (399.3 eV) 
and oxygen (531.7 eV), showing no significant differences in percentage 
element composition between solvent treated (control) and samples 
treated with glutaraldehyde (data not shown). However, XPS data did show 
the presence of a new carbon environment on the surface of both 
polyurethane-encapsulated glutaraldehyde polyurethane coated with 
glutaraldehyde (287.6 eV; Fig. 4.4(a) and (c)). This indicates the presence of 
a new ketone-type C (1s) environment, corresponding to glutaraldehyde 
(Fig. 4.1). Additionally, another oxygen peak was shown exclusively on the 
surface of polyurethane-encapsulated glutaraldehyde, indicating the 
presence of an aldehyde group representing the biocide at the surface (Fig. 
4.4(b)). This data suggests that even after encapsulating the biocide, it 
mainly resides on the polymer surface.  
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Fig. 4.3 ATR-FTIR spectra of (a) solvent treated polyurethane (control), (b) polyurethane-
encapsulated glutaraldehyde and (c) polyurethane coated with glutaraldehyde. 
 
(a) 
(b) 
(c) 
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Fig. 4.4 XPS spectra for polyurethane-encapsulated glutaraldehyde surface: (a) carbon 
(1s) region and (b) oxygen (1s) region and for polyurethane surface coated with 
glutaraldehyde: (c) carbon (1s) region. 
 
The wetting properties of all modified samples were tested to see any 
changes in hydrophobicity of the samples when the biocide was 
incorporated either by encapsulating or coating. The water contact angles 
of untreated and treated samples indicate that polyurethane has a 
hydrophobic surface. After adding glutaraldehyde to the polymer (either 
by coating or encapsulating), there was a negligible change in 
hydrophobicity of the material, with contact angles varying by a maximum 
of ±1 degree. 
 
 
 
 114 
4.3.3 Antibacterial Activity 
The antibacterial activity of the following modified polyurethane samples 
was tested against S. aureus 8325-422 and E. coli ATCC 25922 in the dark: 
(a) control (solvent treated), (b) polyurethane-encapsulated glutaraldehyde 
and (c) glutaraldehyde-coated polyurethane. There are two control 
samples for this investigation: one is treated with a 1:1 ratio of 
acetone/water and the other is treated with water only. Both were tested 
for antibacterial activity and there was no significant difference between 
them, therefore the results shown in Fig. 4.5 and 4.6 only show the 
antibacterial activity of one control polymer (treated with 1:1 ratio of 
acetone/water).  
Following 30 minutes of incubation (Fig. 4.5(a)), the control and 
glutaraldehyde-coated samples did not show significant kill of S. aureus 
8325-4, whereas polyurethane-encapsulated glutaraldehyde displayed ~0.5 
log reduction of S. aureus 8325-4 (P < 0.001). After 1 hour (Fig. 4.5(b)), 
control polyurethane did not show any significant kill, but glutaraldehyde-
coated polymer demonstrated an ~1.5 log reduction in bacterial numbers. 
Polyurethane-encapsulated glutaraldehyde exhibited the greatest kill, 
reducing numbers of S. aureus 8325-4 to below the detection limit of 100 
cfu/mL (≥ 4 log; P < 0.001). After 1 hour of incubation (Fig. 4.5(c)), control 
polymer and glutaraldehyde-coated polyurethane did not show any 
reduction of E. coli ATCC 25922. However, polyurethane-encapsulated 
glutaraldehyde demonstrated a statistically significant reduction of the 
bacteria (~1.3 log; P < 0.001). Following 2 hours of exposure to E. coli ATCC 
25922 (Fig. 4.5(d)), solvent treated polyurethane did not demonstrate any 
significant bacterial kill, however, glutaraldehyde-coated polyurethane 
resulted in ~0.7 log reduction of the bacteria (P < 0.001). Furthermore, 
polyurethane-encapsulated glutaraldehyde showed considerable 
antibacterial activity by reducing bacterial numbers to below the detection 
limit (≥4 log; P < 0.001). 
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Fig. 4.5 Viable counts of S. aureus 8325-4 after incubation at 20oC on modified 
polyurethane squares for: (a) 30 min and (b) 1 h, and viable counts of E. coli ATCC 25922 
after incubation on modified polyurethane squares for: (c) 1 h and (d) 2 h. Control samples 
are solvent treated. * indicates bacterial numbers reduced below the detection limit of 
100 colony forming units/mL (cfu/mL).  
 
Table 4.2  Summary of the antibacterial activity of polyurethane-encapsulated 
glutaraldehyde and polyurethane-coated glutaraldehyde against S. aureus 8325-4 and E. 
coli ATCC 25922. Bacterial reduction is given in log form. 
Bacterial strain Polyurethane-
encapsulated 
glutaraldehyde 
Polyurethane-
coated 
glutaraldehyde 
S. aureus 8325-4 0.5 log (0.5 h) 
≥4 log (1 h) 
No kill (0.5 h) 
1.5 log (1 h) 
E. coli ATCC 25922 1.3 log (1 h) 
≥4 log (2 h) 
No kill (1 h) 
0.7 log (2 h) 
(a) (b) 
(c) (d) 
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Following 15 days of storage at room temperature, the antibacterial 
longevity of polyurethane encapsulated and coated with glutaraldehyde 
was tested against S. aureus 8325-4 and E. coli ATCC 25922 (Fig. 4.6). 
Polyurethane-encapsulated glutaraldehyde showed a reduced bactericidal 
effect against S. aureus 8325-4 and E. coli ATCC 25922, as both bacteria 
were only reduced by ~0.5 log in comparison to previous results which 
demonstrated ≥4 log reduction after 1 hour and 2 hours, respectively. 
Glutaraldehyde-coated polyurethane exhibited no significant antibacterial 
activity following 15 days and after 30 days, the bactericidal activity of both 
samples was undetectable (data not shown).  
 
 
Fig.  4.6 Viable counts (colony forming units/mL (cfu/mL)) of (a) S. aureus 8325-4 for 1 h 
and (b) E. coli ATCC 25922 for 2 h after incubation at 20oC on modified polyurethane 
squares left for 15 days. Control samples are solvent treated. 
 
A commonly used disinfectant in hospitals was incorporated into 
polyurethane at a very low concentration to test its bactericidal activity 
against S. aureus 8325-4 and E. coli ATCC 25922 as representative Gram-
positive and Gram-negative bacteria. The results clearly show that the 
antibacterial activity of polyurethane-encapsulated glutaraldehyde is much 
greater than glutaraldehyde coated onto polyurethane. Polymer-
encapsulated glutaraldehyde samples reduced both bacteria to below the 
detection limit within 2 hours, whereas glutaraldehyde-coated 
(b) (a)  
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polyurethane only caused ~0.7 – 1.5 log reduction against the bacteria 
within the same duration (Fig. 4.5). However, according to XPS data and 
water contact angle measurements, they contain similar amounts of 
biocide on the surface. The only known difference is the indication of an 
aldehyde group on the surface of the polyurethane-encapsulated 
glutaraldehyde (oxygen (1s) region; Fig. 4.4(b)) that is not shown on the 
XPS data for glutaraldehyde-coated polyurethane. This difference could be 
due to a greater concentration of the biocide at the surface that remains 
on polyurethane-encapsulated glutaraldehyde compared to glutaraldehyde 
coated onto the polymer after it has been washed and towel-dried.  
As described previously, monomeric glutaraldehyde undergoes 
polymerisation at alkaline pH, which blocks the active sites on the molecule 
and reduces its biocidal activity.23 This mechanism involves an Aldol 
condensation reaction; causing dehydration and yielding ethylene linkages 
conjugated with aldehyde functionalities.20 In basic conditions, this 
polymerisation reaction shifts the equilibrium of the reaction scheme 
shown in Fig. 4.7 to the left, resulting in more free aldehyde groups.24 
Therefore, by increasing the pH of the biocidal solution used in this 
investigation from ~pH 3 to ~pH 8, we encourage more free aldehyde 
groups to be formed which can undergo the condensation reaction to form 
poly-glutaraldehyde and limit the antibacterial activity of the solution. 
However, this pH change is inevitable when diluting the solution to reduce 
its toxicity, which is a main concern for its potential application as an 
antibacterial surface coating in hospitals.   
 
     
Fig. 4.7 Equilibrium reaction scheme of glutaraldeyde in basic conditions (adapted from 
Margel and Rembaum)24 
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The difference between the antibacterial activity of polyurethane coated 
and encapsulated with glutaraldehyde is possibly due to the rate of 
polymerisation that occurs on the biocide film once the samples have been 
prepared. It is likely that encapsulating the biocide prevents or delays 
polymerisation of the biocide, whereas coating the polymer with 
glutaraldehyde allows this process to occur at a faster rate. Even though 
XPS detected a similar low level of glutaraldehyde at the surface of both 
modified samples, it is still an effective amount to completely reduce both 
bacteria within only 2 hours. It is possible that encapsulating 
glutaraldehyde into the polymer substrate protects it from polymerisation 
and then it slowly leaches out causing an increased concentration of the 
biocide at the surface. Polymerisation may occur more slowly when the 
biocide is impregnated into the polymer matrix where there is a lower 
oxygen concentration and the molecule has less opportunity for monomer-
monomer interaction as a result of reduced diffusion.20  
Glutaraldehyde solution has many benefits as a hospital sterilant, including 
cost effectiveness25 and exceptional material compatibility.26 It is used as a 
cold sterilant to disinfect and clean heat-sensitive medical, surgical and 
dental equipment. Its biocidal activity is very similar to formaldehyde and 
works by either denaturing proteins or modifying nucleic acids by 
alkylation.27 This is favoured by more basic conditions (≥ pH 8), but in such 
conditions the molecule undergoes polymerisation and loses its 
bactericidal response.28 Following 15 days of storage, the antibacterial 
activity of polyurethane-encapsulated glutaraldehyde significantly reduced. 
Thus, these polymeric materials would be more suited for temporary uses, 
for example, disposable plastic covers to cover light handles in operating 
theatres and equipment.29,30 
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4.4 Conclusion 
For the first time, a well-known biocide used in hospitals was incorporated 
into polyurethane to show the effectiveness of the ‘swell-encapsulation-
shrink’ method compared to simply coating the polymer surface with the 
antibacterial agent. Polyurethane samples encapsulated and coated with 
glutaraldehyde were tested against representative Gram-positive and 
Gram-negative bacteria for potential use in hospitals in lowering the risk of 
spreading nosocomial infections. To minimise toxicity, a very low 
concentration of glutaraldehyde was used compared to reports in the 
literature.9,12,15,18 Functional tests showed that the hydrophobicity of the 
samples did not change as a result of adding glutaraldehyde, which is 
important in preventing biofilm formation at the surface.  
These antibacterial polymers have shown significant bactericidal activity in 
the dark compared to previous work on light-activated materials.31-36 
Chapter 3 revealed a greater swelling capability of polyurethane in 
comparison to silicone; thus, polyurethane was used in this investigation to 
ensure a larger amount of glutaraldehyde was impregnated into the 
polymer. For polyurethane-encapsulated glutaraldehyde, numbers of S. 
aureus 8325-4 and E. coli ATCC 25922 were reduced to below the detection 
limit after only 1 or 2 hours, respectively. However, glutaraldehyde-coated 
polyurethane did not exhibit such efficacious bactericidal activity. The 
outstanding results obtained from these polymers show that they could be 
suitable for surfaces that are not exposed to light, where light-activated 
surfaces would be less effective. 
This investigation has shown the potential for glutaraldehyde to be used as 
an antibacterial surface for reducing HAIs if the longevity of its antibacterial 
activity can be improved. The results have shown that encapsulating the 
biocide into the polymer retains bactericidal activity for longer than when 
the biocide is coated onto the polymer, but further work is needed to 
identify new methods that will increase its antibacterial activity over time. 
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Traditionally this biocide is widely used in solution form to disinfect 
medical and surgical equipment. However, this investigation has 
demonstrated that glutaraldehyde can be incorporated into a polymer 
matrix as a potential short-term antibacterial surface or coating. 
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Chapter 5 
5. Polyurethane Encapsulated with Crystal Violet 
and 18 nm ZnO Nanoparticles; White Light 
Activated Antimicrobial Polymers 
 
5.1 Introduction 
HAIs have become a severe burden to the NHS, costing them around £1 
billion each year.1 Patients who acquire these infections can experience 
discomfort, disability, and even death. Almost 80% of HAIs are transmitted 
by touch, due to the fact that a significant amount of patients, visitors and 
staff infrequently practice the high standard of personal hygiene that is 
required in healthcare environments.2 Frequently touched surfaces, such 
as push plates, door handles, electronic devices and food trays, act as 
bacterial reservoirs for transmission.3 Therefore, staff and visitors can 
become contaminated by either direct contact with a patient or from 
touching a contaminated surface, facilitating the spread of these infections.  
Chapters 3 and 4 focused on the encapsulation of antibacterial agents into 
polymers that do not require UV or white light to activate their bactericidal 
properties. These polymers have proven to reduce hospital pathogens in 
the dark within exposure times of only a few hours. However, as shown in 
Chapter 4 with polyurethane-encapsulated glutaraldehyde, the 
antibacterial activity of these polymers dramatically declines after 2 weeks 
following preparation. It is possible that glutaraldehyde is killing the 
bacteria by leaching from the polymer surface which diminishes its 
antibacterial activity over time. Chapter 3 demonstrated the highly 
effective bactericidal effect of copper-incorporated polymers. Mechanistic 
studies suggested that these polymers might reduce bacteria by leaching 
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copper ions and/or by electrostatic interaction between the nanoparticle 
surface and the bacterial membrane. The results indicated that ROS were 
not being produced and thus, were not responsible for the antibacterial 
activity observed from these polymers.  
This chapter introduces the development of self-sterilising surfaces which 
incorporate photosensitiser dyes into the polymer. These photo-activated 
surfaces reduce bacteria by producing ROS when illuminated at specific 
wavelengths of light, using a process known as photodynamic therapy 
(PDT).4 The main advantage of PDT is that these antibacterial agents can 
destroy bacteria via multiple pathways, thus, the development of 
resistance is unlikely.5 These photosensitisers (molecular dyes) are non-
toxic, but when irradiated by light, the molecule is promoted from an 
excited singlet state to an excited triplet state, producing ROS species via a 
Type I (electron transfer) and/or Type II (energy transfer) photochemical 
processes.6 Type I involves the production of cytotoxic ROS such as 
superoxide anion and hydroxyl radicals, and Type II produces highly 
reactive singlet oxygen.7 It is difficult to determine whether a Type I or 
Type II mechanism is causing the photodamage because it is unclear if the 
effects are exclusively due to the production of ROS. Photosensitisers do 
not display the same toxicity towards mammalian cells as bacterial cells. It 
requires a much greater density of photosensitiser molecules to cause 
irreversible cell damage to mammalian cells as they are more resistant and 
larger than bacterial cells.8,9 
As demonstrated in Chapter 3, some nanoparticles are highly effective at 
killing bacteria without light activation. However, other nanoparticles, such 
as TiO2, require UV illumination to induce antibacterial activity.10,11 Metal 
oxide nanoparticles (such as MgO, CuO, Fe2O3 and ZnO) have been studied 
previously for their antibacterial properties against a wide range of 
bacteria, including E. coli and S. aureus.12-15 ZnO nanoparticles (ZnO NPs) 
have been extensively reviewed for their bactericidal activity because they 
are non-toxic, cheap and used in many applications such as food 
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packaging13 and as a UV protector in cosmetics.16 The exact mechanism of 
the antibacterial activity of ZnO NPs is not yet understood, although some 
studies suggest that their antibacterial activity is a result of releasing Zn2+ 
that cause bacterial cell membrane disruption and from producing ROS 
(and consequently H2O2), which are harmful towards the cells.13,17 ZnO has 
a wide band gap of 3.3 eV and exhibits high absorption in the UV region.18 
However, ZnO NPs have shown to produce ROS without UV illumination, 
i.e. in the dark, due to surface defects that can enable electron transfer to 
oxygen.13 They demonstrate selective antibacterial activity but exhibit a 
minimal effect on mammalian cells.19  
The Materials Research Centre at UCL has studied the antibacterial activity 
of photosensitisers, such as crystal violet (CV), methylene blue (MB) and 
toluidine blue O (TBO), when incorporated into polymers.20-22 Moreover, 
the incorporation of nanoparticles with the photosensitiser can 
significantly enhance the bacterial kill of the photosensitiser.23-30 This has 
either been achieved by activating the polymer samples using short-term 
illumination from a laser source, or over a longer period using hospital 
lighting of different intensities. These samples have been prepared by using 
a simple, two step ‘swell-encapsulation-shrink’ method which incorporates 
the nanoparticles into the polymer (step 1) and then incorporates the dye 
in the polymer (step 2). In particular, CV dye has demonstrated efficacious 
antibacterial activity when coated onto two different types of silicone 
material.22,23,28-30 Table 5.1 summarises the antibacterial activity of 
polymers containing CV against E. coli ATCC 25922 within various 
irradiation times and intensities.  
CV, also known as Gentian Violet, is a cationic triarylmethane dye which is 
FDA approved and known to exhibit antimicrobial properties.31,32 
Fluorophores such as CV are a type of molecular rotor, which contain an 
electron donor group in π-conjugation with an electron acceptor group 
(Fig. 5.1).33 Unlike other typical photosensitisers such as MB and TBO, the 
emission properties of CV are highly dependent on solvent viscosity.31 
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Solvents with high viscosity can limit any intramolecular twisting from the 
planar, non-twisted conformation, resulting in a change in the 
photophysical properties of CV.34 In solvents such as water with a relatively 
low viscosity, CV is unable to produce singlet oxygen since the triplet state 
quantum yield is negligible. However, under an increased viscosity the 
molecular rotor is restricted, which stabilises the excited singlet state to 
allow intersystem crossing to populate the triplet state.31 Therefore, by 
incorporating CV into a polymer matrix (i.e. an environment with high 
viscosity), singlet oxygen can be produced via the Type II mechanism.  
 
 
Fig. 5.1 Molecular structure of crystal violet dye 
 
In this study, CV dye is coated onto medical grade polyurethane sheets and 
tested for antibacterial activity against S. aureus 8325-435 and E. coli ATCC 
25922. Monodisperse ZnO NPs (~18 nm) were synthesised from the 
thermal decomposition of a metal-oleate precursor and incorporated into 
the polymer. Lethal photosensitisation was observed from CV-coated 
polyurethane against both bacteria and a further enhancement in 
antibacterial activity of the dye was observed when the semi-conducting 
ZnO NPs are incorporated into the polymer. Lastly, the mechanism of 
antibacterial activity of these CV and ZnO-incorporated polyurethane 
samples (CVZnO) was investigated to determine whether Type I and/or 
 129 
Type II processes are responsible for killing the bacteria when exposed to a 
white light source and in the dark.  
 
Table 5.1 Overview of the antibacterial activity of silicone polymer samples prepared and 
tested by the Materials Chemistry Research Centre at UCL against E. coli ATCC 25922. (CV: 
crystal violet-coated polymer, CVAu: crystal violet and 2 nm gold-incorporated polymer, 
CVMBAu: crystal violet, methylene blue and 2 nm gold-incorporated polymer) 
Polymer Dye 
combination 
Irradiation Time Log kill 
Medical grade silicone 
sheets23,28,29 
CV 
CVAu 
635 nm laser 
635 nm laser 
13.5 min 
13.5 min 
No kill 
~ 2.5 
 CVMBAu White light 
(4,000 lux) 
3 h ~ 2 
 CVMBAu Dark 18 h ~ 1.5 
Silicone elastomers from 
viscous liquid 
polydimethylsiloxane22,30 
CV 
12345678 
CVZnO 
12345678 
CVZnO 
White light 
(11,500 lux) 
White light 
(11,500 lux) 
Dark 
6 h 
123456 
4 h 
12345 
4 h 
≥ 4 
123455 
≥ 4 
12345 
~ 0.5  
 
 
5.2 Experimental 
5.2.1 ZnO Nanoparticles 
5.2.1.1 Chemicals and Reagents 
All chemicals used to synthesise the ZnO NPs were purchased from Sigma-
Aldrich Chemical Co; including zinc chloride (98%), oleylamine (technical 
grade, ≤70%), sodium oleate (≤82% fatty acid content), 1-octadecene 
(technical grade, 90%), and oleic acid (technical grade, 90%). 
 
5.2.1.2 Nanoparticle Synthesis 
ZnO NPs were synthesised by a thermal decomposition of zinc oleate, 
adapted from a method developed by Park et al.36 Firstly, zinc oleate was 
prepared by heating a zinc (II) chloride suspension (10 mmol, 1.36 g) and 
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sodium oleate (20 mmol, 6.08 g) in a solvent mixture of hexane (140 ml), 
ethanol (80 ml) and deionised water (60 ml) at 60 ○C for 4 h. To remove 
sodium oleate, the organic layer was separated and washed, and then 
dried in vacuo to remove hexane, forming a white solid (zinc oleate).  Zinc 
oleate (1 g, 1.6 mmol) and oleic acid (0.1784 ml) were dissolved in 1-
octadecene (20 ml) and stirred at room temperature. The reaction mixture 
was heated at a rate of 3.3 oC min-1 to 320 oC under nitrogen and then held 
at a constant temperature of 320 oC for 1 h, yielding a brown solution. 
Once the solution cooled to room temperature, ethanol (80 ml) was added 
to precipitate the nanoparticles. This solution was centrifuged (20 oC, 504 
g, 6 min) to form a solid precipitate. The supernatant was discarded and 
the solid precipitate was dispersed in hexane (30 ml).       
 
5.2.1.3 Nanoparticle Characterisation 
The nanoparticles were characterised (in hexane) using transmission 
electron microscopy (TEM) and energy dispersive X-ray spectroscopy (EDX). 
TEM micrographs and EDX spectra were performed using a Jeol 2100 
HRTEM with a LaB6 source operating at an acceleration voltage of 200 kV 
with an Oxford Instruments XMax EDS detector running AZTEC software. 
The images were recorded on a Gatan Orius Charge-coupled device (CCD). 
The ZnO NP suspension was drop-casted onto a 400 Cu mesh lacy carbon 
film TEM grid (Agar Scientific Ltd). The images were analysed using ImageJ 
software.  
 
5.2.2 Polymer Samples 
5.2.2.1 Chemicals and Reagents 
Medical grade flat polyurethane sheets (thickness 0.8 mm) were purchased 
from American Polyfilm Inc. (Branford, CT, USA). To prepare the polymer 
samples, the following reagents were used: CV (Sigma, UK), ZnO NPs 
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suspended in hexane (method adapted from Park et al36), hexane (Sigma-
Aldrich, UK) and dichloromethane (VWR, UK). Deionised water was used 
(resistivity 15 MΩ cm) during synthesis and preparation. 
 
5.2.2.2 Material Preparation 
Polymer System Optimisation 
(a) Organic Solvent - 1 cm2 polyurethane sheets were immersed in the 
following organic solvent solutions made up at a 1:1 ratio: 
hexane/dichloromethane (DCM), hexane/acetone, and 
hexane/tetrahydrofuran (THF). They were left to swell for 24 h in the dark, 
then removed, air-dried overnight, washed and towel-dried. 
(b) Hexane/DCM Ratio - 1 cm2 polyurethane squares were immersed in the 
following hexane/DCM ratios: 1:0, 7.5:2.5, 1:1, 2.5:7.5 and 0:1. They were 
allowed to swell for 24 h in the dark, removed and air-dried overnight, and 
then washed and towel-dried.  
(c) CV Dye Concentration - Polyurethane squares were immersed in the 
following CV solutions in distilled water for up to 72 h: 0.00001 M, 0.0001 
M and 0.001 M. The squares were then removed from solution, washed 
and towel-dried. 
(d) CV Dye Immersion Time - The samples were immersed in 0.001 M CV 
solution for various dipping times: 0, 0.5, 1, 4, 8, 16, 24, 48, 72 and 96 h. 
They were removed from solution, washed and towel-dried. 
 
Polymer Samples Prepared for Antibacterial Testing 
The following modified polyurethane samples (1 cm2) were prepared for 
antibacterial testing (Fig. 5.2):  
(a) Control samples were immersed in a 1:1 hexane/DCM swelling 
solution (24 h, dark conditions). 
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(b) Crystal violet-coated samples (CV) were (i) immersed in a 1:1 
hexane/DCM swelling solution (24 h, dark conditions), removed, 
washed and dried, and then (ii) dipped into a 0.001 M CV solution 
for 72 h, removed, washed and towel-dried. 
(c) Polyurethane-encapsulated ZnO nanoparticles (ZnO) immersed in a 
1:1 ratio of hexane/DCM swelling solution containing ZnO 
nanoparticles (24 h, dark conditions), washed and towel-dried. 
(d) Polyurethane coated with CV and encapsulated with ZnO (CVZnO) 
were prepared by: (i) immersion in a 1:1 hexane/DCM swelling 
solution containing ZnO NPs (24 h, dark conditions), followed by (ii) 
immersion in 0.001 M crystal violet solution for 72 h in the dark, 
washed and towel-dried.  
 
 
 
Fig. 5.2 Schematic step-by-step method illustrating the preparation of crystal violet and 
ZnO incorporated into polyurethane (CVZnO). Squares indicate 1 cm2 polymer squares 
used.  
 
5.2.2.3 Material Characterisation 
A Perkin Elmer Fourier transform Lambda 950 UV-vis spectrometer was 
used to measure the absorption spectra of the modified polyurethane 
polymers over a wavelength range of 400 – 700 nm. 1 cm2 flat 
polyurethane sheets were immersed in a 0.001 M CV solution for 72 h. 
They were removed from solution, washed, towel-dried and then 
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embedded vertically in paraffin blocks. 15 µm thick cross-sections of the 
polymer were cut using a microtome and mounted on Vectabond (Vecta 
Laboratories, UK) treated slides for fluorescence imaging. The cross-
sections were imaged using a 10x objective light microscope (Olympus UK 
Ltd., model BH2) with a colour CCD digital camera (Lumenera Inc., model 
Infinity 1) using Infinity capture software for analysis. The same 15 µm 
thick cross-sections were used in fluorescence microscopy; they were 
imaged (10x objective) using a cooled scientific-grade 16-bit digital CCD 
camera (Princeton Instruments Inc., Model PIXIS 512) operated by Win-
Spec software, coupled to an inverted fluorescence microscope (Olympus 
UK Ltd., Model IMT-2). The fluorescence signal from CV present in the 
polymer was detected using a bandpass filter centred at 640 nm (Omega 
Optical Inc., 640DF35) using excitation by a 532 nm laser diode (Thorlabs 
Inc.). 
Inductively coupled plasma-optical emission spectroscopy (ICP-OES) was 
used to determine the extent of ZnO NPs leaching from the polymer 
samples. ICP-OES was measured on a Perkin Elmer Optima 2000 DV. ZnO-
incorporated samples were immersed in 2 mL deionised water for up to 48 
h. The solution was diluted to 5 mL and the concentration of zinc was 
calculated using a calibration curve determined from solutions containing 
[Zn] = 0, 0.1, 1 and 10 mg/L. 
 The infrared absorbance spectra of the modified polymer samples were 
measured using a Brüker Platinum ATR, within the range 4000 – 400 cm-1 
with an accumulation of 16 scans per sample. X-ray photoelectron 
spectroscopy (XPS) analysis was carried out on the modified polymers using 
a Thermo Scientific K-Alpha spectrometer to classify the different elements 
present as a function of polymer depth. All binding energies were 
calibrated to C 1s peak at 284.5 eV. Equilibrium water contact angle 
measurements were obtained for each type of sample prepared for 
microbiological investigation, using a FTA 1000 Drop Shape Instrument. The 
average contact angle measurement over ≥10 measurements was 
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calculated using a droplet of deionised water (~5.0 µL) dispensed by gravity 
from a gauge 30 needle, with a camera to photograph the samples side on. 
The data was analysed using FTA32 software.  
The stability of crystal violet coated-polyurethane was investigated in 
phosphate buffered saline (PBS, Dulbecco A) to determine the extent of 
leaching of the dye (2.5 mL PBS, 37 ○C) over an extended period of time. 
The UV-vis absorbance (596 nm, Pharmacia Biotech Ultrospec 2000) of PBS 
was measured periodically to monitor any leaching of the dye from the 
modified polymer into the surrounding solution. The concentration of CV 
released into PBS was determined by comparing the absorbance of the 
solution at 596 nm with a CV dye calibration curve. The extent of leaching 
of ZnO NPs from the modified polymer was tested in a similar fashion, 
where the UV-vis absorbance of the ZnO NP suspension was compared to 
the PBS solution containing polymer-encapsulated ZnO sample up to 48 h 
at room temperature. 
 
5.2.3 Antibacterial Activity 
5.2.3.1 Microbiology Assay 
The antibacterial activity of the following polymer samples were tested 
against S. aureus 8325-4 and E. coli ATCC 25922 as representative Gram-
positive and Gram-negative bacteria, respectively: (a) solvent treated 
(control), (b) CV-coated polyurethane (CV), (c) polyurethane-encapsulated 
ZnO (ZnO) and (d) polyurethane-encapsulated CV and ZnO (CVZnO). S. 
aureus 8325-4 and E. coli ATCC 25922 were stored at -70 ○C in Brain-Heart-
Infusion broth (BHI, Oxoid) containing 20% (v/v) glycerol and propagated 
onto Mannitol Salt agar (MSA, Oxoid) in the case of S. aureus or 
MacConkey agar (MAC, Oxoid) in the case of E. coli for a maximum of 2 
subcultures at 2 week intervals.  
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BHI broth was inoculated with 1 bacterial colony and cultured in air with 
shaking (37 oC; 18 h; 200 rpm). The bacterial pellet was recovered by 
centrifugation, (20 oC , 2867.2 g, 5 min), washed in PBS (10 mL), centrifuged 
again to recover the pellet (20 oC, 2867.2 g, 5 min), and then the bacteria 
were re-suspended in PBS (10 mL). The washed suspension was diluted 
1000-fold to obtain an inoculum of ~106 cfu/mL. In each experiment, the 
inoculum was confirmed by plating 10-fold serial dilutions on agar for 
viable counts. A minimum of duplicates of each polymer sample type were 
inoculated with 25 µL of the inoculum and covered with a sterile cover slip 
(2.2 cm2). The samples were irradiated for up to 4 h using a white light 
source (General Electric 28 W Watt MiserTM T5 2D compact fluorescent 
lamp) emitting an average light of 6600 ± 990 lux at a distance of 25 cm 
from the samples. A further set of samples (minimum of duplicates) was 
incubated in the dark for the same duration as the irradiated samples.  
Following incubation, the inoculated samples and cover slips were added 
to PBS (450 µL) and vortexed (20 s). The neat suspension and 10-fold serial 
dilutions were plated on agar for viable counts and incubated aerobically at 
37 ○C for 48 h (S. aureus) or 24 h (E. coli).  
 
5.2.3.2 Statistical Significance 
Each experiment contained a minimum of 2 technical replicates and the 
experiment was repeated three times. The statistical significance of the 
following comparisons in both the light and dark was analysed using the 
Mann-Whitney U test: (i) control polymer vs. inoculum; (ii) CV or ZnO alone 
vs. control polymer; (iii) CVZnO vs. CV alone.  
 
5.2.3.3 Hydrogen Peroxide and Singlet Oxygen Detection 
Specific hydrogen peroxide and singlet oxygen inhibitors were used against 
E. coli ATCC 25922 to understand the mechanism operating in the 
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photobactericidal activity of the CVZnO polymers and in the dark. Bovine 
catalase, bovine serum albumin (BSA) and L-histidine (Sigma-Aldrich, UK) 
were filter sterilised using a 0.2 µm syringe filter (VWR, UK). Catalase (220 
U mL-1 in PBS) was used to eliminate hydrogen peroxide in radical 
formation, and BSA (0.03% in water) and L-histidine (1 mM in PBS) were 
used as singlet oxygen quenchers. The enzyme/ROS inhibitors were added 
to the E. coli suspension and exposed to the polymer using the protocol 
described above. 
 
5.3 Results and Discussion 
5.3.1 ZnO Nanoparticle Synthesis and Characterisation 
ZnO NPs were synthesised via a two-step method adapted from Park et 
al.36 A reaction between zinc chloride and sodium oleate produced zinc-
oleate precursors, followed by the formation of nanoparticles using a 
thermal decomposition method in a mixture of solvents at 320oC. The 
nanoparticles were finally centrifuged, re-suspended in hexane and 
characterised using TEM and EDX (Fig. 5.3). They were prepared for TEM by 
drop-casting the nanoparticle suspension (in hexane) onto a gold TEM grid 
with a holey carbon film (Agar Scientific, UK) and left to dry before analysis. 
The TEM images displayed monodisperse ZnO NPs (18.3 ± 4.9 nm in 
average diameter size) forming anisotropic hexagonal and triangular 
shaped particles. EDX analysis showed the elemental composition of ZnO 
NPs, demonstrating ratios well within error limits.  
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Fig. 5.3 (a) TEM images and (b) EDX spectrum of ~18 nm ZnO nanoparticles.  
 
5.3.2 Preparation and Characterisation of Polymer Samples 
Hexane alone is unable to swell polyurethane samples, therefore another 
organic solvent was required to swell-encapsulate the nanoparticles into 
the polymer matrix. 1 cm2 polyurethane samples were immersed into 
different organic solvent solutions made up at a 1:1 ratio with hexane. 
Hexane/acetone swelled the polymer 30% more than its original size, 
however, hexane/DCM swelled the polymer up to 42% more than its 
original size. Hexane/THF swelled the polymer the most (72%) but after the 
polymer was left to shrink and dry overnight it became distorted and 
curled around the edges. As hexane/DCM swelled polyurethane effectively 
without deforming its size and shape, various ratios of this solvent mixture 
were tested to optimise the ‘swell-encapsulation-shrink’ method. The 
following hexane/DCM ratios were used: 1:0, 7.5:2.5, 1:1, 2.5:7.5 and 0:1. 
100% hexane did not swell the polymer at all and 100% DCM resulted in a 
very distorted polymer. 7.5:2.5 ratio of hexane/DCM did not swell the 
polymer as much as 1:1, and a 2.5:7.5 hexane/DCM solution resulted in 
distorted polymer squares which were curled at the edges. To carry out 
(a) 
(b) 
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reproducible antibacterial testing on the samples, it is essential that all 1 
cm2 polymer squares return back to their original size and shape after the 
swelling process. Therefore a 1:1 hexane/DCM ratio was used to swell-
encapsulate the NPs into the polymer. 
The polymer squares were also immersed in different concentrations of CV 
dye: 0.00001 M, 0.0001 M and 0.001 M. UV-vis absorption spectroscopy 
was used to determine the best concentration of CV to use. As shown in 
Fig. 5.4, all CV-coated polymer samples exhibited an absorption peak for CV 
at λ = ~590 nm and a smaller shoulder peak at λ = ~548 nm. As the 
concentration of the dye increased to 0.001 M, there was a greater uptake 
of the dye. Additionally, the absorbance values did not directly scale 
linearly with dye concentration, implying that some dimerisation has 
occurred. To further optimise the polymer system, the samples were 
immersed in 0.001 M CV solutions for various immersion times for up to 96 
h (Fig. 5.5). An immersion time of 72 h was optimal as it allowed an even 
colouration of the polymer without absorbing too much of the dye. 
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Fig. 5.4 UV-vis absorbance spectra of crystal violet-coated polyurethane (CV) prepared by 
dipping in a CV solution for 72 h at the following concentrations: 0.00001 M, 0.0001 M 
and 0.001 M. Spectrum for crystal violet and ZnO incorporated into polyurethane (CVZnO) 
sample is also shown, prepared by immersing in a 0.001 M CV solution (measured in 400 – 
700 nm range). 
 
 
 
Fig. 5.5 1 cm2 polymer samples prepared by immersion in 0.001 M crystal violet solution 
for increasing lengths of time (up to 96 h). 
 
A polymer sample immersed in 0.001 M CV solution for 72 h was analysed 
using a light microscope attached to a CCD camera to determine the 
efficiency of dye uptake and distribution within the polymer (Fig. 5.6). Fig. 
5.6(a) shows that the dye diffuses throughout the polymer bulk with a 
greater uptake towards the edges of the sample. It also shows that the 
polymer matrix contains many straight ridges and scattered ‘spots’. The 
same polymer section was analysed using fluorescence microscopy, shown 
in false colour (Fig. 5.6(b)). The false colour scale corresponds to a low 
fluorescence (shown in black) to a high fluorescence (shown in white). The 
fluorescence measurements also confirmed that the dye diffuses 
throughout the polymer bulk but is more concentrated at the surface. 
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There is a stronger fluorescence at the surface and inside the ‘spots’ 
located within the polymer substrate, where the dye has possibly 
aggregated within the pores. 
 
 
 
Fig. 5.6 (a) An image of a 15 µm thick crystal violet-coated polyurethane section prepared 
by immersing the polymer in a 0.001 M crystal violet solution for 72 h. The image was 
recorded using a 10x objective (scale bar corresponds to 100 µm). The actual thickness of 
the polymer sample is 0.8 mm. (b) A CCD false coloured fluorescence microscopy image of 
the same polymer section shown in (a). The polymer sample is shown on the left hand side 
of the image, where the black part of the image represents the background (no 
fluorescence). There is a fluorescence intensity scale, increasing from black 
(background/no fluorescence) to white (maximum fluorescence). The image resolution is 
512 x 512 pixels and corresponds to 557 x 557 µm (100 µm scale bar). 
 
The amount of CV released from CV-coated polyurethane was measured 
using UV-vis absorption spectroscopy. The samples were immersed in a 
pre-heated solution of PBS (37 oC) for up to 360 h. The concentration of CV 
dye leached from the sample was compared to the optical density of the 
surrounding PBS solution with a CV calibration curve. Fig. 5.7 shows that a 
small amount of dye leaches into the solution initially, which then plateaus 
rapidly over time. Overall, the leaching concentrations were at the 
(a) 
(b) 
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detection limit of the spectrometer and remained below 1.5 x 10–6 M after 
360 h. Temperatures of 37 oC were used as these novel materials are 
potentially for use in medical devices. The amount of dye that leached 
from the polymer was minimal at 37 oC, thus it is expected that at room 
temperature (appropriate if these materials were used for hospital 
surfaces), it would be even less significant. A major disadvantage of PDT is 
the ability of the photosensitiser to localise at high concentrations within 
the body or onto the skin.37 For example, swelling, sunburn and blistering 
can result from the unwanted accumulation of a photosensitiser to the skin 
and eyes if the patient is exposed to bright light for several days after 
treatment.38 Thus, this would not be an issue for CV-coated polyurethane 
as a potential material for invasive devices as it demonstrates minimal 
amounts of leaching.  
 
 
Fig. 5.7 Leaching of dye from crystal violet-coated polyurethane (0.001 M) in PBS solution 
at 37 oC measured as a function of time. 
 
The two-step ‘swell-encapsulation-shrink’ method was used to incorporate 
ZnO NPs into the polymer substrate and then coat the polymer with CV dye 
(Fig. 5.2). It is a simple method that enables the nanoparticles to diffuse 
throughout the polymer bulk without the need for covalent attachment. 
ICP-OES analysis was used to determine whether any zinc species leached 
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from the modified polymer samples when the films were immersed in 
water for up to 48 h. The results showed that only 0.132 ± 0.0002 mg/L of 
zinc leached from the polymer after 2 h and 1.696 ± 0.017 mg/L after 48 h. 
Although the nanoparticles are non-toxic, they are well incorporated into 
the polymer with minimal amounts of leaching into surrounding solutions 
or possibly transferred by human contact.    
CVZnO was analysed using UV-vis spectroscopy (Fig. 5.4). When ZnO NPs 
were added with CV to the polymer, there was an increase in the 
absorption maxima of the main absorption peak at ~590 nm and shoulder 
peak at 548 nm. There was also a minor blue (hypsochromic) shift as the 
main absorption peak for CV shifted to ~586 nm and the peaks became 
broader. Thus, the presence of the ZnO NPs affects dye uptake, since 
spectral features such as peak shape, position and intensity differ from CV-
coated polyurethane. The addition of ZnO NPs alone affects the colour of 
the polymer prior to adding CV. This is because the nanoparticle 
suspension is slightly yellow in colour due to the surfactants present in the 
solution. Therefore, CVZnO samples are slightly darker than CV-coated 
polyurethane.  
ATR-FTIR spectra (Fig. 5.8) did not show any significant changes between 
the modified and untreated polyurethane samples. This can be attributed 
to the strong absorbance bands of the polymer and due to the low 
concentrations of dye and nanoparticles present in the samples. 
Nevertheless, this confirms that the “swell-encapsulation-shrink” method 
does not affect the polyurethane substrate in terms of a recognisable 
chemical change when incorporating the dye or ZnO NPs. Water contact 
angle measurements exhibited a negligible difference between material 
hydrophobicity of untreated and modified polyurethane samples, varying 
in contact angle ±10o.   
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Fig. 5.8 ATR spectrum of (a) solvent treated (control), polyurethane encapsulated with (b) 
ZnO, (c) crystal violet, and (d) crystal violet and ZnO. 
 
XPS was used to determine the efficacy of the ‘swell-encapsulation-shrink’ 
method for incorporating ZnO NPs into the polymer (Fig. 5.9). From both 
the control and ZnO-incorporated polymer, peaks attributed to the 
presence of carbon 1s (284.5 eV), nitrogen 1s (399.5 eV) and oxygen 1s 
(531.9 eV) on the surface were observed, with no significant difference in 
percentage element composition between the samples (data not shown). 
XPS depth profile analysis for all samples demonstrated no change in 
carbon and nitrogen composition, but a decrease in oxygen content with 
polymer depth. Zn (2p) was detected on the surface of ZnO-incorporated 
polyurethane (Fig. 5.9(a)) and an even higher zinc content (1021.5 eV) was 
demonstrated within the bulk in comparison to the surface (Fig. 5.9(b) and 
(c)).   
 
 
(a) (b) 
(c) (d) 
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Fig. 5.9 Zn 2p region XPS spectra for: (a) ZnO-incorporated surface; (b) ZnO-incorporated 
polymer sputtered 50 s; and (c) ZnO-incorporated polymer sputtered 100 s.  
 
5.3.3 Antibacterial Activity 
The photobactericidal activity of the following modified polyurethane 
samples was tested against S. aureus 8325-4 and E. coli ATCC 25922 as 
representative Gram-positive and Gram-negative nosocomial pathogens, 
respectively: (i) solvent treated (control), (ii) crystal violet-coated (CV), (iii) 
encapsulated with ZnO NPs (ZnO), and (iv) encapsulated with CV and ZnO 
(CVZnO). The samples were exposed to a white light source for up to 4 h, 
mimicking the lighting in a typical UK hospital ward (~6600 lux) and a 
further set of samples were incubated in the dark for the same incubation 
time.  
Fig. 5.10 displays the lethal photosensitisation of S. aureus 8325-4 
following 1 or 2 h of white light exposure emitting an average light 
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intensity of 6600 ± 990 lux at a distance of 25 cm from the modified 
samples. After 1 h of incubation in the dark (Fig. 5.10(a)), none of the 
control, CV or ZnO-coated polymers caused any significant kill of S. aureus 
8325-4, whereas CVZnO demonstrated a statistically significant reduction 
in bacterial numbers (~1.5 log; P = 0.002). Following 1 h of white light 
exposure, there was no bactericidal activity observed from the control or 
ZnO sample. However, CV-coated polyurethane resulted in ~2 log 
reduction in bacterial numbers (P = 0.002). In addition to this, CVZnO 
resulted in the greatest kill, reducing S. aureus 8325-4 numbers to below 
the detection limit (≥ 4 log; P = 0.002). 
Following 2 h of exposure in the dark (Fig. 5.10(b)), control and ZnO-coated 
polyurethane did not cause any significant kill of S. aureus 8325-4, whereas 
CV alone caused ~1.4 log reduction in bacterial numbers. Furthermore, 
CVZnO demonstrated statistically significant bactericidal activity (≥ 4 log; P 
= 0.002). By exposing the samples to white light for 2 h, both CV and 
CVZnO resulted in highly significant bactericidal activity (≥ 4 log; P = 0.002). 
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Fig. 5.10 Viable counts of S. aureus 8325-4 after incubation on modified polyurethane 
samples incubated at 20 oC in the dark and exposed to white light illumination for: (a) 1 h 
and (b) 2 h. White light source emitted an average light intensity of 6600 ± 990 lux at a 
distance of 25 cm from the samples. * indicates bacterial numbers reduced to below the 
detection limit of 100 colony forming units/mL (cfu/mL).  
 
The photobactericidal activity of the modified polyurethane samples was 
also tested against E. coli ATCC 25922 under the same conditions but for an 
extended period of time. As shown in Fig. 5.11(a) none of the samples 
demonstrated any significant kill of E. coli ATCC 25922 after 2 h of 
incubation in the dark. However, a 2 h exposure to white light induced ~1 
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log reduction in bacterial numbers with CV alone, whereas the control and 
ZnO samples did not cause any significant kill. The combination of CV and 
ZnO in the polymer enhanced the bactericidal activity demonstrated by CV 
alone, resulting in ~2.5 log reduction of E. coli ATCC 25922 (P = 0.004). 
By increasing the incubation time to 4 h in the dark (Fig. 5.11(a)), the 
control and ZnO samples still did not display significant kill of E. coli ATCC 
25922, whereas CV alone caused ~1.3 log reduction. Most significantly, 
CVZnO exhibited lethal photobactericidal activity against E. coli ATCC 25922 
by reducing bacterial numbers to below the detection limit (≥ 4 log; P = 
0.002). Following 4 h of white light exposure, both CV and CVZnO caused 
≥4 log reduction in the numbers of E. coli ATCC 25922 (P = 0.002). 
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Fig. 5.11 Viable counts of E. coli ATCC 25922 after incubation on modified polyurethane 
samples incubated at 20 oC in the dark and exposed to white light illumination for: (a) 2 h 
and (b) 4 h. White light source emitted an average light intensity of 6600 ± 990 lux at a 
distance of 25 cm from the samples. * indicates bacterial numbers reduced to below the 
detection limit of 100 colony forming units/mL (cfu/mL). 
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Table 5.2 Summary of the antibacterial activity of polyurethane coated with CV and 
encapsulated with CVZnO in the dark and following white light incubation (6600 ± 900 lux) 
against S. aureus 8325-4 and E. coli ATCC 25922.  The bactericidal activity of  control 
polyurethane and coated with ZnO were not included as they did not demonstrate any 
significant activity. Bacterial reduction is given in log form. 
Bacterial strain CV  
dark 
CV 
 white light 
CVZnO 
 dark 
CVZnO 
 white light 
S. aureus 8325-4 No kill (1 h) 
1.4 log (2 h) 
2 log (1 h)  
≥4 log (2 h) 
1.5 log (1 h) 
≥4 log (2 h) 
≥4 log (1 h) 
≥4 log (2 h) 
E. coli ATCC 25922 No kill (2 h) 
1.3 log (4 h) 
1 log (2 h) 
≥4 log (4 h) 
No kill (2 h) 
≥4 log (4 h) 
2.5 log (2 h) 
≥4 log (4 h) 
 
Oleic acid-capped ZnO NPs (~18 nm) have been synthesised and 
incorporated into medical grade polyurethane sheets. These modified 
polymers have been coated with CV dye and their antibacterial activity has 
been examined against two hospital pathogens; S. aureus 8325-4 and E. 
coli ATCC 25922. CVZnO has shown exceptional bactericidal effects against 
both bacteria in the light, but more significantly, considerable dark kill has 
been observed within only 4 h. Thus, these polymeric surfaces have the 
potential of reducing bacteria in a clinical environment where lighting 
conditions are not optimal. Previous studies using CV and ZnO 
nanoparticles (as shown in Table 5.1) have demonstrated a lesser 
bactericidal effect against E. coli ATCC 25922.22,23,28-30 For example, CV and 
ZnO coated onto silicone has demonstrated lethal activity using a higher 
white light intensity of ~11,500 lux after 6 h and only exhibits ~0.5 log 
reduction of E. coli ATCC 25922 after 4 h in the dark.30 Moreover, silicone 
samples containing CV combined with MB and/or 2 nm Au NPs also do not 
display the same bactericidal activity as this CVZnO combination.23,28 This 
could be due to the fact that these ZnO NPs are more effective at 
enhancing the bactericidal effect of the dye. On the other hand, it could be 
due to the polymer itself; as shown in Chapter 3 with Cu NPs, NP-
incorporated polyurethane is more effective at reducing bacteria than NP-
incorporated silicone.  
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The exact mechanism of the CVZnO polymer materials is not yet fully 
understood. XPS depth profile data show that the ZnO NPs are well-
incorporated into the polyurethane matrix as well as adsorbed onto the 
surface. Leaching experiments show that the dye and the NPs exhibit 
minimal leaching over an extended period of time. It is possible that the 
nanoparticles are leaching at a concentration that causes an enhanced 
bactericidal effect of the dye, as it should be noted that the NPs have no 
activity alone. However, this does imply that the NPs are not leaching at a 
concentration significant enough to induce any bactericidal activity on their 
own. The ZnO NPs increase the antibacterial activity of CV in the light and 
in the dark compared to CV alone; enhancing any light-activated and 
intrinsic (dark) bactericidal effects of the dye itself. Therefore, this suggests 
that the mechanism of CVZnO operates via a Type I and/or Type II 
photochemical pathway.  
The two possible mechanisms for the photosensitised generation of ROS 
include electron transfer (Type I) and energy transfer from the 
photosensitiser triplet state to molecular oxygen to form singlet oxygen 
(Type II).  To investigate this further, quenchers of Type I and Type II 
mechanisms were added to the antibacterial testing protocol to see their 
effects on the bactericidal results obtained above in Fig. 5.10 and 5.11. A 
H2O2 scavenger (catalase, 220 U mL-1) and quenchers of 1O2 (BSA, 0.03% 
and L-histidine, 1 mM) were used in the microbiological investigation 
against E. coli ATCC 25922. The concentration of these inhibitors is based 
on other studies reported in the literature.31,39,40 As described in Chapter 3, 
BSA acts as an organic contaminant to mimic a ‘real-world’ clinical 
environment (e.g. from hand sebum) as well as a quencher of singlet 
oxygen. It also contains tryptophan which reacts readily with singlet 
oxygen, similar to other aromatic amino acids such as L-histidine.41,42,43 Fig. 
5.12 shows the bactericidal activity of control polymer, CV, and CVZnO-
incorporated samples against E. coli ATCC 25922 using the same conditions 
described above with the addition of catalase, BSA and L-histidine. An 
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experiment labelled ‘control’ (as shown in Fig. 5.13) has also been carried 
out to show the effects of adding each variable separately to the 
experiment. ZnO-incorporated polyurethane was not tested in these 
experiments as it did not demonstrate any significant kill in the previous 
results (Fig. 5.10 and 5.11).  
 
 
Fig. 5.12 Radical species and singlet oxygen quenchers/inhibitors of Type I and II 
photochemical pathways used in this investigation (BSA: bovine serum albumin). 
 
Fig. 5.13(a) illustrates the lethal photosensitisation of the polymer samples 
against E. coli ATCC 25922 when exposed to white light for 2 h. The 
addition of catalase, BSA and L-histidine to the bacterial suspension did not 
affect the bacterial count for the control polymer sample. Conversely, CV-
coated polymer only demonstrated ~0.8 log reduction in the presence of 
catalase and ~1 log reduction when BSA was added, compared to ~1.5 log 
reduction of E. coli ATCC 25922 when no quencher or scavenger was 
present (P = 0.002). Additionally, the addition of L-histidine to the bacteria 
resulted no significant bactericidal activity of CV (P = 0.002). 
 For CVZnO samples, the bacterial count was reduced by ~3 log when no 
quencher/scavenger was added to the system following 2 h white light 
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activation. However, the reduction in bacterial numbers decreased to ~0.5 
log, ~1 log and ~2 log with the addition of L-histidine, BSA and catalase, 
respectively. These results show that the singlet oxygen scavengers have 
affected the lethal activity of CVZnO more than catalase, however, all 
additives have negatively impacted the antibacterial activity observed in 
the control experiment. These samples were also tested with and without 
the quenchers in the dark for 2 h and did not exhibit any significant kill 
(data not shown).  
The samples were then tested against E. coli ATCC 25922 for 4 h in the dark 
with the addition of catalase, BSA or L-histidine (Fig. 5.13(b)). Within this 
time, neither the control nor CV samples showed any significant 
bactericidal activity. In the control experiment (without any additives), 
CVZnO demonstrated ≥4 log reduction (P = 0.002) in the numbers of E. coli 
ATCC 25922. However, with the addition of catalase or BSA, the 
antibacterial activity of CVZnO decreased by ~2.5 log, and no bacterial kill 
was observed when L-histidine was added to the bacterial suspension. 
Following 4 h of white light activation, the antibacterial activity of the 
samples did not change between the control, catalase, BSA and L-histidine 
experiments (data not shown). 
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Fig. 5.13 (a) Viable counts of E. coli ATCC 25922 following 2 h of white light illumination on 
modified polyurethane samples for a control, catalase, bovine serum albumin (BSA) and L-
histidine experiment. The white light source emitted an average light intensity of 6600 ± 
990 lux at a distance of 25 cm from the samples. * indicates that the bacterial numbers 
were reduced to below the detection limit of 100 colony forming units/mL (cfu/mL). (b) 
Viable counts of E. coli ATCC 259222 following 4 h incubation in the dark on modified 
polyurethane samples for a control, catalase, BSA and L-histidine experiment. 
 
The results clearly show that all scavengers effectively reduce the 
antibacterial activity of CV-coated polyurethane in the light and CVZnO in 
the light and dark. This suggests that both Type I and Type II mechanisms 
are occurring in the CV and CVZnO polymeric system. The addition of 
catalase reduces the antibacterial effectiveness of the CVZnO system, 
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which suggests that any production of H2O2 that would normally damage 
the bacteria has been ‘deactivated’ by conversion to H2O and O2 using 
catalase. This process also prevents the formation of hydroxyl species 
formed from the Fenton reaction. Catalase is able to react with singlet 
oxygen; however, at the low concentrations used in this investigation it is 
not possible. Therefore, the Type I mechanism is operating in the 
bactericidal activity of CVZnO in the light and dark. It is possible that CV is 
adsorbed or is in close proximity to the surface of the ZnO NPs, which 
allows electron transfer to or from its excited singlet state through 
interaction with the conduction band of the semiconductor (ZnO). This has 
been suggested for the interaction between ethyl ester of fluorescein 
(FLEt) and colloidal TiO2 particles under visible light excitation.44 A Type I 
electron transfer mechanism will produce more ROS (superoxide anion 
radicals in particular), which can dismutate to form H2O2 that can diffuse to 
the bacterial cell. H2O2 can also decompose via the Fenton reaction to 
produce cytotoxic hydroxyl radicals.45 
The addition of BSA and L-histidine to the bacterial suspension has also 
provided evidence to suggest that a Type II mechanism is occurring within 
this dye and nanoparticle combination. When the bacterium is in contact 
with CVZnO, BSA significantly reduces the kill (more so in the dark). 
Additionally, BSA acts as an organic contaminant during the experiment. 
The results indicate that in a real clinical setting, the bacterial kill could be 
supressed in the presence of organic impurities, such as skin oils from 
patient or staff contact. Moreover, the addition of L-histidine to the 
experiment shows an even greater reduction in bactericidal activity in both 
the light and dark. These quenchers have inhibited singlet oxygen 
production, indicating that singlet oxygen contributes to the bactericidal 
activity of CVZnO (i.e. a Type II mechanism). By adding L-histidine to the 
bacterium, singlet oxygen is able to chemically react with the imidazole 
ring of the quencher to produce oxidised products instead.46 Therefore, the 
data strongly suggests that there is a synergistic enhancement in 
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bactericidal activity of CV combined with ZnO NPs and both Type I and 
Type II mechanisms are occurring together.  
Surprisingly, the inhibitors have a greater effect on the antibacterial activity 
of CVZnO in the dark compared to the photoactivated experiment. This 
suggests that both mechanisms also occur in the dark, where the NPs are 
able to significantly increase the antibacterial activity of CV without white 
light activation. This could be due to surface defects on the ZnO NPs which 
allow CV to further produce ROS. Additionally, the encapsulation of the 
NPs could be responsible for a greater uptake of the dye (as shown by UV-
vis absorption spectra; Fig. 5.4), which in turn allows a greater production 
of radical species and singlet oxygen. However, it should be noted that CV-
coated polymers have been pre-treated with 1:1 hexane/DCM prior to 
coating with the dye so the organic solvents are not responsible for this 
change. Although the results show that both mechanisms play a pivotal 
role in killing the bacterium, there is evidence to suggest that the Type II 
process dominates in inducing bacterial cell damage (as shown by adding 
BSA and L-histidine). There are many studies that have supported that a 
Type II process is more responsible for photo-initiated cell death,37,47-49 as 
some cells in vivo are partially protected against the effects of PDT by 
scavengers such as L-histidine, and some skin cells are rather resistant to 
PDT in the absence of molecular oxygen.50-52 
For conventional applications of a photosensitiser in vivo, it is vital that the 
photosensitiser exhibits minimal dark toxicity and negligible cytotoxicity in 
the absence of light.47 This is so that when the photosensitiser is 
introduced into the body and accumulates in diseased tissue it does not 
cause any adverse side effects to the body when the treatment is not 
undergoing. However, this is not a concern for the purpose of antibacterial 
surface coatings. In fact, any dark kill observed from these polymer 
samples is especially beneficial in hospital environments with dim or no 
lighting. As described above, the polymeric materials allow CV to produce 
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singlet oxygen as its molecular rotor is restricted. In an aqueous solution of 
CV (a low viscosity environment) singlet oxygen is not produced. 
  
5.4 Conclusion 
In this chapter, oleate-capped ZnO NPs have been synthesised via a 
thermal decomposition method developed from Park et al, forming 
monodisperse nanoparticles with an average diameter size of 18 nm. They 
were suspended in a 1:1 ratio of hexane/DCM and incorporated into 1 cm2 
flat polyurethane sheets. They were then dip-coated into an aqueous 
solution of CV (0.001 M) to produce CVZnO polymer samples. Fluorescence 
microscopy showed that the dye was incorporated throughout the polymer 
matrix but resided mostly at the polymer surface and XPS data confirmed 
that the NPs were also incorporated throughout the polymer bulk and 
incorporated onto the surface. CV-coated polyurethane exhibited 
insignificant leaching of the dye into the surrounding PBS solution. At 
certain concentrations CV is non-toxic to mammalian cells and is widely 
used medically and in dentistry. It has antibacterial and antifungal 
properties and was previously used as a topical antiseptic.32,33 It is still 
listed by the World Health Organisation despite being replaced by newer 
drugs in medical treatment.31 
For the first time, CV and ZnO NPs have been incorporated into 
polyurethane and tested for antibacterial activity against E. coli and S. 
aureus as representative Gram-negative and Gram-positive bacteria. The 
results showed a clear photobactericidal response; with CVZnO reducing 
numbers of S. aureus 8325-4 and E. coli ATCC 25922 to below the detection 
limit (≥4 log reduction) within only 1 h and 4 h, respectively. More 
significantly, CVZnO was able to reduce both bacteria without any white 
light activation within only 2 h (in the case of S. aureus 8325-4) and 4 h (in 
the case of E. coli ATCC 25922). This is, to our knowledge, the best dark kill 
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achieved by any photosensitiser and/or nanoparticle combination 
incorporated into a polymer. 
In order to gain a better understanding of the mechanism operating within 
the CVZnO polymer, ROS and singlet oxygen scavengers (catalase, BSA and 
L-histidine) were added to the bacterium to examine their effect on the 
bacterial kill observed in Fig. 5.11 against E. coli ATCC 25922. A clear 
reduction in bacterial kill was observed in the light and in the dark when all 
three scavengers were added to the microbiological protocol. This 
indicated that both Type I and Type II mechanistic pathways are 
responsible for the lethal antibacterial activity observed from CV and 
CVZnO. Moreover, by adding BSA to the bacterium, there is a possibility 
that organic contaminants found in hospital environments may affect the 
efficiency of these polymers. However, this enzyme also scavenges singlet 
oxygen so the result is most likely a combination of both factors. Fig. 5.13 
also suggests that Type I and Type II photochemical pathways are operating 
without any light activation, which could be a result of ZnO NP surface 
defects that allow the photosensitiser to produce additional ROS. This 
could be due to any stored energy within the ZnO lattice structure that 
allows electrons and holes at the surface to react with the photosensitiser, 
possibly causing an enhanced bactericidal effect. It is unlikely that the NPs 
leach to cause any cell damage, especially due to the fact that they do not 
cause any bacterial reduction themselves. It is only when the ZnO NPs and 
CV are combined that they exhibit considerable bactericidal activity.  
These antibacterial surfaces have the potential to maintain low bacterial 
levels and minimise the risk of HAIs spreading around hospitals.  They can 
be applied to a wide range of medical devices and frequently touched 
surfaces such as telephones, keyboards and iPad covers. There is a 
synergistic enhancement in bactericidal activity when the NPs are 
combined with CV, compared to CV or ZnO alone. For the first time, 
mechanistic studies have provided evidence to support both Type I and 
Type II photochemical pathways are responsible for the antibacterial 
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activity of CVZnO in the light and the dark, although there is more evidence 
to suggest a greater contribution of singlet oxygen production (Type II). The 
exceptional dark kill observed from CVZnO against a Gram-negative 
bacterium within only a few hours is promising for these materials to be 
useful for reducing the impact of HAIs in a clinical environment.  Further 
studies using electron paramagnetic resonance (EPR) detection would be 
valuable to confirm Type I vs. Type II mechanisms.  
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Chapter 6 
6. Polyurethane Encapsulated with Crystal Violet 
and 3 nm ZnO Nanoparticles; Antimicrobial 
Polymers Activated by Low Intensity White light 
Source 
 
6.1 Introduction 
Photodynamic therapy (PDT) is widely used in medicine to treat patients 
without the need for surgery. It can be used to treat parts of the body 
where a light source can reach easily, including the skin, eyes, mouth, 
oesophagus and lungs.1 PDT can also be used to treat certain types of 
cancer, such as lung, skin, mouth and oesophageal cancer.1-3 Chapter 5 has 
shown the efficacy of coating polymers with a photosensitiser for use as 
self-sterilising surfaces. By coating the polymer with the photosensitiser, 
there is a minimal risk to the patient that would otherwise occur from 
prolonged exposure to the dye in vivo.4,5 These light-activated antibacterial 
surfaces have the potential of reducing the risk of hospital-acquired 
infections (HAIs) under standard laboratory white light and more 
significantly, in the dark.  
As shown previously, 18 nm-sized zinc oxide nanoparticles (ZnO NPs) were 
incorporated into medical grade polyurethane sheets and demonstrated 
strong bactericidal activity against Gram-negative and Gram-positive 
bacteria when combined with crystal violet (CV) dye. The ZnO NPs were 
synthesised via a metal-oleate precursor and were incorporated into the 
polymer substrate as well as adsorbed onto the surface. It was the 
combination of CV with ZnO NPs (CVZnO) in the polymer that induced 
lethal activity, as the ZnO NPs themselves displayed no significant 
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antibacterial effect alone. Not only did the CVZnO polymer samples 
demonstrate highly significant bactericidal activity, they also caused 
significant kill in the dark within only a few hours. For the first time, the 
mechanism of the dye-nanoparticle combination was examined by using 
radical species and singlet oxygen quenchers to inhibit either a Type I or 
Type II photochemical pathway. The results indicated that both pathways 
were responsible for the bactericidal activity of CVZnO, with a greater 
contribution from the Type II mechanism, i.e. by producing singlet oxygen. 
The antibacterial activity exhibited by CVZnO is very promising, however, 
there are some improvements that can be made on the experimental set-
up to more closely mimic a clinical environment.  
HAIs cause an estimated 5000 deaths per year in the UK and lead to 
increased financial costs for the NHS.6 As the incidence of HAIs rises due to 
bacteria expressing multidrug resistance, the development of novel 
antibacterial procedures becomes increasingly urgent.7 Carbapenem-
resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus 
aureus (MRSA) infections are resistant to most antibiotics that are 
currently available and are a major problem in healthcare environments.8 
The use of broad-spectrum antibiotics also is a problem because it 
increases the risk of hospital-associated diarrhoea due to infection from C. 
difficile.9 Patients who acquire this infection shed endospores (a dormant 
form of C. Difficile that have evolved for prolonged survival in the 
environment) in their faeces that subsequently transmits to patients and 
frequently touched surfaces. These spores can survive in the environment 
for many months and orally infect patients whose protective microbiota 
has been damaged by broad-spectrum antibiotics.9,10 Furthermore, 
Pseudomonas infections can easily occur in hospitals from healthcare 
workers spreading the bacteria on their hands or from contaminated 
equipment which is not properly cleaned.11 Patients with compromised 
immune systems are mostly at risk, however, mild illnesses caused by 
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Pseudomonas aeruginosa (P. aeruginosa) can also affect healthy people 
after exposure to contaminated water.11,12  
As previously described, the antibacterial activity of ZnO NPs has attracted 
much attention in recent years due to their biocompatibility and multi-
functionality.13 They demonstrate selective toxicity towards bacteria 
showing a minimal effect on mammalian cells.14 The suggested 
mechanisms of the bactericidal activity of ZnO NPs includes disruption to 
the bacterial cell membrane from Zn2+ ions and the production of cytotoxic 
reactive oxygen species (ROS).13 Particle properties such as size, surface 
defects, morphology and concentration can affect the antibacterial action 
of NPs. For example, smaller sized NPs (i.e. a larger surface area) and a 
higher concentration of NPs results in greater bactericidal activity; they can 
easily penetrate into bacterial cell membranes due to their large interfacial 
area.13,15 When considering shape, truncated-triangular NPs are reported 
to be more effective at killing bacteria. However, spherical-shaped NPs are 
still considered to be optimal for practical applications.16,17 In this chapter, 
smaller ZnO NPs (3-4 nm) are synthesised using the same method but with 
two different capping agents, di(octyl)-phosphonic acid and oleic acid, to 
form ZnO NPs capped with di(octyl)phosphinate (DOPA) and oleate ligands 
(as shown in Fig. 6.1). 
 
 
 
 
 
 
 
 
Fig. 6.1 Diagram illustrating ZnO nanoparticles capped with a (a) di(octyl)-phosphinate 
ligand (DOPA) and an (b) oleate ligand. 
 
This study used various modifications from the previous protocol in an 
effort to more closely simulate a ‘real world’ clinical environment: (i) using 
(a) 
(a)                                                   (b) 
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natural ‘wild’ isolates of bacteria rather than adapted laboratory strains; (ii) 
using a lower light intensity than previously used to replicate the lighting 
commonly experienced in UK hospitals18 (~500 lux compared to ~6600 lux). 
Thus, the polymer samples are exposed to ambient lighting on a laboratory 
bench; (iii) the bacterial suspension was not covered with a coverslip when 
in contact with the polymer and the samples are not placed into a humidity 
chamber. Previously, a coverslip has been used (Chapter 3-5) to ensure a 
close, uniform contact between the bacteria and the hydrophobic polymer 
surface, and the humidity chamber was used to prevent evaporation of the 
bacterial suspension. Instead, the bacterial suspension was simply dropped 
onto the polymer surface and allowed to dry naturally rather than being 
‘forced’ to interact with the entire surface area of the polymer.  
ZnO NPs capped with a DOPA ligand (ZnO_DOPA) and ZnO NPs capped with 
an oleate ligand (ZnO_oleate) were incorporated separately into medical 
grade polyurethane squares and coated with CV to obtain CVZnO_DOPA 
and CVZnO_oleate polymer samples. Their antibacterial activity was 
assessed against Escherichia coli (E. coli) ATCC 25922 and an epidemic 
strain of MRSA (EMRSA-16), one of two clones known to predominate in 
the UK (PHE).19 The best performing polymer was then tested against 
highly resistant hospital pathogens such as P. aeruginosa NTCC 10662, E. 
coli 1030 and C. difficile spores. Both ZnO NPs enhance the 
photobactericidal activity of CV under low intensity lighting within 
relatively short incubation times. More surprisingly, for the first time, 
significant bactericidal activity of both ZnO NPs alone was demonstrated 
against E. coli ATCC 25922 under low intensity lighting and in the dark 
within only 2/3 h. These antibacterial polymer surfaces exhibited higher 
activity than previously reported for the CVZnO combination, showing 
outstanding potential in combating the incidence of HAIs. Finally, an in 
depth analysis into the antibacterial mechanism of these NPs was carried 
out using a variety of quenchers to inhibit both Type I and Type II 
photochemical pathways.  
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6.2 Experimental 
6.2.1 ZnO Nanoparticles 
6.2.1.1 Nanoparticle Synthesis 
All chemicals and reagents were purchased from Sigma-Aldrich Chemical 
Co. except for toluene (Fischer Scientific, UK). The Schlenk line and 
glovebox techniques were used to manipulate air sensitive chemicals (i.e. 
diethyl zinc is pyrophoric). Liquid chemicals (e.g. diethyl zinc, oleic acid) 
were measured by negative weight of the donor flask. Toluene was pre-
dried over potassium hydroxide and then further dried by refluxing over 
sodium. It was then degassed by freeze pump thaw techniques and stored 
under nitrogen to halt any ripening of the NPs which may occur in the solid 
state.20 ZnO NPs were kindly provided by Dr. Sebastian Pike (Imperial 
College London, UK) and prepared with DOPA and oleate ligands following 
an established route (summarised in Fig. 6.2)21: 
(i) DOPA-capped ZnO NPs: ZnEt2 and 0.2 equivalents of di-
octylphosphinic acid were dissolved in toluene and to this a 0.4 
M solution of water (in excess, two equivalents used) in acetone 
was added dropwise to hydrolyse the organometallic reagent. 
Acetone was then added to precipitate the formed NPs, which 
were centrifuged, washed with acetone and left to air dry 
overnight.  
(ii) Oleate-capped ZnO NPs: Oleic acid was placed into a Schlenk 
flask with a stirrer and dried under vacuum. Dry toluene was 
added to the ligand in a glovebox and then either 5 equivalents 
of diethyl zinc (ZnEt2) was added dropwise to the solution whilst 
stirring. A 0.4 M solution of water in acetone was added to the 
mixture to hydrolyse the organometallic precursors to form ZnO 
NPs. The NP suspension was precipitated by adding acetone, 
centrifuged and washed by toluene and acetone with 
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subsequent centrifugation steps. The particles were air dried 
overnight.  
 
 
Fig. 6.2 General form of ZnO nanoparticle synthesis: (a) DOPA-capped and (b) oleate-
capped. 
 
6.2.1.2 Nanoparticle Characterisation 
X-ray diffraction (XRD) was performed using an X’Pert Pro diffractometer 
(PANalytical B. V., The Netherlands) and X’Pert Data Collector software, 
version 2.2b. It was used in the theta/theta reflection mode and fitted with 
a nickel filter, 0.04 rad Soller slit, 10 mm mask, 1/4° fixed divergence slit, 
and 1/2° fixed antiscatter slit. The XRD diffraction patterns were analysed 
using Fityk (version 0.9.0; Marcin Wojdyr, 2010) and the peaks were fitted 
to a SplitPearson7 function. The particle size was calculated using the fitted 
full-width half-maximum using the Scherrer Equation. UV-vis spectroscopy 
was recorded using a PerkinElmer Lambda 950 spectrophotometer from 
NPs suspended in toluene. Elemental micro-analysis was determined by 
Stephen Boyer at London Metropolitan University. Thermogravimetric 
analysis was undertaken under an air atmosphere using a Mettler/Toledo 
TGA/DSC 1LF/UMX instrument at a heating rate of 10K/min. TEM 
micrographs were taken using a Jeol 2100 HR-TEM with a LaB6 source 
operating at an acceleration voltage of 200 kV with an Oxford Instruments 
XMax EDS detector running AZTEC software. TEM samples were prepared 
by drop-casting the NP suspension (in toluene) onto a 400 Cu mesh lacy 
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carbon film TEM grid (Agar Scientific Ltd). Micrographs were recorded onto 
a Gatan Orius charge-coupled device and analysed using ImageJ software. 
 
6.2.2 Polymer Samples 
6.2.2.1 Polymer Sample Preparation 
Polymer squares (1 cm2) were prepared from medical grade polyurethane 
sheets (0.8 mm thickness), purchased from American Polyfilm Inc. 
(Branford, CT, USA). They were then prepared by using the ‘swell-
encapsulation-shrink’ method as described in Chapter 5 (Fig.  5.2). The 
polymer squares were immersed into swelling solutions containing DOPA-
capped and oleate-capped ZnO NPs separately in toluene (1 mg/mL). They 
were kept in the swelling solutions for 24 h to incorporate the NPs, 
removed and left in the dark for 24 h to shrink back to their original shape 
and size. They were then washed, air-dried and dipped into an aqueous 
solution of CV (0.001 M) for 72 h (dark conditions, RT). For antibacterial 
testing, control samples were also prepared (solvent treated only) as well 
as polymer samples containing only ZnO NPs or CV alone.  
 
6.2.2.2 Material Characterisation 
UV-vis absorption spectra of modified polymer samples were measured in 
the range 300 – 750 nm using a PerkinElmer Lambda 25 UV-vis 
spectrometer. A Thermo K-Alpha spectrometer using monochromated Al 
K𝛼 radiation was used to perform X-ray photoelectron spectroscopy (XPS) 
of modified polymer samples. High-resolution scans (0.1 eV) were collected 
at a pass energy of 50 eV, including principal peaks of Zn (2p), O (1s), N (1s) 
and C (1s). A depth profile was measured at the polymer surface and 
sputtered 50 seconds. All binding energies were calibrated to the C (1s) 
peak (284.5 eV).   
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Water contact angle measurements of all modified polymer squares were 
obtained using a FTA 1000 Drop Shape Instrument. The average contact 
angle measurement was calculated using a droplet of deionised water (~5 
µL) dispensed by gravity from a gauge 30 needle with a camera to 
photograph the samples side on, and the data was analysed using FTA32 
software. ZnO_DOPA and ZnO_oleate samples were placed in 2 mL of de-
ionised water for up to 48 h to determine the extent of NP leaching into 
the surrounding solution. After removing the polymer squares from the 
aqueous solutions, they were diluted to 5 mL and analysed by inductively 
coupled plasma optical emission spectrometry (ICP-OES) using a Perkin 
Elmer Optima 2000 DV. The zinc concentration in each solution was 
calculated using a calibration curve determined from solutions containing 
[Zn] = 0, 0.1, 1 and 10 mg/L. 
All polymers containing CV dye were stored in a light box for up to 60 days 
to measure the photo-degradation of the dye when exposed to a white 
light source emitting an average light intensity of 2800 ± 510 lux at a 
distance of 33 cm from the samples. The UV-vis absorption spectra of the 
samples were measured (range 400 – 750 nm) to determine the extent of 
photodegradation over time. Confocal fluorescence imaging of CV-coated 
and CVZnO_oleate polymers were performed using a Leica TCS SPE 
confocal system with an upright microscope and a 20x objective (UCL 
confocal microscopy facility, Rockefeller building). A 532 nm laser was used 
as the excitation source and CV fluorescence was detected at 630 nm.  
 
6.2.3 Antibacterial Activity 
6.2.3.1 Microbiology Assay 
The antibacterial activity of the following modified polymer samples was 
tested against E. coli ATCC 25922 and S. aureus NCTC 13142 (one of two 
types of MRSA that dominates in UK hospitals; EMRSA-1619): control 
(solvent treated), polyurethane-coated CV (CV), polyurethane-
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encapsulated ZnO (ZnO_DOPA and ZnO_oleate), and polyurethane-
encapsulated CV and ZnO (CVZnO_DOPA and CVZnO_oleate). Further 
antibacterial testing was carried out on ZnO_oleate-containing polymer 
samples only (i.e. ZnO_oleate and CVZnO_oleate) against the following 
bacteria: P. aeruginosa NCTC 10662, a multidrug resistant strain of E. coli 
positive for both NDM and OXA-48-like carbapenemase genes, (J. Wade, 
King’s College Hospital, London) and endospores of C. difficile 630Δerm 
using a protocol designed to mimic a ‘real world’ clinical situation.  
E. coli ATCC 25922, S. aureus NCTC 13143, P. aeruginosa NCTC 10662 and 
E. coli 1030 were stored at -70 ○C in Brain-Heart-Infusion broth (BHI, Oxoid) 
containing 20% (v/v) glycerol and propagated on MacConkey agar (MAC, 
Oxoid) in the case of Gram-negative bacteria (P. aeruginosa and E. coli) or 
Mannitol Salt agar (MSA, Oxoid) in the case of Gram-positive bacterium (S. 
aureus NCTC 13143), for a maximum of 2 subcultures at intervals of 2 
weeks.  
BHI broth was inoculated with 1 bacterial colony and cultured in air with 
shaking (37 oC, 200 rpm, 18 h). The bacterial suspension was centrifuged to 
recover the bacterial pellet, (20 oC , 2867.2 g, 5 min), washed in PBS (10 
mL), centrifuged again to recover the pellet (20 oC, 2867.2 g, 5 min), and 
finally re-suspended in PBS (10 mL). The washed suspension was diluted 
1000-fold to achieve an inoculum (~106 cfu/mL). The inoculum was 
confirmed by plating 10-fold serial dilutions on agar for viable counts. 
Triplicates of each polymer sample type were inoculated with 25 µL of the 
inoculum and incubated in the dark or irradiated for up to 6 h using 
standard laboratory white light emitting an average light intensity of ~500 
lux. Following exposure to light, the inoculated samples were added to PBS 
(450 µL) and mixed using a vortex mixer (15 s). The neat suspension and 
10-fold serial dilutions were plated on agar for viable counts and incubated 
aerobically at 37 ○C for 24 h (E. coli/P. aeruginosa) or 48 hours (S. aureus).  
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6.2.3.2 Statistical Significance 
The experiment was repeated three times and the statistical significance of 
the following comparisons was analysed using the Mann-Whitney U test: (i) 
control polymer vs. inoculum; (ii) CV or ZnO_DOPA/ZnO_oleate vs. control; 
(iii) CVZnO_DOPA/CVZnO_oleate vs. CV alone.  
 
6.2.3.3 Clostridium difficile Endospore Preparation  
C. difficile endospores were prepared as described by Burns et al22 with the 
following modifications. C. difficile 630Δerm was grown on BHI blood agar 
for 48 h, and then one bacterial colony was inoculated into 10 ml of BHIS 
(brain heart infusion supplemented with L-cysteine [0.1%; Sigma] and yeast 
extract [5 mg/ml; Oxoid]) broth. The culture was incubated anaerobically 
with shaking (37° C, 50 rpm, 16 h). 1 ml of the overnight culture was used 
to inoculate 60 mL of BHIS broth. The culture was then incubated in the 
anaerobic cabinet with shaking (37° C; 50 rpm; 6 days to ensure the highest 
level of sporulation).  The spores were harvested by centrifugation (5000 
rpm; 10 min) and resuspended in sterile water (5 mL). The suspension was 
heated in a water bath to kill any remaining vegetative cells (80°C; 30 min). 
The spores were then washed 3 times with sterile, ice-cold water and the 
pellet was resuspended in PBS (2 mL). The suspension was then divided 
into 200 µL aliquots and stored at -80° C. Prior to use, one aliquot of the 
bacterial suspension was thawed and diluted with PBS (20 mL), ready for 
antibacterial testing. Sodium taurocholate (0.1%; Sigma, UK) was added to 
BHI agar (Oxoid) to stimulate spore germination. The spores were added to 
the polymer samples for up to 72 h using the same method described 
above. 
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6.2.3.4 Ligand Variation to Determine Oleate Ligand Influence 
To investigate the influence of the oleate ligand on bactericidal activity, 
ZnO NPs were synthesised with different capping ligands (with a 5:1 metal 
to ligand ratio). In addition to this, oleate-capped ZnO NPs were also 
prepared with a 10:1 metal to ligand ratio. The following NPs were 
synthesised and incorporated into the polymer with CV using a similar 
method as described in section 6.2.1: 3.6 nm stearate-capped ZnO (5:1), 
4.0 nm linoleate-capped ZnO (5:1), and 4.9 nm oleate-capped ZnO (10:1). 
 
6.2.3.5 Detection of Superoxide and Singlet Oxygen 
Superoxide dismutase (SOD), L-histidine and bovine serum albumin (BSA)23-
25 were purchased from Sigma-Aldrich, UK, filter-sterilised and added to 
bacterial suspensions of S. aureus NCTC 13143 and E. coli ATCC 25922 in 
the microbiology protocol to determine the mechanism of CVZnO_oleate. 
SOD (50 U mL-1) was used to eliminate superoxide (a precursor of hydrogen 
peroxide in radical formation), L-histidine (1 mM) was added as a quencher 
of singlet oxygen and BSA (0.03% in water) was added as an organic 
contaminant as well as a singlet oxygen quencher. Furfuryl alcohol (FFA) 
was also used as a singlet oxygen trap26 using the decrease in its UV 
absorbance upon photo-oxidation. Since FFA does not absorb in the visible 
region it is unaffected by the visible illumination source used for bacterial 
treatment. FFA was added to the solution covering the CVZnO_oleate 
samples (no bacteria present) and were illuminated with the same visible 
light source and time conditions used in the antibacterial testing. 200 μL of 
deionised water containing 5.75 x 10-8 M of FFA was used to measure the 
concentration of singlet oxygen after contact with the sample.27 The 
absorbance of this compound was measured at 222 nm from the control 
polymer and compared with CV and CVZnO_oleate to see any reductions in 
absorption intensity. Finally, L-ascorbic acid (1 mM)28 was also added to the 
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bacterial suspension to quench singlet oxygen production from CV and 
CVZnO_oleate samples. 
 
6.3 Results and Discussion 
6.3.1 ZnO Nanoparticle Synthesis and Characterisation 
~3 nm ZnO NPs were synthesised and surface stabilized by either DOPA or 
oleate ligands. They were synthesised by the controlled hydrolysis of ZnEt2 
in the presence of 0.2 equivalents of di-octylphosphinic acid (in the case of 
DOPA-capped ZnO NPs) or oleic acid (in the case of oleate-capped ZnO 
NPs) to give a 5:1 metal to ligand ratio.21 The NPs were kept under N2 to be 
contained in an inert environment, as there is evidence to suggest that 
they may slowly ripen over several months if exposed to atmospheric 
moisture.20 Elemental micro-analysis and thermal gravimetric analysis 
determined the ligand content of these samples and calculated the 
metal:ligand ratio as 6:1 and 5.4:1 for DOPA-capped and oleate-capped 
ZnO NPs, respectively, suggesting a very slight loss of ligand during the NP 
synthesis. ZnO surface coverage (%) was determined by UV spectra 
analysis, indicating a partial coverage of the DOPA-capped NPs (~60%) and 
less ligand coverage of the oleate-capped NPs (~95%).  
The NPs were characterised by powder XRD (Fig. 6.3) and UV spectroscopy 
(Fig. 6.4-6.5) to determine the size of the particles.29 The size of the NPs 
was determined from XRD spectra (Fig. 6.3) by use of the Scherrer equation 
and gave estimated diameters of 2.2 ± 0.3 nm for the DOPA-capped ZnO 
NPs and 3.4 ± 0.6 nm for the oleate-capped ZnO NPs. Due to the small size 
of these ZnO NPs, quantum confinement increases their absorption energy 
relative to bulk ZnO.30 A Tauc plot measured from UV spectroscopy 
measured the band onset of the particles suspended in toluene, estimating 
the band gap to be 3.76 ± 0.1 eV for DOPA-capped ZnO NPs (Fig. 6.4(a)) 
and 3.48 ± 0.01 eV for oleate-capped ZnO NPs (Fig. 6.4(b)). Both sets of 
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ZnO NPs were relatively spherical and monodisperse, as shown by TEM 
(Fig. 6.6).  
 
 
  
Fig.  6.3 Powder XRD patterns of ZnO nanoparticles with (a) dioctylphosphinate (DOPA) 
and (b) oleate, linoleate and stearate ligands (Wurzite ZnO reference pattern indicated, 
JCPDS card 00-001-1136, patterns stacked with +1000 intensity to each in turn). The size 
of the particles may be estimated by analysis of the peak width using the Scherrer 
equation. The signals at 2θ = 47.5 and 56.6 were analysed for each batch of nanoparticles 
giving sizes of: ZnO_DOPA (5:1), 2.2 nm; ZnO_oleate (5:1), 2.8-4.1 nm; ZnO_oleate (10:1), 
4.9-7.4 nm; ZnO_linoleate (5:1), 2.8-3.6 nm, ZnO_stearate (5:1), 2.8-3.3 nm. The broad 
signals at 2θ = 18-25° are assigned to the organic ligands, in the case of ZnO_stearate a 
minor trace of impurity Zn(stearate)2 may also be present.21 
 
  (b) 
  (a) 
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Fig. 6.4 Tauc plots derived from UV absorption spectra of ZnO nanoparticles. Band gaps 
determined: (a) ZnO_DOPA (5:1) = 3.76 ± 0.01 eV and (b) ZnO_oleate (5:1) = 3.48 ± 0.01 
eV; ZnO_oleate (10:1) = 3.39 ± 0.01 eV; ZnO_linoleate (5:1) = 3.46 ± 0.01 eV, ZnO_stearate 
(5:1) = 3.47 ± 0.01 eV.  
 
 
 
  (b) 
  (a) 
 179 
 
 
 
Fig. 6.5 UV spectra of ZnO nanoparticles dissolved in toluene (approx 0.4 mg/mL). An 
estimate of the particle size can be made by the onset of UV absorption.29 Sizes were 
calculated from the maximum gradient of the UV absorption onset corresponding to: (a) 
ZnO_DOPA (5:1), 2.7 nm and (b) ZnO_oleate (5:1), 3.8 nm; ZnO_oleate (10:1), 4.9 nm; 
ZnO_linoleate (5:1), 4.0 nm, ZnO_stearate (5:1), 3.6 nm. All sizes are a close match for the 
sizes estimated by XRD (see Fig 6.3). 
 
 
  (a) 
  (b) 
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Fig. 6.6 TEM images of (a) ZnO_DOPA and (b) ZnO_oleate (5:1). 
 
6.3.2 Preparation and Characterisation of Polymer Samples 
DOPA-capped and oleate-capped ZnO NPs were synthesised and 
incorporated within polyurethane squares to test their antibacterial 
efficacy against Gram-positive and Gram-negative bacteria with and 
without crystal violet dye (ZnO_DOPA / ZnO_oleate / CVZnO_DOPA / 
CVZnO_oleate). The NPs were added to the toluene swelling solution (1 
mg/mL) and 1 cm2 polymer samples were immersed into the NP 
suspension for 24 h in the dark. They were removed and left to dry for 24 h 
to allow enough time for the polymer squares to shrink back to their 
original shape and size. They were then washed, towel-dried and immersed 
into a solution of CV (0.001 M) for 72 h.  
The modified polymer samples were characterised by UV-vis spectroscopy 
and XPS, and the wetting properties, extent of NP leaching and 
photostability of the samples were examined. As shown in the UV-vis 
spectrum (Fig. 6.7), CV-coated polyurethane, CVZnO_DOPA and 
CVZnO_oleate showed an absorbance maxima at λ = 590 nm. However, 
  (a) 
  (b) 
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there was no characteristic absorption peak observed for the ZnO NPs in 
either sample, presumably due to the low concentration of NPs 
incorporated. The absorption intensity of CV increased with the addition of 
the NPs, implying a greater concentration of CV added to the polymer 
samples. However, CV-coated polyurethane was pre-treated with toluene, 
so the solvent is not responsible for the differences in absorption intensity. 
 
 
 
 
 
 
 
 
Fig. 6.7 UV-vis absorption spectra measured in the range of 400 – 700 nm of crystal 
violet-coated polyurethane (CV), CV and ZnO_DOPA-incorporated polyurethane 
(CVZnO_DOPA) and CV and ZnO_oleate-incorporated polyurethane (CVZnO_oleate). Both 
ZnO NPs with 5:1 metal:ligand ratio. 
 
XPS was used to determine intensity of the NPs at the polymer surface and 
throughout the bulk (Fig. 6.8). Peaks in the C (1s) region, N (1s) region and 
O (1s) region were observed on all modified polyurethane samples (data 
not shown). A doublet in the Zn (2p) region indicating Zn in ZnO was shown 
on the surface and within the polymer substrate for CVZnO_DOPA (Fig. 
6.8(a) and (b)). XPS depth profile data demonstrated a decrease in zinc 
content within the polymer bulk. For CVZnO_oleate the data also 
confirmed that the NPs were incorporated throughout the polymer bulk 
and on the polymer surface (Fig. 6.8(c) and (d)), illustrating a doublet in the 
Zn (2p) region. XPS depth profile data for CVZnO_oleate demonstrated an 
increase in zinc content within the polymer substrate rather than on the 
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polymer surface. Equilibrium water contact measurements (~5.0 µl) of all 
modified polymer samples were measured under standard laboratory 
conditions. The results showed a slight increase in hydrophobicity of the 
samples with the addition of the ZnO NPs and the photosensitiser (varying 
± 8o in contact angle).  
 
 
 
Fig. 6.8 XPS spectra for Zn (2p) on (a) CVZnO_DOPA surface, (b) CVZnO_DOPA sputtered 
50 s, (c) CVZnO_oleate surface and (d) CVZnO_oleate sputtered 50 s (both 5:1). 
 
ICP–OES was used to determine if any zinc species leached from 
ZnO_DOPA or ZnO_oleate polymer samples when they were immersed in 2 
mL distilled water for a period of 2 h and 48 h. After removing the polymer 
sample from the solution, it was diluted to 5 mL and analysed by ICP-OES 
for [Zn]. The results (summarised in Table 6.1) showed that a higher 
concentration of Zn2+ leached from ZnO_oleate compared to ZnO_DOPA, 
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especially after 2 days. However, the amount of leaching (mg/L) was 
negligible compared to the amount of ZnO incorporated into the sample 
(from using a NP swelling solution of 1 mg/mL). 
 
Table 6.1 Amount of leaching (mg/L) of Zn2+ ions from modified polymer samples after 2 
hours and 2 days (SD = standard deviation). 
Polymer sample 
2 hours 2 days 
[Zn] SD [Zn] SD 
ZnO_DOPA (5:1) 0.083 0.001 0.169 0.005 
ZnO_oleate (5:1) 0.096 0.002 1.008 0.006 
 
The photostability of CV, CVZnO_DOPA and CVZnO_oleate polyurethane 
samples was examined under a ~3880 lux white light source for up to 60 
days (Fig. 6.9). The UV-vis spectra showed that all samples were strongly 
photostable (Fig. 6.9(a) and (b)), even under a light source ~19-fold more 
intense than that of many hospital corridors and wards (~200 lux).18 Over 
60 days, CV-coated polyurethane demonstrated 34% photodegradation 
compared to 30% for CVZnO_DOPA and 39% for CVZnO_oleate, showing 
that these materials are likely to exhibit long term photostability within 
hospitals.  
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Fig. 6.9 UV-vis absorbance spectra measured in the range 400 – 700 nm of (a) CV-coated 
polymer, (b) CV and ZnO_DOPA-incorporated polymer and (c) CV and ZnO_oleate-
incorporated polymer. The samples were exposed to a white light source emitting an 
average light intensity of 3880 ± 200 lux at a distance of 35 cm from the samples. (d) The 
rate of photodegradation of CV, CVZnO_DOPA and CVZnO_oleate polymers upon 
exposure to a high lux intensity white light source (60 days; 3880 lux) shown as a change 
in absorbance at the CV absorbance maxima (λ = ~590 nm) over time. Data shown with 
control polymer readings subtracted.  
 
Confocal images of CV-coated and CVZnO_oleate showed that the 
photosensitiser penetrated uniformly throughout the polymer bulk (Fig. 
6.10), as demonstrated in Chapter 5 using fluorescence microscopy.  
 
                             
Fig. 6.10 Confocal fluorescence imaging of (a) untreated polymer, (b) CV-coated polymer 
and (c) CV and ZnO_oleate-incorporated polymer using a Leica TCS SPE confocal system 
with an upright microscope and a 20x objective. A 532 nm laser was used as the excitation 
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source and CV fluorescence was detected at 630 nm. There is a 100 µm scale bar on the 
image. The polymer sample is on the left hand side of the image, where the black part of 
the image represents the background (no fluorescence). The image resolution is 512 x 512 
pixels and corresponds to 367 x 367 microns. 
 
6.3.3 Antibacterial Activity 
6.3.3.1 CVZnO_DOPA vs. CVZnO_oleate 
The antibacterial activity of CVZnO_DOPA and CVZnO_oleate was 
compared by testing them against two species of bacteria commonly found 
in hospitals: E. coli ATCC 25922 and S. aureus NCTC 13143 (a clinical strain 
of EMRSA-16), in the dark and under low intensity white light (~500 lux). 
This lower light intensity has been used to mimic the ambient light levels 
found in most hospital wards and corridors. The protocol used to test the 
antibacterial activity of the samples against the Gram-negative bacterium, 
E. coli ATCC 25922, was similar to the previous set-up described in Chapter 
5, which included the use of a coverslip (2.2 cm2) to spread the bacteria 
evenly on the polymer surface and a humidity chamber to provide a moist 
environment for the samples. This was to ensure that a direct comparison 
could be made between the bactericidal activity of 18 nm ZnO NPs 
(Chapter 5) and these 3 nm ZnO NPs when incorporated into polyurethane 
in the dark. However, when testing the samples against S. aureus NCTC 
13143 (and all bacteria hereafter), the protocol does not include a coverslip 
or humidity chamber in order to investigate the behaviour of the 
antibacterial polymers using conditions that more closely simulate a real 
world exposure. 
Within 2 h of incubation in the dark, the control and CV-coated 
polyurethane displayed no bactericidal activity (Fig. 6.11(a)). However, for 
the first time in this type of study, both ZnO NPs demonstrated significant 
antibacterial activity, with ZnO_DOPA and ZnO_oleate reducing bacterial 
numbers by ~0.8 and ~1.7 log, respectively (P = 0.001). With the addition of 
a photosensitiser, CVZnO_DOPA reduced E. coli ATCC 25922 by ~1 log, 
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whereas CVZnO_oleate caused a ~2.8 log reduction (P = 0.001). Following 2 
h of white light exposure, ZnO_DOPA and ZnO_oleate reduced bacterial 
numbers by ~1.1 log and 2 log, respectively. CVZnO_DOPA reduced E. coli 
ATCC 25922 by ~2.2 log, but the most effective antibacterial activity was 
shown by CVZnO_oleate, which reduced bacterial numbers to below the 
detection limit (≥4 log; P = 0.001).  
By increasing the incubation time to 3 h (Fig. 6.11(b)) in the dark, both 
ZnO_DOPA and ZnO_oleate reduced E. coli ATCC 25922 by ~1.6 log and 
CVZnO_DOPA was able to reduce the bacteria by ~2.2 log. Most 
significantly, CVZnO_oleate reduced the bacteria to below the detection 
limit within only 3 h without photoactivation (≥4 log; P = 0.001). ZnO_DOPA 
exhibited similar antibacterial activity after 3 h of white light illumination as 
it did in the dark (~2 log), whereas ZnO_oleate reduced the bacteria by 
~2.5 log after 3 h. Both CVZnO_DOPA and CVZnO_oleate produced highly 
significant photobactericidal effects against E. coli ATCC 25922 (≥4 log; P = 
0.001). 
ZnO_DOPA and ZnO_oleate-incorporated samples were also tested for 
antibacterial activity against S. aureus  NCTC 13143 without the use of a 
coverslip or humidity chamber in the experimental set-up. As shown in Fig. 
6.11(c), only the combination of CV and ZnO was capable of reducing S. 
aureus NCTC 13143 within 2 h in the dark; with CVZnO_DOPA and 
CVZnO_oleate reducing bacterial numbers by ~0.8 and ~2.3 log, 
respectively. However, by illuminating the samples for 2 h, CV reduced the 
bacteria by ~0.75 log and both CVZnO_DOPA and CVZnO_oleate exhibited 
≥4 log reduction of the EMRSA-16 strain (P = 0.001).  
After 3 h in the dark (Fig. 6.11(d)), ZnO_DOPA and ZnO_oleate caused 
~0.35 log reduction of S. aureus NCTC 13143, whereas CVZnO_DOPA and 
CV_ZnO_oleate reduced the bacteria by ~0.9 and ~2.3 log, respectively. 
Following 3 h of white light exposure, CV-coated polyurethane reduced S. 
aureus NCTC 13143 by ~1.4 log. Moreover, ZnO_DOPA and ZnO_oleate 
reduced the bacteria by ~0.6 log (P = 0.001).  
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Fig. 6.11 Antibacterial activity of CVZnO_DOPA and CVZnO_oleate polymer samples  in the 
dark and under standard laboratory white light (500 ± 300 lux) against: (a) E. coli ATCC 
25922 for 2 h, (b) E. Coli ATCC 25922 for 3 h, (c) S. aureus NCTC 13143 for 2 h and (d) S. 
aureus NCTC 13143 for 3 h. * indicates bacterial numbers reduced to below the detection 
limit of 100 colony forming units/mL (cfu/mL). 
 
The antibacterial activity of CVZnO_DOPA and CVZnO_oleate was then 
tested against both E. coli ATCC 25922 and S. aureus NCTC 13143 for 1 h in 
the dark and under white light activation (Table 6.2). The results clearly 
show that CVZnO_oleate is more effective at reducing both bacteria than 
CVZnO_DOPA. This is also apparent at longer incubation times (as shown in 
Fig. 6.11), where CVZnO_oleate proves to be more effective in the light and 
dark. DOPA-capped ZnO and oleate-capped ZnO NPs were synthesised 
using similar experimental procedures, producing NPs with an average 
diameter size of 3 nm. Thus, both of these factors are not responsible for 
the differences in antibacterial activity. However, these results do suggest 
that the oleate ligand is reponsible for the better antibacterial activity 
exhibited from ZnO_oleate compared to ZnO_DOPA, even though previous 
studies have shown that the ligands on their own do not demonstrate any 
significant antibacterial activity when incorporated into a polymer.23,31 
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Table 6.2  Antibacterial activity of modified polymer samples following 1 hour exposure to 
standard laboratory white light (500 ± 300 lux). 
Polymer sample Bacteria Bacterial reduction 
CVZnO_DOPA E. coli ATCC 25922 No kill 
CVZnO_oleate E. coli ATCC 25922 ~1 log 
CVZnO_DOPA S. aureus NCTC 13143 ~0.5 log 
CVZnO_oleate S. aureus NCTC 13143 ~1.75 log 
 
 
Most strikingly, for the first time, ZnO NPs have been incorporated into 
polyurethane and demonstrated bactericidal activity against a Gram-
negative and a Gram-positive bacterium without a photosensitiser. Both 
ZnO_DOPA and ZnO_oleate are able to reduce E. coli ATCC 25922 within 
only 2 h (in the light and dark). Moreover, they have demonstrated some 
activity against a clinical strain of EMRSA-16. The reduction of both 
bacteria in the dark suggests that these NPs could be killing the bacteria via 
different mechanisms to the photosensitiser, for example, Zn2+ leaching  
into the bacterial cell membrane or electrostatic interaction between the 
metal ions and the negatively charged bacterial cell wall.13-15   
 
6.3.3.2 Further Antibacterial Testing of CVZnO_oleate 
Following the results shown above in 6.3.3.1, the best performing ZnO NP, 
ZnO_oleate, was incorporated into polyurethane with CV and tested 
against more resistant bacterial strains. The antibacterial efficacy of 
CVZnO_oleate was tested against P. aeruginosa NTCC 10662, E. coli 1030 
and C. difficile 630Δerm endospores.22 In these experiments, no coverslip 
was used, and the bacterial suspension was simply dropped onto the 
polymer and allowed to dry rather than being ‘forced’ to interact with the 
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entire polymer surface. Against all bacteria tested in Fig. 6.12-6.14, none of 
the control nor ZnO_oleate polymers produced any significant kill of in the 
dark or after white light illumination.  
Fig. 6.12(a) illustrates the bactericidal activity of modified polymer samples 
tested against P. aeruginosa NCTC 10662 following 4 h of incubation in the 
light and dark. After 4 h in the dark, none of the modified polymers 
demonstrated any bactericidal activity. However, following 4 h exposure to 
white light, CV reduced P. aeruginosa NCTC 10662 by ~0.8 log and 
CVZnO_oleate caused ~2.5 log reduction in bacterial numbers (P = 0.001). 
By increasing the incubation time in the dark to 6 h (Fig. 6.12(b)), CV and 
CVZnO_oleate caused a ~0.6 and ~1 log reduction of P. aeruginosa NCTC 
10662, respectively. Within 6 h of white light activation, CV alone caused a 
~1.3 log reduction of bacteria, whereas CVZnO_oleate reduced bacterial 
numbers to below the detection limit (≥4 log reduction; P = 0.001). 
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Fig. 6.12 Viable counts of P. aeruginosa NTCC 10662 after incubation on modified 
polyurethane samples incubated at 20 oC under dark conditions and exposed to standard 
laboratory white light (500 ± 300 lux) for: (a) 4 h and (b) 6 h. * indicates bacterial numbers 
reduced to below the detection limit of 100 colony forming units/mL (cfu/mL). 
 
The ZnO_oleate samples were then tested against E. coli 1030, a multidrug-
resistant clinical isolate positive for both NDM and OXA-48-like 
carbapenemase genes. None of the samples caused any bacterial kill within 
4 h in the dark except CVZnO_oleate, which demonstrated statistically 
significant bactericidal activity (~1.9 log reduction, P = 0.001). Following 4 h 
in the light (Fig. 6.13(a)), CV alone reduced the numbers of E. coli 1030 by 
~1.5 log, whereas exposure to the CVZnO_oleate polymer reduced the 
numbers by ~4 log (P = 0.001). After 6 h exposure to the bacteria in the 
dark (Fig. 6.13(b)), only the CVZnO_oleate sample reduced bacterial 
numbers (~1.7 log; P = 0.001). However, after 6 h of white light activation, 
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CV caused ~2 log reduction of E. coli 1030 and CVZnO_oleate reduced 
bacterial numbers to below the detection limit (≥4 log reduction; P = 
0.001). 
 
 
 
Fig. 6.13 Viable counts of E. coli 1030 after incubation on modified polyurethane samples 
incubated at 20 oC under dark conditions and exposed to standard laboratory white light 
(500 ± 300 lux) for: (a) 4 h and (b) 6 h. * indicates bacterial numbers reduced to below the 
detection limit of 100 colony forming units/mL (cfu/mL). 
 
Lastly, the photobactericidal efficacy of these polymers containing CV and 
ZnO_oleate were tested against highly resistant C. difficile endospores. A 
reduction in the number of spores would be greatly beneficial as it is 
currently a major threat to patients in hospitals.32 No significant sporicidal 
activity was evident in the dark. However, following 72 h of white light 
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exposure (Fig. 6.14), the polymer containing CVZnO_oleate achieved a 
further ~1.2 log reduction in the number of spores compared to the control 
(P = 0.001).  
 
 
Fig. 6.14 Viable counts of C. Difficile 630Δerm after incubation on modified polyurethane 
samples incubated at 20 oC under dark conditions and exposed to standard laboratory 
white light (500 ± 300 lux) for 72 h. 
 
Table 6.3 Summary of the antibacterial activity of ZnO_oleate and CVZnO_oleate-
incorporated polymers in the dark and following white light incubation (500 ± 300 lux) 
against E. coli ATCC 25922 (3 h), P. aeruginosa NTCC 10622 (6 h), S. aureus NCTC 13143 (2 
h), E. coli 1030 (4 h) and C. difficile 630 endospores (72 h). Bacterial reduction is given in 
log form. 
Bacterial strain / 
incubation time 
ZnO_oleate 
dark 
ZnO_oleate 
white light 
CVZnO_oleate 
dark 
CVZnO_oleate 
white light 
E. coli ATCC 25922 
(3 h) 
2 log 2.5 log  ≥4 log ≥4 log 
P. aeruginosa NTCC 
10662 (6 h) 
No kill No kill 1 log ≥4 log 
S. aureus NCTC 
13143 (2 h) 
No kill No kill 2.4 log ≥4 log 
E. coli 1030 (4 h) No kill No kill 1.9 log 4 log 
C. difficile 630 (72 h) No kill No kill No kill 1.2 log  
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For the first time, ZnO NPs were synthesised with two different capping 
agents and exhibited significant bactericidal activity against E. coli ATCC 
25922 and S. aureus NCTC 13143 within only 3 h when incorporated into 
medical grade polyurethane squares. Both ZnO_DOPA and ZnO_oleate 
were able to significantly reduce the bacteria without the addition of CV or 
illumination. The results also showed that ZnO_oleate exhibited a greater 
bactericidal effect than ZnO_DOPA, with and without a photosensitiser. 
Further antibacterial testing of ZnO_oleate and CVZnO_oleate was then 
carried out for longer time periods against wild bacterial strains more 
recently isolated from hospitals and C. difficile spores.  
ZnO_oleate was unable to reduce the more resistant bacteria (P. 
aeruginosa NTCC 10662, E. coli 1030 or C. difficile spores) without CV. Figs. 
6.11 – 6.14 show that under a lower white light intensity of ~500 lux, CV 
alone is much less effective than previously demonstrated in Chapter 5, 
where a greater white light intensity was used (~6600 lux). However, the 
antibacterial activity of these smaller ZnO NPs supercedes the activity 
exhibited by 18 nm ZnO NPs shown in the previous chapter. The 18 nm ZnO 
NPs were also capped with oleic acid, thus, the smaller sized NPs have 
proven to be better at killing bacteria based on size alone. The antibacterial 
efficacy of the 18 nm and 3 nm ZnO NPs on their own differ, as 18 nm ZnO 
NPs were unable to reduce E. coli ATCC 25922, whereas the smaller ZnO 
NPs (both DOPA- and oleate-capped) prove to be very effective at killing 
the same bacteria. Additionally, the combination of CV and 18 nm ZnO NPs 
is not effective at reducing E. coli ATCC 25922 within 2 h in the dark 
(Chapter 5; Fig. 5.10), whereas 3 nm ZnO_oleate combined with CV 
reduces the bacteria by ~2.8 log (Fig. 6.11(a)). It should be noted that 
different swelling solutions were used to incorporate 18 nm and 3 nm ZnO 
NPs into polyurethane (1:1 ratio of dichloromethane and hexane in the 
case of 18 nm ZnO NPs and toluene in the case of 3 nm ZnO NP). However, 
both solutions caused the polymer to swell up to 142% of its original size 
and therefore, their antibacterial activities can be compared.  It is possible 
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that the smaller nanoparticles are able to penetrate through the bacterial 
cell wall at a higher concentration than the larger ZnO NPs. 
CVZnO_oleate polyurethane samples have demonstrated highly significant 
light-activated bactericidal activity against all pathogens tested in this 
investigation (Figs. 6.11 - 6.14) and even showed good activity against P. 
aeruginosa and a highly resistant strain of E. coli in the dark (Table 6.3). As 
shown for all bacteria tested, there was an increase in the antibacterial 
activity of CV when ZnO_oleate NPs were combined, implying that the NPs 
are responsible for enhancing the intrinsic (dark) bactericidal activity of CV 
itself and also enhancing the light-activated bactericidal activity of the dye.  
CVZnO_oleate demonstrated some photobactericidal activity against C. 
difficile spores. This is encouraging and may have a positive impact on 
infection control, as faecal shedding of spores by C. difficile-infected 
patients and contamination of environmental surfaces is a major infection 
source driving hospital outbreaks.33,34 It is not understood why ≥1 log 
reduction in the numbers of C. difficile spores occurred on the control 
polymer. Since no reduction in the spore counts was apparent on the 
control polymer in the dark, this could be due to reduced recovery of the 
spores from the surface of the light-exposed material as a result of drying. 
 
6.3.4 Mechanistic Evaluation of CVZnO_oleate 
To understand the effect of the oleate ligand on the antibacterial activity of 
CVZnO_oleate, ZnO NPs were synthesised with either oleate, stearate or 
linoleate ligands (structures shown in Fig. 6.15). Moreover, ZnO was 
synthesised again with an oleate capping, but with a greater NP 
metal:ligand ratio (10:1 compared to 5:1 used previously). Furthermore, 
ZnO NPs were  synthesised with stearate and linoleate ligands (5:1) to see 
if changes in the ligand chain structure would alter the antibacterial activity 
of the ZnO NPs. Studies in the literature have shown these ligands to 
possess bactericidal properties.35-37 As shown in Table 6.4, the total surface 
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area of 1 mg of the ZnO NPs remained consistent across all NPs, as the ZnO 
NPs with lesser ligand (more ZnO/g) are coincidentally larger in diameter 
with a lower surface area per particle. This is significant as the swelling 
solutions were prepared with 1 mg of ZnO per mL. It should also be noted 
that the solubility in organic solvents (e.g. toluene) of these ZnO NPs given 
in Table 6.4 was reduced compared to the original oleate-capped ZnO NPs 
(5:1) system.  
 
 
 
 
Fig. 6.15 Structures of (a) stearic acid, (b) oleic acid and (c) linoleic acid. 
 
To assess the antibacterial activity of polyurethane containing these 
different ligand:metal combinations with CV dye, they were tested against 
against E. coli ATCC 25922 after 2 h of standard laboratory white light 
exposure (~500 lux). The results showed (Table 6.4) that the bactericidal 
activity of both linoleate- and stearate-capped ZnO with CV was 
significantly less than CVZnO_oleate (5:1) in the light. CV and linoleate-
capped ZnO and CV and stearate-capped ZnO only achieved ~1 log 
reduction in the numbers of E. coli ATCC 25922 (P = 0.001) compared to ≥4 
log reduction observed from CV and oleate-capped ZnO (5:1). Linoleate-
capped ZnO was the least soluble and did not demonstrate any significant 
kill in the dark when combined with the photosensitiser. CV combined with 
stearate-capped ZnO reduced bacterial numbers by ~1 log in the dark 
(a) 
(b) 
(c) 
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whereas polyurethane containing CV and oleate-capped ZnO (5:1) 
produced a ~2.8 log reduction (P = 0.001).  
Moreover, the antibacterial activity of the different ratios of oleate-capped 
ZnO was compared. The 10:1 ratio was not as effective as the 5:1 ratio, 
presumably because the 10:1 oleate-capped ZnO NPs were larger in size 
(4.9 nm compared to 3.8 nm). Within 2 h of white light activation, 
polyurethane containing CV and oleate-capped ZnO (10:1) reduced 
numbers of E. coli ATCC 25922 by ~2 log (P = 0.001) and exhibited no 
significant kill in the dark. This suggests that a reduction in the ligand 
coverage of the ZnO NP surface (from 95% in the 5:1 ratio to 65% in the 
10:1 oleate-capped ZnO) is not beneficial in enhancing the bactericidal 
properties of the NPs. As reported in the literature and shown by the 
difference in antibacterial activity observed from 3 nm and 18 nm ZnO NPs 
(Chapter 5), this study also shows that the antibacterial activity of ZnO NPs 
is size dependent.13,15,38,39 
 
Table 6.4 Summary of the nanoparticle surface area and ligand coverage of all ZnO 
nanoparticles. Surface coverage determined for a typical average size nanoparticle as 
expected from analysis of UV spectra (Fig. 6.4; note that some size dispersity is likely in the 
particles and this represents an average scenario). Antibacterial activity of the ligands 
incorporated into polyurethane (with CV against E. coli ATCC 25922) after 2 h exposure to 
white light (500 ± 300 lux). 
 
Ligand 
 
Ratio 
wt % ligand 
by 
elemental 
analysis 
(carbon %) 
 
Approximate 
diameter 
(nm) 
ZnO 
surface 
area of 1 
mg of NP 
(m2) 
 
Metal : 
ligand 
ratio 
Estimated 
ligand 
coverage 
(% ZnO 
surface) 
Antibacterial 
activity after 2 
h white light 
(500 ± 300 lux) 
with CV 
Oleate 5:1 39 3.8 0.17 5.3:1 95 ≥4 log 
Oleate 10:1 25.6 4.9 0.16 10.1:1 65 ~2 log 
Stearate 5:1 40 3.6 0.18 5.2:1 93 ~1 log 
Linoleate 5:1 35.2 4.0 0.17 6.3:1 86 ~1 log 
 
In addition to investigating the properties of the capping ligand on the NPs, 
different Type I and II inhibitors were used to help understand the 
mechanism operating within the ZnO_oleate and CVZnO_oleate (5:1) 
polymer systems (Fig. 6.16). Previous studies have suggested that a Type I 
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process is dominant within antibacterial polymers,40 whereas others show 
a greater contribution from the Type II process, depending on the 
photosensitiser.41 Bovis et al demonstrated that both Type I and Type II 
mechanisms can operate in the photosensitisation of silicone doped with 
methylene blue and nanogold,42 and results from Chapter 5 show that both 
photochemical pathways are involved in the bactericidal activity of 18 nm 
CVZnO_oleate, but there is a greater involvement from the Type II 
mechanism.23  
 
 
Fig. 6.16 Radical species and singlet oxygen quenchers/inhibitors of Type I and II 
photochemical pathways used in this investigation (SOD: superoxide dismutase; BSA: 
bovine serum albumin; FFA: furfuryl alcohol). 
 
To investigate the mechanism responsible for the bactericidal activity of 
polyurethane containing CVZnO_oleate, superoxide dismutase (SOD) and L-
histidine were added separately to the antibacterial protocol as Type I and 
Type II inhibitors, respectively.23-25 SOD (50 U mL-1) was added to the 
bacterial suspension to eliminate superoxide anions and determine the 
contribution of a Type I photochemical pathway. Moreover, L-histidine (1 
mM) was used as a singlet oxygen quencher to study the involvement of 
the Type II mechanism. SOD or L-histidine was added to the bacterial 
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suspension prior to exposure to CVZnO_oleate and tested against S. aureus 
NCTC 13143 and E. coli ATCC 25922 for 2 h in the light and dark to assess 
any changes in antibacterial activity compared to a control experiment 
without inhibitors (Figs. 6.17 - 6.18). It should be noted that these standard 
concentrations of SOD and L-histidine are taken from literature and SOD at 
this concentration does not affect singlet oxygen production. 
Fig. 6.17 shows the antibacterial activity of control polyurethane and 
CVZnO_oleate against S. aureus NCTC 13143 following 2 h in the dark and 
after exposure to standard laboratory white light (~500 lux). The 
antibacterial activity of ZnO_oleate on its own was not tested as it 
displayed no significant kill within 2 h. After 2 h in the dark (Fig. 6.17(a)), 
both SOD and L-histidine reduced the antibacterial activity of 
CVZnO_oleate by ~0.8 - 1 log. Following 2 h of white light exposure, both 
inhibitors caused ~3.3 log reduction in the antibacterial activity of 
CVZnO_oleate, whereas in the control experiment the polymer was able to 
reduce S. aureus NCTC 13143 to below the detection limit without the 
inhibitors. In addition, the antibacterial efficacy of control polyurethane, 
ZnO_oleate and CVZnO_oleate was tested against E. coli ATCC 25922 using 
the same experimental conditions. This time, the antibacterial activity of 
ZnO_oleate was tested as it significantly reduced numbers of E. coli ATCC 
25922 in the control experiment within 2 h. Fig. 6.18 displays a similar 
effect of the inhibitors on CVZnO_oleate, as both SOD and L-histidine 
reduced its antibacterial response by a similar extent (in the light and 
dark). Therefore, these tests confirm that both Type I and II photochemical 
pathways contribute to the antibacterial activity of CVZnO_oleate at a 
similar rate in the dark and after white light exposure. 
However, the results of this experiment implied that the Type I and II 
mechanisms were not involved in the bactericidal mechanism observed 
from ZnO_oleate on its own, as they did not affect its antibacterial activity. 
ICP-OES data showed that some leaching of Zn2+ occurred from ZnO_oleate 
after 48 h of immersion in water (1.008 mg/L). To see whether the amount 
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of leaching was significant enough to reduce the bactericidal activity of 
ZnO_oleate, it was removed from water after 48 h and tested against E. 
coli ATCC 25922. The results demonstrated no change between the 
antibacterial activity of ZnO_oleate immersed in water and ZnO_oleate 
control (data not shown). Therefore, this shows that the ZnO NPs do not 
leach at a significant concentration in the surrounding solution to cause 
bacterial reduction.  
 
 
 
Fig. 6.17 Viable counts of S. aureus NCTC 13143 after 2 h (a) in the dark and (b) exposure 
to standard laboratory white light (500 ± 300 lux) on modified polyurethane samples for a 
control, superoxide dismutase (SOD) and L-histidine experiment. * indicates bacterial 
counts were reduced to below the detection limit of 100 colony forming units/mL 
(cfu/mL). 
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Fig. 6.18 Viable counts of E. coli ATCC 25922 after (a) 2 h in the dark and (b) 2 h of 
exposure to standard laboratory white light (500 ± 300 lux) on modified polyurethane 
samples for a control, superoxide dismutase (SOD) and L-histidine experiment. * indicates 
bacterial counts were reduced to below the detection limit of 100 colony forming 
units/mL (cfu/mL). 
 
Further experiments were carried out to investigate the effect of adding 
bovine serum albumin (BSA; 0.03%) to the bacteria as an organic 
contaminant as well as a singlet oygen quencher.18,23  After 2 h of white 
light exposure and in the dark, BSA was able to reduce the bactericidal 
efficacy of CZnO_oleate against both E. coli ATCC 25922 and S. aureus 
NCTC 13143. Conversely, BSA did not affect the antibacterial activity of 
ZnO_oleate, which  suggests that singlet oxygen is not involved in killing 
the bacteria. This also implies that ZnO_oleate polyurethane samples 
would be unaffected by possible organic contamination that would be 
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present in hospitals, which is a great advantage compared to other 
photoactivated systems (i.e. 18 nm CVZnO).23  
 
Table 6.5  Bacterial reduction (in log form) of E. coli ATCC 25922 and S. aureus NCTC 13143 
after 2 h exposure to ZnO_oleate and CVZnO_oleate-incorporated polyurethane with and 
without the addition of bovine serum albumin (BSA; 0.03%) (a) in the dark and (b) 
following white light incubation (500 ± 300 lux). 
E. coli ATCC 25922 (dark) S. aureus NCTC 13143 (dark) 
Polymer Bacterial 
Reduction 
without BSA 
Bacterial 
Reduction 
with BSA 
Polymer Bacterial 
Reduction 
without BSA 
Bacterial 
Reduction 
with BSA 
Control No kill No kill Control No kill No kill 
ZnO_oleate ~2.5 log ~2.5 log ZnO_oleate No kill No kill 
CVZnO_oleate ~3 log ~2 log CVZnO_oleate ~2.2 log ~3.5 log 
 
E. coli ATCC 25922 (~500 lux) S. aureus NCTC 13143 (~500 lux) 
Polymer Bacterial 
Reduction 
without BSA 
Bacterial 
Reduction 
with BSA 
Polymer Bacterial 
Reduction 
without BSA 
Bacterial 
Reduction 
with BSA 
Control No kill No kill Control No kill No kill 
ZnO_oleate ~2 log ~2 log ZnO_oleate No kill No kill 
CVZnO_oleate ≥4 log ~3 log CVZnO_oleate ≥4 log ~3 log 
 
To confirm singlet oxygen production within CVZnO_oleate under white 
light activation, two widely used chemical traps of singlet oyxgen, furfuryl 
alcohol (FFA)27 and L-ascorbic acid,28 were added separately to the 
antibacterial protocol. At 222 nm wavelength, FFA consumption was 
monitored after 3 h exposure to CVZnO_oleate. Table 6.6 shows a much 
greater decrease in FFA absorbance in the photoactivation of 
CVZnO_oleate compared to polyurethane containing CV alone (and none 
produced from ZnO_oleate or the control polymer). None of the modified 
polymers showed any quenching of FFA in the dark (data not shown) and it 
should be noted that FFA does not absorb in the visible spectrum and thus, 
was not deactivated during the 3 h experiment. 
(a) 
(b) 
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Using the same experimental set-up as described with SOD, L-histidine and 
BSA, L-ascorbic acid (1 mM) was added to the E. coli ATCC 25922 
suspension. Following 4 h of white light exposure, CVZnO_oleate with L-
ascorbic acid resulted in a ~2 log reduction of the bacteria, compared to ≥4 
log reduction without the presence of the quencher (Fig. 6.19). L-ascorbic 
acid added to CV alone reduced E. coli ATCC 25922 by ~1 log, in 
comparison to CV alone which caused ~2 log reduction after white light 
illumination. The quencher did not affect the antibacterial activity of the 
modified polymers in the dark (data not shown). These results show that 
upon light activation, singlet oxygen is chemically quenched as it reacts 
readily with ascorbate, producing hydrogen peroxide.28 In addition, 
CVZnO_oleate produces more singlet oxygen than CV alone, despite the 
fact that ZnO_oleate itself does not produce singlet oxygen.  It should be 
noted that L-ascorbic acid is not active in the dark.   
 
Table 6.6 UV-vis absorbance values at 222 nm of furfuryl alcohol after 3 h exposure to 
standard laboratory white light (500 ± 300 lux) on control, ZnO_oleate CV, and 
CVZnO_oleate-incorporated polymer samples.  
Polymer Absorbance (A) 
Control 0.158 
ZnO_oleate 0.153 
CV 0.138 
CVZnO_oleate 0.039 
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Fig. 6.19 Viable counts in colony forming units/mL (cfu/mL) of E. coli ATCC 25922 after 4 h 
exposure to standard laboratory white light (500 ± 300 lux) on modified polyurethane 
samples with the addition of L-ascorbic acid (1 mM). 
 
6.4 Conclusion 
In this chapter, 3 nm ZnO NPs have been synthesised with two different 
capping agents and incorporated into polyurethane with CV dye. They were 
tested against E. coli ATCC 25922 and a clinical strain of EMRSA-16 (S. 
aureus NCTC 13143) for up to 3 h and demonstrated highly significant 
bactericidal activity. For the first time, these NPs demonstrated 
considerable antibacterial activity without a photosensitiser when 
incorporated into the polymer. Oleate-capped ZnO NPs demonstrated 
greater bactericidal activity than DOPA-capped ZnO NPs, suggesting that 
the oleate ligand is partially responsible for the enhanced antibacterial 
activity exhibited from the NPs. CVZnO_oleate samples were then tested 
against more resistant bacteria found in hospitals, such as P. aeruginosa 
NTCC 10662 and a highly resistant form of E. coli. Additionally, a 
statistically significant reduction in the number of C. difficile spores was 
exhibited using CVZnO_oleate with 72 h of white light (~1.2 log reduction; 
P = 0.001). These polymer surfaces have obtained exceptional results 
against C. difficile endospores that can survive on surfaces for many 
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months and pose a major threat to hospitals as they are resistant to many 
forms of cleaning methods.43,44 
In this investigation, singlet oxygen and radical species inhibitors have been 
used to give mechanistic evidence for the photochemical pathways 
occurring from CVZnO_oleate when exposed to light and in the dark. The 
data has shown that both Type I and Type II mechanisms are occurring in 
the bactericidal activity of CVZnO_oleate. However, the antibacterial 
activity of ZnO_oleate polymer samples is barely affected by the presence 
of the inhibitors, indicating that it does not involve the production of 
superoxide or singlet oxygen. ICP-OES analysis indicated small amounts of 
Zn2+ leaching from ZnO_DOPA and a slightly greater extent of Zn2+ leaching 
was observed from ZnO_oleate within 2 h. This suggests that the ligand 
could be partially responsible for the leaching mechanism, as any Zn2+ ions 
released from the polymer could be taken up by the bacteria.  
The results from this investigation have clearly demonstrated that the 
combination of the smaller ZnO NPs and the oleic acid capping agent 
results improves the antibacterial activity observed from these polymers, 
as the DOPA-capped ZnO NPs were not as effective. Furthermore, the 
antibacterial activity of 18 nm ZnO NPs combined with CV was also not as 
effective as these smaller 3 nm-sized particles. The addition of BSA to the 
bacterial suspension exposed to 18 nm CVZnO_oleate (Fig. 5.12; Chapter 5) 
and 3 nm CVZnO_oleate shows that the smaller NPs are less affected by 
the organic contaminant and singlet oxygen quencher. This suggests that 
the smaller NPs in CVZnO_oleate operate via a more equal contribution of 
Type I and Type II mechanisms, or it implies that the antibacterial activity 
of the 3 nm CVZnO_oleate system is more effective because of the NPs 
themselves rather than the dye, as the NPs are unaffected by BSA. The 
smaller NPs have the potential of electrostatically interacting with the 
bacterial cell wall due to a larger surface area, or penetrating through to 
the cell membrane at a higher concentration than the larger NPs. 
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These polymers have demonstrated exceptional antibacterial activity as 
potential surfaces in hospitals to minimise the risk and spread of HAIs. They 
have various prospective applications, including covers for laptops, 
keyboards mousepads and iPad covers. Highly significant bacterial kills 
have been achieved under low intensity lighting (~500 lux) and in the dark, 
proving more effective than other antibacterial polymer systems previously 
tested which used much higher white light intensities (3,000-10,000 
lux).23,27,30,41,45-47 The antibacterial efficacy of these samples has been 
tested without the use of a coverslip to spread the bacteria evenly onto the 
entire polymer surface and without a humidity chamber to prevent 
evaporation. This has created an experimental set-up that represents a 
more realistic clinical environment and demonstrates how effective these 
polymers would be in a hospital setting. Furthermore, these polymers have 
exhibited bactericidal activity against a much higher bacterial load than 
what would be present in a hospital; ~1 x 105 cfu/cm-2 of bacteria used in 
this investigation compared to an average of 1 x 102 cfu/cm-2 found in a 
clinical setting.31,46,47  
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Chapter 7 
Conclusion 
As bacterial drug resistance rises, the need to decrease the spread of 
bacterial contamination in hospitals and reduce the risk of hospital-
acquired infections becomes increasingly urgent. Antibacterial surfaces can 
significantly reduce the risk of these infections by minimising the spread of 
bacterial contamination between patients, staff and frequently touched 
surfaces. In this thesis, different antibacterial surfaces have been prepared 
with the potential to kill bacteria that come into contact with the surface 
within only a few hours.  
In the first experimental chapter, Chapter 3, small copper nanoparticles 
were incorporated into two widely used polymers, medical grade silicone 
and polyurethane squares. These polyurethane-encapsulated Cu samples 
were able to reduce Gram-negative and Gram-positive bacteria without 
any white light activation or a photosensitiser. The bactericidal activity of 
polyurethane-encapsulated Cu was more effective than silicone-
encapsulated Cu, since polyurethane was able to swell more and thus, 
incorporate more nanoparticles within the polymer matrix. Silicone-
encapsulated Cu was able to completely reduce E. coli and MRSA within 6 
hours, whereas polyurethane-encapsulated Cu completely reduced 
bacterial numbers within only 3 hours. Further experiments showed that 
these polymers were stable for more than 90 days after preparation and 
were unaffected by bovine serum albumin (BSA), which was added to the 
bacteria as an organic contaminant (and singlet oxygen quencher). 
Secondly as described in Chapter 4, a well-known disinfectant used in 
hospitals, glutaraldehyde, was incorporated into polyurethane to 
determine its antibacterial activity. Glutaraldehyde is a commonly used 
biocide for sterilising medical devices and equipment, but its use in 
hospitals is somewhat questionable at high concentrations due to possible 
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toxicity towards mammalian cells. Therefore, a very low concentration of 
glutaraldehyde was incorporated into the polymer to test its bactericidal 
properties. Additionally, polyurethane samples were prepared with 
glutaraldehyde only coated onto the polymer, in order to investigate the 
efficacy of the ‘swell-encapsulation-shrink’ method that has been used to 
impregnate antibacterial agents effectively into the polymer substrate. As 
predicted, the bactericidal activity of polyurethane-encapsulated 
glutaraldehyde was far more effective than glutaraldehyde coated onto 
polyurethane. These modified polymers were highly effective within a few 
hours and did not require any light activation. However, after 14 days, the 
antibacterial activity of the samples dramatically reduced due to 
polymerisation of the aldehyde groups under basic conditions. Thus, these 
biocidal polymers would be more effective as disposable or short-term 
antibacterial covers or surfaces, unless their stability was improved at 
lower concentrations.  
Next, this thesis focused on the use of photodynamic therapy to kill the 
bacteria by coating polyurethane with crystal violet (CV) dye, as described 
in Chapter 5 and 6. To enhance the bacterial reduction observed from CV-
coated polyurethane, 18 nm zinc oxide nanoparticles (ZnO NPs) were also 
incorporated into the polymer. Polyurethane-encapsulated CV and ZnO 
samples (CVZnO) were highly effective at reducing both E. coli and S. 
aureus within 4 h of white light activation, and more significantly, in the 
dark. For the first time, the mechanism operating within the dye-
nanoparticle combination was investigated by using radical species and 
singlet oxygen quenchers: bovine catalase, L-histidine and BSA. The results 
indicated that both radical species (Type I) and singlet oxygen (Type II) 
were involved in the bactericidal mechanism of CVZnO.  
Following the efficacious results achieved from CVZnO, smaller 3 nm ZnO 
NPs were synthesised with two different capping agents and incorporated 
into polyurethane with CV dye. Previous studies carried out by Perni et al 
demonstrated that smaller Au NPs exhibited greater antibacterial activity 
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when combined with methylene blue. Therefore, this thesis investigated 
the bactericidal activity of a different nanoparticle-dye combination. In this 
study, 3 nm DOPA-capped ZnO and oleate-capped ZnO NPs were 
synthesised and incorporated into the polymer. Most strikingly, these 
smaller ZnO NPs demonstrated highly significant bactericidal activity 
without a photosensitiser within only 3 hours in the light and dark. 
Furthermore, CV combined with these smaller ZnO NPs achieved even 
greater antibacterial activity in the light and in the dark. These results 
confirmed that smaller nanoparticles elicited better antibacterial activity, 
presumably because the smaller NPs can penetrate through the bacterial 
cell wall more efficiently. It is also possible that the smaller NPs can 
interact more effectively with the dye itself, causing a greater 
enhancement in bacterial kill than what was observed in Chapter 5. 
Noimark et al studied the antibacterial activity of CV combined with DOPA-
capped ZnO NPs incorporated into silicone, which was not as effective as 
polyurethane. This has also been demonstrated in Chapter 3, where Cu NPs 
reduced bacterial numbers more effectively when incorporated into 
polyurethane compared to silicone. Moreover, Ozkan et al investigated the 
bactericidal activity of CV and commercially available <100 nm ZnO NPs 
incorporated into silicone, which also were not as effective as these smaller 
NPs.  
The combination of CV and ZnO NPs capped with an oleate ligand 
(CVZnO_oleate) exhibited the most significant bactericidal activity and was 
then tested against more resistant bacteria, as well as C. difficile 
endospores. For the first time, CVZnO polymers were exposed to highly 
resistant bacteria and spores. These polymers were able to reduce bacteria 
such as P. aeruginosa and a wild strain of E. coli within 6 h in the light and 
dark. More significantly, CVZnO_oleate displayed significant 
photobactericidal activity against C. difficile spores within 72 h. 
CVZnO_oleate achieved outstanding results against highly resistant 
bacterial strains using a much lower light intensity than previously used in 
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the experiments (~500 lux compared to ~6600 lux). This suggested that the 
oleic acid capping agent is crucial for this bactericidal activity, even though 
the ligand displayed no significant antibacterial activity on its own. ZnO NPs 
were synthesised with linoleate and stearate capping agents and did not 
show the same bactericidal activity as oleate-capped ZnO NPs. 
Furthermore, DOPA-capped NPs did not demonstrate the same lethal 
activity exhibited from the oleate-capped NPs, even though they were 
similar in size.  
Moreover, the experimental set-up was changed to replicate a more 
realistic clinical setting by removing the use of a coverslip and a humidity 
chamber. An extensive investigation was carried out to study the 
mechanism operating within the CVZnO_oleate polymer system. ZnO NPs 
were synthesised again with a varied metal:ligand ratio, as well as using 
different ligands (i.e. stearate and linoleate ligands). However, these newer 
ZnO NPs with alternative ligands did not reduce the bacteria as effectively 
as the original CVZnO_oleate, confirming that the oleate ligand plays a role 
in its bactericidal activity. In addition, mechanistic studies on the ROS-
mediated processes involved in bacterial killing were carried out. ROS 
inhibitors were added to the bacteria to determine the involvement of 
each photochemical pathway in the antibacterial activity of CVZnO_oleate. 
The results indicated that both Type I (superoxide) and Type II (singlet 
oxygen) photochemical pathways were operating in the light and dark.  
The antibacterial activity of 3 nm CVZnO_oleate was more effective than 
18 nm CVZnO_oleate. This is most likely due to the differences in NP size, 
as both NPs were synthesised with an oleate-capping agent. BSA affected 
18 nm CVZnO_oleate more than 3 nm CVZnO_oleate, which could be due 
to the fact that BSA affects the antibacterial activity of the photosensitiser 
more than the antibacterial activity of the NPs. The protocol used to 
determine the antibacterial activity of 18 nm CVZnO_oleate used a higher 
light intensity (~6600 lux) which showed significant bactericidal activity 
from the sample. However, CV was not as effective on its own using ~200 
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lux intensity as shown from the 3 nm CVZnO_oleate investigation. The NPs 
are more responsible for the bactericidal activity observed from 3 nm 
CVZnO_oleate than 18 nm CVZnO_oleate (as they did not kill on their own). 
This was also confirmed from ZnO_oleate and Cu-incorporated polymer 
samples, as their antibacterial activities were not affected by the addition 
of BSA to the bacterial suspension. 
The overall results have shown that all polymer surfaces are capable of 
reducing bacteria within short incubation times against hospital pathogens.  
Two polymeric materials were tested for bactericidal activity, which 
demonstrated that polyurethane performed more effectively. Additionally, 
the ‘swell-encapsulation-shrink” method was established to be a much 
better method for preparing these materials compared to dip-coating the 
polymers with the active agent. Smaller sized nanoparticles (2-3 nm Cu and 
ZnO NPs) exhibited considerable antibacterial activity without light-
activation. The mechanism operating within these systems differ to the 
mechanism operating within light-activated antibacterial polymers. The 
mechanism by which the nanoparticles kill bacteria on their own needs to 
be further investigated in order to understand the longevity of their 
activities, i.e. if the ions are operating via a leaching mechanism. It is 
possible that the nanoparticles are killing the bacteria by an electrostatic 
interaction between the metal ions and the negatively charged bacterial 
cell wall.  The smaller NPs may be able to diffuse through the bacterial 
membrane more effectively than larger NPs; hence they have 
demonstrated better antibacterial activity. The results also showed that 
nanoparticles incorporated into polyurethane alone are not affected by 
organic contamination. On the other hand, the mechanism of photo-
activated polymers clearly operates via the combination of a Type I and 
Type II photochemical pathway, but are affected by organic contamination.  
This thesis has described the preparation and antibacterial activity of novel 
materials that are highly effective at reducing resistant bacteria and has 
progressed our understanding on the mechanism that kills the bacteria. 
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The efficacy of these antibacterial surfaces has vastly improved, as this 
thesis presents work which demonstrates highly significant bacterial 
reduction under very low intensity white light and in the dark. Previous 
work has focused on laser light activation to cause bacterial kill, however, 
in a hospital environment it would be highly beneficial for the surface to be 
self-sterilising and efficient in low lighting conditions. Additionally, this 
thesis presents surfaces which are able to reduce bacteria without a 
photosensitiser, and thus, are not affected by radical and singlet oxygen 
inhibitors. To progress on the work presented in this thesis, clinical studies 
are underway to investigate the bactericidal activity of these surfaces 
against more resistant pathogens. For these polymers to be used as 
antibacterial surfaces for hospitals, such as iPad, keyboard and phone 
covers, there needs to be a greater understanding on their durability over a 
longer period of time and how they could be commercially manufactured 
at a larger scale.   
 
 
7. 1 Future Work 
It is very important to understand the stability and longevity of these 
polymer samples to see how effective they are months/years after 
preparation. Even though these samples are able to reduce bacterial 
numbers within short exposure times, it is crucial to understand how 
effective they are after longer periods of time, with and without routine 
cleaning. It would also be interesting to directly compare the effect of using 
a coverslip vs. no coverslip in the same experiment, as well as using BSA 
and a lower light intensity in all future experiments. It is important to 
replicate a realistic clinical setting as much as possible when studying the 
antibacterial activity of these surfaces. This thesis has investigated the 
effects of organic contamination and humidity on the bactericidal activity 
of these antibacterial polymers. It would be interesting to see how factors 
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such as temperature and method/frequency of cleaning would alter the 
antibacterial efficacy of the samples. 
Furthermore, a different method could be used to drop-cast the bacteria 
onto the polymer samples. For example, an aerosol-type spray method 
could be used to coat the polymer with bacteria, which would more 
accurately reflect the natural situation, i.e. sneezing or coughing or other 
aerosol generated from body fluids. Moreover, the antibacterial activity of 
these surfaces should be assessed against biofilms as well as planktonic 
bacteria, since biofilm formation would enhance the ability of the bacteria 
to survive harsh conditions and resist antibacterial treatment. To 
investigate the antibacterial efficacy of these polymer samples in an actual 
clinical setting, experiments are currently underway to see how they will 
behave in a naturally contaminated hospital environment.  
Further investigation on the interaction between the bacterial cells and the 
polymer surface would give valuable information on how the nanoparticles 
kill the bacteria (without a photosensitiser), i.e. using electron microscopy 
to see the larger nanoparticles inside the bacterial cell. Live-dead could be 
used to determine the proportion of bacteria live-dead in a time course. 
Additionally, atomic-force microscopy (AFM) could be used to determine 
the strength of interaction between the bacteria and the modified polymer 
surface.  
 
